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Abstract 
Developing artificial visual systems to restore sight in blind patients has long 
been the dream of scientists, clinicians and the public at large. After decades of 
research, the greatest success in the field has been achieved with electronic 
retinal prostheses. To date, 3 retinal prosthetic systems have made the 
transition from laboratory / clinical research to entering the commercial market 
for clinical use, namely the Argus® II Retinal Prosthesis System (Second Sight), 
the alpha-IMS system (Retinal Implant AG), and the IRIS® II (Pixium Vision). 
The following body of work describes the Argus® II Retinal Prosthesis system, 
which obtained regulatory approval in the European Economic Area in 2011 
(CE marking) and later on in the USA (FDA approval in February 2013), based 
on the results of an international multi-centre clinical feasibility trial (Clinical Trial 
identifier: NCT 00407602).  
This thesis aims to examine the long-term clinical and functional outcomes in an 
early cohort of subjects chronically implanted with the Argus® II system, from 
the original feasibility study. A further aim is to elucidate the characteristics of 
the artificial vision that is perceived and its long-term repeatability and 
reproducibility in individual subjects. These two broad aims will assist in 
understanding the nature of the visual performance provided by this device, as 
well as to add to the current data that is defining the feasibility of constructing 
predictable pixelated patterns to achieve useful artificial vision in the future. 
Finally, we explored the feasibility of real-time imaging of visual cortex activation 
in response to electrical retinal stimulation with the Argus® II system, using 
functional near infra-red spectroscopy (fNIRS). Development of this real-time 
imaging tool will enable future investigations into the differences in the cortical 
activities in response to different stimulations and in different subjects. This may 
in turn help us understand the variability in their visual performance, as well as 
to further explore the extent and effect of cross-modal plasticity at the cortical 
level, in this cohort of patients who have been deprived of visual inputs for 
decades. 
Visual function was assessed in terms of: a) form recognition and b) spatial 
localisation under both 2-dimensional (2D) screen-based laboratory settings 
and 3-dimensional (3D) paradigms simulating real-life settings. A prospective 
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study of 11 Argus® II subjects showed that the subjects could identify distinct 
geometric shapes presented in high contrast better with the prosthetic system 
switched on (median % of correct identification = 20.0%, IQR = 18.8), versus off 
(median = 12.5%, IQR = 5.0). The accuracy of shapes identification could be 
further improved by enhancing the outlines of the geometric shape (median = 
33.1%, IQR = 21.6). 
A further prospective study from a subset of 7 subjects showed that this 2D 
shape identification could be translated into improved identification of 3D 
objects. These subjects could identify 8 common daily-life objects presented in 
high contrast with the prosthetic system switched on (median = 31.3%, IQR = 
20.3) versus off (median = 12.5%, IQR = 12.5). Scrambling of the transmission 
signals within the prosthetic system in order to separate light information from 
form information (i.e. “scrambled mode”) hindered the identification in some but 
not all subjects (median = 25.0%, IQR = 12.5). The accuracy of object 
identification could also be improved by enhancing the edges of objects 
(median = 43.8%, IQR = 15.6). 
Previously published data showed that Argus® II subjects were able to locate 
and point to white squares presented on touch screens against a black 
background more accurately with the prosthetic system switched on versus off. 
We demonstrated with a prospective study of 5 subjects that they could localise 
an object on the table, reach out and grasp the object (prehension) with great 
accuracy (66.7 – 100%) when the prosthetic system was switched on, versus 
no object prehension (0%) with the system switched off. 
A prospective study of 6 Argus® II subjects illustrated that while there was a 
wide variation in the shape and size of the phosphenes perceived by individual 
subjects, the elicited phosphenes were consistently reproducible in each subject 
using fixed stimulating parameters, with inter-stimuli intervals ranging from 20 
minutes apart, down to 1 second. The perceived location of the phosphenes 
grossly matched retinotopic agreement, with 4 subjects drawing phosphenes in 
the same visual field quadrant as predicted by the relative stimulus-fovea 
position, and 2 subjects depicting phosphenes in the same hemi-field as the 
expected locations. 
A retrospective study of 3 Argus® II subjects who underwent MRI brain scan 
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(for unrelated medical reasons) showed that MRI brain scans of up to 1.5 Tesla 
field strength appeared to have no detrimental effect on the subjects and their 
implant function. The Argus® II implant produced an artefact of around 50mm x 
50mm in size which would prevent visualisation of structures within the orbit, but 
visualisation of surrounding tissues outside this areas are unaffected. 
The use of functional MRI as a tool of exploring visual cortex activation in 
Argus® II subjects was discounted, due to concerns of signal interference from 
the radiofrequency telemetry of Argus® II system with that of MRI. 
Subsequently, we have demonstrated in a prospective study that an alternative 
neuro-imaging technique, functional near infra-red spectroscopy (fNIRS), was 
capable of capturing real-time cortical activation in 5 out of 6 Argus® II subjects, 
and maybe a feasible tool for future investigation into cortical function and 
interactions. 
The work in this thesis has shown that the Argus® II retinal prosthesis system 
could improve visual function both in terms of form recognition, as well as object 
localisation in 3D in situations simulating real-life settings, in a cohort of patients 
with end-stage retinitis pigmentosa or other outer retinal diseases such as 
choroideremia. The wide variation in the visual performance level observed 
could in part be attributable to the diversity in the phosphene features perceived 
by these subjects. Nevertheless, the consistency and reproducibility with which 
these phosphenes could be elicited, with fixed stimulating parameters within 
each subject, provides an encouraging basis for the construction of more 
complicated pixelated images.  
Future work to determine the underlying factors influencing the perceived 
phosphene characteristics, may allow for better prediction of functional 
outcome, which could in turn be useful for patient selection and tailored pre-
operative counselling. For those subjects already implanted with the Argus® II 
system, future work into determining the suitable stimulating parameters for 
each electrode / quad stimulation may be required for individual subjects, to 
achieve the construction of optimised and useful, pixelated prosthetic vision. 
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Prostheses are artificial replacements designed to substitute a destroyed or 
damaged part of the body in order to restore function and / or cosmesis. Using 
visual prostheses to restore visual function in blind patients has long been the 
dream of many scientists, clinicians and has captured the imagination of the 
public. Over the years, several devices have been developed with varying 
degrees of success, though none of these come close to emulating the 
complexity or resolution of the human visual system. 
According to the Bulletin of World Health Organisation 2004 (Grover et al., 
1999; Milam et al., 1998; Resnikoff et al., 2004), the prevalence of blindness 
worldwide in 2002 (defined as visual acuity of less than 3/60, or a 
corresponding visual field loss to less than 10 degrees in the better eye with 
best possible correction) was estimated to be 37 million people, of which 1.368 
million were children under the age of 15. In the developed countries, retinal 
diseases are the leading cause of childhood and adult visual loss (Apte et al., 
2001; Attebo et al., 1996; Dimitrov et al., 2003; Hartong et al., 2006; Klaver et 
al., 1998; Klein et al., 1995; Krumpaszky et al., 1999; Muñoz et al., 2000; 
Sakaguchi et al., 2012; Santos, 1997; Stone, 1992). Age-related macular 
degeneration (AMD), which peaks in the 8th and 9th decade of life (Klaver et al., 
1998), contributes to more than half of blindness registration (Yong et al., 2006). 
Inherited retinal / macular dystrophy, on the other hand, while less common, 
can lead to blindness during the 2nd or 3rd decade of life (Liew et al., 2014). Of 
these, retinitis pigmentosa (RP) is the most common with a prevalence of 1 in 
3000 worldwide (Hamel, 2006; Hartong et al., 2006; Humayun et al., 2012; 
Michaelides et al., 2003). Collectively, AMD and RP, diseases both affecting the 
outer retina (photoreceptors and RPE), are responsible for a large proportion of 
adult blindness. Replacement of outer retina function by means of a retinal 
prosthesis therefore represents a potential treatment target for prosthetic vision. 
1.1 Visual Pathway & Visual Processing 
Vision represents the outcome of a complex physiological process and the 
visual system is the most complex and developed sensory system in our body 
(Holmes, 1945; Perry and Morton, 1992; Wurtz and Kandel, 2013). To achieve 
optimal visual function, several principle steps are involved: 
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1. Capture of electromagnetic waves in the visible spectrum as emitted from or 
reflected by the physical world onto the retina as focused images; 
2. Conversion of these electromagnetic waves into a voltage gradient in the 
photoreceptors; 
3. Propagation of a neurological signal by means of action potentials along the 
visual pathway; 
4. Simultaneous processing of the images to extract visual information along 
the visual pathway; 
5. Interpretation of the visual information by the visual cortex. 
1.1.1 Retina 
The human retina is a complex neural network organised into multiple regular 
and integrated layers (see Figure 1.1). The deepest layer of this network is a 
layer of photosensitive photoreceptors. Electromagnetic energy that enters the 
eye as a focused pattern of visible light is converted into electrical energy in the 
photoreceptors. This transduced signal is then propagated via bipolar cells layer 
(with modification from amacrine and horizontal cells) to the ganglion cells layer.  
The axons of the ganglion cells aggregate to exit the eyeball as the optic nerve. 
Within the retina, image processing and information extraction begins and 
continues throughout the visual pathway (Bear et al., 2015; Kolb, 2003). 
In a human with normal retinal anatomy, there are around 5 million cones and 
120 million rods. Processing such a significant amount of input into the visual 
system requires complex intercellular interactions and involve summation and 
integration of signals from different cells (Carpenter and Reddi, 2012; Potts and 
Inoue, 1969; Potts et al., 1968; Wurtz and Kandel, 2013). 
The first level of signal processing begins at the bipolar cells. There are two 
broad classes of bipolar cells: the rod bipolar cells, which receive signals from 
the rods (and later form the magnocellular pathway); and the cone bipolar 
cells, which synapse with the cones (and later form the parvocellular pathway). 
Summation of information occurs as many photoreceptors converge and 
synapse onto the same bipolar cells (except at the fovea, see Section 1.2.4). 
Together with modifications from the laterally communicating horizontal cells 
(which form synapses amongst neighbouring bipolar cells), integration of the 
summated photoreceptor signals (in the form of graded membrane potentials) 
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result in the concentric, antagonistic centre-surround receptive field of the 
bipolar cells. The ON bipolar cells depolarise when light is shone in their 
receptive field centre (and hyperpolarise when light is shone in the surrounding 
of their receptive field), while OFF bipolar cells hyperpolarise to light in their 
receptive field centre (and depolarise with the light in the surrounding).  
 
Figure 1.1: Schematic drawing of the different layers of retina. Electromagnetic 
visible light waves travel through the pupil and the virtually transparent retinal 
layers to activate the photosensitive photoreceptors. Conversion of 
electromagnetic light waves into electrical energy takes place in the 
photoreceptors, which then propagate the resultant signal to the bipolar cells 
layer, and then to the ganglion cells layer. The collective axons of the ganglion 
cells exit the globe as the optic nerve. In each of these retinal cell layers, 
summation and integration of information take place as part of visual 
processing. (Image from (“Special Senses,” n.d.)) 
The next level of information summation and processing occurs at the ganglion 
cells layer, where information within each bipolar cell is further converged and 
synapsed onto the 1.5 million ganglion cells. The parvocellular P-type ganglion 
cells receive signals from cone bipolar cells; while the magnocellular M-type 
ganglion cells receive inputs from the rod bipolar cells. Again, with modification 
and integration of information from laterally communicating amacrine cells, 
ganglion cells exhibit various types of response to light. Some ganglion cells 
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maintain the concentric antagonistic centre-surround receptive fields as seen in 
bipolar cells. Others exhibit “on response” (transient burst of action potentials in 
response to an increase in illumination), “off response” (transient burst of action 
potentials to a decrease in illumination), “on-off response” (transient burst of 
action potentials at the commencement and at the cessation of a period of 
steady illumination), or “sustained response” (persistent action potentials when 
a steady illumination is on, and fades when the illumination is switched off).  
1.1.2 Lateral Geniculate Nucleus (LGN) of the Thalamus 
After interactions at the ganglion cells layer, ganglion cell axons bundle together 
to form the optic nerve and exit the eye to continue as the intracranial portion of 
the visual pathway. The first major synapse and relay of the intracranial visual 
pathway is the lateral geniculate nucleus (LGN) of the thalamus, where more 
than 90% of the ganglion cell axons terminate. The remaining 10% of the 
ganglion cell axons project to superior colliculus (which controls saccadic eye 
movements) and the pretectum in the midbrain (which controls pupillary 
reaction). This small proportion of ganglion cells are also thought to be 
responsible for blindsight – a limited residual vision which appears to function at 
a subconscious level, and will not be discussed further. 
In primates, the LGN consists of 6 layers (see Figure 1.2). The magnocellular 
ganglion cells (containing inputs from rod bipolar cells) from the nasal hemi-
retina project to layer 1 of the contralateral LGN; while those from the temporal 
hemi-retina project to layer 2 of the ipsilateral LGN. This magnocellular pathway 
contains information on movement, depth, and brightness (i.e. high sensitivity 
to luminance contrast), and transmits signals that are transient and rapid in 
nature. The parvocelluar ganglion cells (containing inputs from cone bipolar 
cells), on the other hand, project to levels 4 and 6 of the contralateral LGN (from 
nasal hemi-retina) and levels 3 and 5 of the ipsilateral LGN (from the temporal 
hemi-retina). This parvocellular pathway transmits information on colour, form 
and fine details, and the signals are slow and sustained in nature, with low 
sensitivity to luminance contrast. Further more, LGN cells driven by the same 
area of retina form a single radial column, thereby preserving the retinotopic 
organisation of the signals originating from the retinal images. Such 
preservation of retinotopy is crucial for later form construction and interpretation 
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in the primary visual cortex at the occipital lobe (see Figure 1.3). The LGN also 
receives substantial feedback from other brain areas, in particular the reticular 
formation and the visual cortex (in fact only 10 – 20% of the presynaptic inputs 
in the LGN are from the retina), thereby acting as a gateway for controlling the 
information passing from the retina to the cortex (Wurtz and Kandel, 2013). 
 
Figure 1.2: Histology slide of a coronoal section through the lateral geniculate 
nucleus (LGN) of the rhesus monkey. In primates, the LGN consists of 6 layers. 
The magnocellular ganglion cells from the nasal hemi-retina project to layer 1 of 
the contralateral LGN; while those from the temporal hemi-retina project to layer 
2 of the ipsilateral LGN. This magnocellular pathway (labelled in black) contains 
information on movement, depth, and brightness, and transmits signals that 
are transient and rapid in nature. The parvocelluar ganglion cells project to 
levels 4 and 6 of the contralateral LGN (from nasal hemi-retina) and levels 3 
and 5 of the ipsilateral LGN (from the temporal hemi-retina). This parvocellular 
pathway (labelled in purple) transmits information on colour, form and fine 
details, and the signals are slow and sustained in nature, with low sensitivity to 
luminance contrast. Further more, LGN cells driven by the same area of retina 
form a single radial column, thereby preserving the retinotopic organisation of 
the signals originating from the retinal images. (Image from (“Slide Show: The 
Neural Control of Vision D-1,” n.d.)) 
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Figure 1.3: Schematic representation of the visual pathway from the retina to 
the visual cortex. Theoretically, electrical stimulation at any point along the 
visual pathway could elicit transient visual percepts known as phosphenes. 
Visual prostheses have been developed for direct electrical stimulation at the 
following sites (circled in red): retina, optic nerve, thalamus and the visual 
cortex. (Image from (“Neuroscience for Kids: the visual pathway Interesting 
information on what can happen if there's any damage | Teaching: Physics - 
Vision | Pinterest | Pathways…,” n.d.)) 
1.1.3 Visual Cortex 
From the LGN the neurones leave the thalamus, traversing the white matters of 
the brain (antero-posteriorly) as the optic radiations to arrive at the occipital 
lobe. Further inputs and outputs to other cortical regions also occur, to facilitate 
final processing and interpretation in the visual cortex. 
The primary visual cortex (also known as striate cortex or Brodmann’s area 17), 
is also composed of 6 layers (see Figure 1.4). Layer 4 is the main receiving 
layer and is subdivided into 4A, 4B and 4C. Layer 4Cα (a further sub-layer) 
receives input from the LGN magnocellular pathway (containing M-type cells), 
which relays to the 4B layer; while layer 4Cß receives input from the LGN 
parvocellular pathway (containing P-type cells), and relays onto layer 3. Apart 
from the predominate magnocellular and parvocellular pathways, a third 
koniocellular pathway is also present. Little is known about the function of this 
koniocellular pathway, but it is thought that they originate from non-M non-P 
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koniocellular ganglion cells in the retina, synapsing at the intra-laminar layers of 
the LGN, and terminate in the “blobs” areas of layers 2 and 3. 
 
Figure 1.4: Schematic drawing of the 6 layers of the primary visual cortex. Layer 
4 is the main receiving layer and is subdivided into 4A, 4B and 4C. Layer 4Cα 
(a further sub-layer) receives input from the LGN magnocellular pathway 
(containing M-type cells), which relays to the 4B layer; while layer 4Cß receives 
input from the LGN parvocellular pathway (containing P-type cells), and relays 
onto layer 3. Apart from the predominate magnocellular and parvocellular 
pathways, a third koniocellular pathway is also present. Little is known about the 
function of this koniocellular pathway, but it is thought that they originate from 
non-M non-P koniocellular ganglion cells in the retina, synapsing at the intra-
laminar layers of the LGN, and terminate in the “blobs” areas of layers 2 and 3. 
(Image modified from (“The Primary Visual Cortex by Matthew Schmolesky – 
Webvision,” n.d.)) 
Once at the visual cortex, visual processing proceeds as 3 parallel channels, 
each focusing on extracting different aspects of the visual information (see 
Figure 1.5): 
a) M channel 
 Page 33 
b) P-IB channel 
c) Blob channel 
a) M channel 
The M channel processes information from the magnocellular pathway. 
Originating from magnocellular ganglion cells (which in turn receive 
inputs from rods), M-type cells have large, concentric, centre-surround 
antagonistic receptive fields, with particular sensitivity to movement and 
luminance contrast.  
On arriving in the visual cortex at the 4C cortex, the information is 
relayed (via layer 4B) onto and processed by the simple cells in layers 2 
and 3. Simple cells’ receptive fields are linear and highly orientation 
specific, flanked by an antagonistic surround. As such, they can detect 
both the orientation and location of a stimulus.  
From the primary visual cortex, the M channel projects to the middle 
temporal (MT) area in the posterior parietal lobe, where motion 
detection takes place. The M channel is therefore responsible for 
processing visual information related to motion and localisation, with 
high sensitivity under low luminance setting. 
b) P-IB Channel 
The P-IB channel processes information from the parvocellular pathway 
and consists of parvocellular ganglion cells (P-type cells), which receive 
inputs from cones. P-type cells have small, concentric centre-surround 
antagonistic receptive fields. 80% of the P-type cells are also sensitive to 
light wavelength changes (i.e. colour sensitive), and have red-green or 
blue-yellow centre-surround antagonistic receptive fields.  
After arriving at the 4Cß layer of the primary visual cortex, the 
information flows to the “inter-blobs” (IB) areas of layers 2 and 3, to 
undergo further integration and processing by the complex cells at 
these layers.  
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Complex cells, in contrast to simple cells, respond to more complex sets 
of stimuli. The receptive fields of complex cells are generally larger than 
that of simple cells, as many complex cells receive inputs from several 
simple cells. In addition to being orientation specific, complex cells also 
respond to a target placed anywhere within their receptive field. They are 
therefore sensitive to changes in direction of movement, with some 
neurones showing responses to movement in the opposite direction. 
Some complex cells (end-stopped complex cells) require both the 
orientation as well as length of the stimulus to be correct to elicit a 
response. All in all, these responses allow extraction of information on 
shapes and form by the P-IB channel. 
While simple cells always receive information from one eye, some 
complex cells receive information from both eyes, whereby they have 
receptive fields in both eyes. For some, the receptive fields are identically 
situated with respect to fovea in each eye; while in others, the receptive 
field location in one eye does not correspond with that in the other eye. 
Such retinal disparity provides information on distance judgement, as 
well as depth perception (stereopsis). 
Beyond the primary visual cortex, information from the P-IB channel 
flows to the inferior temporal cortex where interactions with other cortical 
areas allow complex functions such as objects and facial recognition. 
c) Blob Channel 
Information from the parvocellular pathway is also processed in “blobs”. 
80% of the retinal ganglion cells in this channel are parvocellular in origin 
(P-type cells), while the remaining consist some of the little known 
koniocellular ganglion cells. After arriving at the 4Cß layer of the primary 
visual cortex, the information is relayed to the “blobs” areas of layers 2 
and 3. Cells in “blobs” areas are sensitive to changes in light 
wavelengths, thereby allowing colour differentiation in the inferior 
temporal cortex as the information flow proceeds there. 
With these 3 channels of parallel information processing, the primary visual 
cortex is organised into functioning units called cortical modules (see Figure 
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1.5). Each module has a surface area of 2mm x 2mm. Within layer 3, all the 
orientation specific simple cells and complex cells are grouped together in 
columns perpendicular to the cortical surface, such that all the cells in a 
particular column have the same preferred orientation (i.e. an orientation 
column). This orientation preference changes in a systematic way across the 
cortical surface, thereby encompassing the full range (360˚) of orientation with 
every 2mm of cortical surface. The 2mm x 2mm area also encompasses 16 
“blobs” from layer 3 for colour recognition. In layer 4, the primary visual cortex 
receives 2 sets of alternating inputs from left and right eye (the ocular 
dominance columns) with every 2mm of cortical surface. Collectively, each 
cortical module therefore contains all the cells required to process all aspects of 
visual information from a particular point in the visual field. Communications 
amongst cortical modules (by virtue of horizontal connections within layer 3) 
allow patterns of synchronous activity in different patches of cortical modules to 
be compared and interpreted.  
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Figure 1.5: Schematic drawing of two cortical modules, one from each eye, 
representing the ocular dominance column. Each module has a surface area of 
2mm x 2mm. Within layer 3, all the orientation specific simple cells and complex 
cells are grouped together in columns perpendicular to the cortical surface, 
such that all the cells in a particular column have the same preferred orientation 
(i.e. an orientation column). This orientation preference changes in a 
systematic way across the cortical surface, thereby encompassing the full range 
(360˚) of orientation with every 2mm of cortical surface. The 2mm x 2mm area 
also encompasses 16 “blobs” from layer 3 for colour recognition. In layer 4, the 
primary visual cortex receives 2 sets of alternating inputs from left and right eye 
(the ocular dominance columns) with every 2mm of cortical surface. 
Collectively, each cortical module therefore contains all the cells required to 
process all aspects of visual information from a particular point in the visual 
field. (Image from (“The Primary Visual Cortex by Matthew Schmolesky – 
Webvision,” n.d.)) 
From the primary visual cortex, information is believed the processed in two 
different streams (Goodale and Milner, 1992; Grover et al., 1999; Hartong et al., 
2006; Klaver et al., 1998; Klein et al., 1995; Milam et al., 1998; Norman, 2002; 
Resnikoff et al., 2004; Stone, 1992). The dorsal stream (from occipital lobe to 
parietal lobe) is involved in the processing of motion and spatial information; 
while the ventral stream (from occipital lobe to temporal lobe) is involved in the 
processing of form representation and object recognition. Interconnections exist 
between these two streams, as well as with the multimodal association areas of 
parietal lobe, whereby information from all other sensory modalities are 
assimilated to form a coherent percept. This in turn allows the human brain to 
direct attention and coordinate behavioural responses accordingly (Perry and 
Morton, 1992; Wurtz and Kandel, 2013). Further analysis and integration of 
such activities in deeper subcortical regions may be the key to functional vision. 
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1.2 Development of Visual Prostheses  
For a visual prosthesis to mimic natural vision as much as possible, it should 
ideally achieve the following steps: 
1. Transformation of electromagnetic light wave energy into electrical 
impulses to set up action potentials in visual pathway neurones; 
2. Visual processing to allow accurate presentation of information to the 
visual cortex and beyond for interpretation; 
3. Completion of the above functions in “real-time” in order to allow 
accurate assessment of spatial-temporal relationships of the visualised 
scenes; 
4. Coupling of the prosthetic vision with the subject’s eye movement to 
allow integration with proprioception and vestibular reflex, so the subject 
can accurately localise the visualised scene in relation to oneself. 
5. The prostheses must also be made of biocompatible material with 
minimal toxicity and damage to the surrounding tissues despite 
prolonged stimulation. 
The first documented method of external stimulation to elicit a visual response 
was by direct stimulation of the visual cortex with electric currents. As early as 
1874, surgeons have been aware of the fact that electrical stimulations of the 
human brain could produce physical or “pschophysical” effects (Bartholow, 
1874). Foerster (Foerster, 1929) and Krause & Schum (1932) (Krause et al., 
1932; Stingl et al., 2013b) were the first to expose the occipital cortex and found 
that by stimulating a focal point on the occipital pole electrically, the subject saw 
a small spot of light which was localised in space. This reproducible visual 
phenomenon in response to direct electrical stimuli is known as a phosphene. 
Krause & Schum also showed that phosphenes could be elicited in a patient 
who had lost vision more than eight years previously from a gunshot wound to 
the optic radiation. This finding suggested that the adult visual cortex is capable 
of retaining some function despite prolonged deprivation of visual input. 
Hodgkin and Huxley first described the electrical nature of signal propagation 
along all nervous systems by the means of action potentials in 1952 (Hodgkin 
and Huxley, 1952; Mokwa et al., 2008; Roessler et al., 2009). During electrical 
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stimulation of any nervous tissue with an external electrode, injection of 
electrical charges creates a localised depolarisation, activating the voltage-
gated ion channels in the nearby nervous cell plasma membrane. Influx of 
sodium (Na+) ions ensue, resulting in the opening of more Na+ channels and 
delayed opening of potassium (K+) channels for K+ ions outflux to set up and 
complete an action potential cycle. This in turn depolarises the adjacent area of 
plasma membrane and the sequence of Na+/K+ ions movements repeat to allow 
propagation of the action potentials along the axons.  
As voltage-gated ion channels are ubiquitous in all excitable tissues, electrical 
stimulation could theoretically be applied to anywhere along the visual pathway 
to elicit phosphenes. Over the past few decades, visual prostheses stimulating 
various sites along the visual pathway have been developed by different 
research groups including: the visual cortex, thalamus, optic nerve head and the 
retina (see Figure 1.2). Of these, development of retinal prostheses is the most 
advanced, followed by cortical prostheses. 
Since propagation of the elicited signals requires normal functioning of the 
downstream pathway, the more distal the point of prosthetic stimulation, the 
greater the proportion of the visual pathway needs to be intact. Retinal 
prostheses could therefore only benefit patients in whom the outer retina is 
damaged with preservation of the rest of the visual pathway; while at the other 
end of spectrum, cortical prostheses could potentially benefit patients whose 
entire visual pathway is damaged but still have intact visual cortex function.  
1.2.1 Cortical Prosthesis 
The first ever visual prosthesis developed was a cortical prosthesis implanted 
by Brindley et al. in 1968, whereby the stimulating electrodes were placed 
directly on the primary visual cortex of a patient (Brindley and Lewin, 1968; 
Roessler et al., 2011). It consisted of an intracranial component of 80 platinum 
electrodes implanted over the calcarine and neighbouring cortex (see Figure 
1.3). This intracranial implant was in turn connected to an extracranial 
component consisting of 80 radio receivers, which were secured to the skin 
beneath the pericranium. 
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To activate the electrodes, the patient had to wear a helmet containing 80 radio 
transmitters, corresponding to each of the 80 extracranial receivers. By 
selectively transmitting radio frequency pulses to individual receivers, individual 
intracranial electrodes could be activated. Brindley et al. demonstrated that 
while some electrodes produced single discrete phosphenes when activated, 
some gave rise to “a pair of points”; others also gave rise to “rows of three 
points” or “clusters of ten or more dim points”. Such diverse and ill-understood 
patterns of visual response to direct electric stimuli reflect the complexity of 
visual processing prior to the visual cortex, and the challenges we need to 
overcome to decipher this neural code before we can present comprehensible 
visual information to the visual cortex to gain useful vision. 
 
Figure 1.6: Skull x-ray of the patient implanted with the cortical prosthesis by 
Brindley et al. Eighty intracranial platinum electrodes were implanted over the 
calcarine and neighbouring cortex, which were in turn connected to 80 
corresponding extracranial radio receivers, embedded under the pericranium. 
(Image from (Brindley and Lewin, 1968)) 
The next major step in cortical prosthesis development came with the 
development of the “Dobelle eye” by the late Dr. William H. Dobelle’s team. 
Dobelle et al. developed a platinum foil of 64 superficial cortical electrodes, 
each electrode connected by a wire to a connector contained in a carbon 
percutaneous pedestal (Dobelle, 2000; 1998; Dobelle et al., 1974; 1979). The 
patient wore a pair of sunglasses which had a mini-television camera built in. 
The image captured by the camera was transmitted to a sub-notebook 
computer either via cable or wirelessly via radio-frequency (RF) telemetry. Once 
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the visual image was processed by the sub-notebook computer, electric 
stimulation signals were sent to the implanted cortical electrode array via a 
micro-controller system. The first group of patients underwent surgery in the 
1970s to receive temporary implants for a few days. Permanent electrode 
arrays were then implanted in 5 patients between 1974 and 1978. Two of the 
patients had their implants removed after 3 months and 14 years respectively, 
while the remaining 3 retained their implants for more than 20 years to date 
without infection or other complications. The Dobelle eye allowed previously 
blind patients to recognise 6-inch characters at 5 feet (approximately 20/1200 
visual acuity). However, due to the density of neural pathways at the visual 
cortex, overlapping areas with uncontrolled numbers of phosphenes were 
observed with stimulation of each electrode (Henderson et al., 1979). Large 
electrodes also caused pain and occasionally acted as epileptic foci, resulting in 
partial seizures. Moreover, apart from the foveal region, the rest of the visual 
field project to areas of primary visual cortex lying deep within the calcarine 
fissure. To stimulate those neurones, higher stimulation charges are required, 
which may lead to further discomfort and damage to the underlying tissues.  
To overcome these problems with superficial cortical electrodes, intracortical 
penetrating electrodes were devised, to allow for higher density and better-
localised stimulation with finer electrodes. One group working on this area is the 
University of Utah research group led by Professor Normann (Normann et al., 
2009). They devised a 100 electrode array 4 x 4 mm in size, with each 
electrode 0.4mm apart, termed the “Utah Electrode Array (UEA)” (see Figure 
1.4). A scanning electron micrograph of UEA showed that the electrodes are 
essentially multiple silicon spikes, each 1.5mm in length, allowing them to reach 
and stimulate the 4Cβ layer of the visual cortex, the major input layer for the 
parvocellular pathway from LGN. 
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Figure 1.7: Scanning electron microgragh of the Utah Electrode Array (UEA). It 
contains 100 microelectrodes over an area of 4mm x 4mm. Each electrode is 
1.5mm in length, separated from each other by 0.4mm. The length of the 
electrode allows penetration into and direct stimulation of the 4Cβ layer of the 
visual cortex. (Image from (Normann et al., 2009)) 
Experiments on primates have shown that this device is capable of producing 
phosphenes. However, concerns on the safety of long term stimulation, and 
accurate mapping of phosphenes to spatial orientation of stimuli need to be 
investigated before useful prosthetic vision could be achieved by cortical stimuli.  
1.2.2 Thalamic Prosthesis 
The LGN of the thalamus, being the first major synaptic relay centre of the optic 
nerve, has been explored as potential stimulation site. Potential patients include 
those suffering from end-stage glaucoma.  
Experiments on Wistar rats (Panetsos et al., 2009) and pigs (Choi et al., 2014) 
showed that it is possible to elicit comparable responses in the visual cortex to 
that driven by natural visual stimuli, by electrically stimulating the animals’ 
thalami. Further experiments on trained macaque monkeys showed that 
behaviourally, they responded to localised electrical stimulation of the LGN in 
the same manner as to a focal visual target, by making saccadic eye 
movements to the target. This indicates that focal electrical stimulations of the 
LGN can produce focal visual precepts in the visual field predicted by 
retinotopic arrangement within the LGN (Pezaris and Reid, 2007; Velikay-Parel 
et al., 2009). 
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However, due to the relative inaccessibility of the thalamus as a subcortical 
structure compared with the other more anatomically superficial sites, 
development of thalamic prostheses has been limited to animal experiments. 
1.2.3 Optic Nerve Prosthesis 
Optic nerve prosthesis can potentially benefit patients who have a damaged 
retina, such as diabetic retinopathy and inoperable retinal detachment. Three 
groups lead research in this field: the Université Catholique de Louvain 
(Brussels, Belgium), the Osaka University of Japan, and the Chinese Project for 
Sight (C-Sight) at Jiao-Tong University in Shanghai. 
a) Université Catholique de Louvain  
Two prototypes of optic nerve prostheses have been developed by this 
group. The first prototype was developed over 2 phases: the 
Microsystems-Based Visual Prosthesis (MiVip) project, from 1996 to 
2000, culminating in the implantation of a self-sizing, 4 contact-electrode 
spiral cuff (designed by (Naples et al., 1988; Velikay-Parel et al., 2010) 
around the optic nerve, in a 59-year-old patient with end-stage RP in 
1998. This prosthesis was implanted intracranially, through a pterional 
transsylvian approach. Phosphene perceptions were reliably reported 
and their locations corresponded to the expected quadrant of the visual 
field according to the point of optic nerve contact. Of all the phosphenes, 
37% were reported to be “moving”. Moreover, attributes of the 
phosphenes elicited by the same contact electrode could be varied by 
changing pulse duration, current level or train frequencies (Chow et al., 
2001; Veraart et al., 1998). A further operation was carried out in 2000 to 
implant a neuro-stimulator with an antenna for RF telemetry into the 
parietal cranium of the same patient (Chow et al., 2010; Delbeke et al., 
2002).  
The second phase, the Optic Nerve Visual Prosthesis (OPTIVIP) project 
(from 2000 to 2005), focused on studying the visual sensations produced 
by optic nerve stimulation. By altering the amplitude, duration and 
frequency, and number of pulses in stimulus trains, 109 reproducible 
phosphenes have been identified. The patient could perform recognition 
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tasks of 45 simple patterns with an accuracy of 63% and orientation 
discrimination of an L shaped pattern with 100% accuracy after training 
(Veraart et al., 2003).  
More recently, a second prototype was implanted in a 68-year-old 
endstage RP patient in 2006 (Brelén et al., 2006). This prototype allowed 
intra-orbital implantation of the spiral nerve cuff via a medial canthotomy 
approach with detachment of the medial rectus and lateral canthotomy, 
thereby negating the need for craniotomy (i.e. less invasive), and greatly 
reduced the surgical as well as recovery time (see Figure 1.8). Results of 
preliminary assessments suggested that this intraorbitally implanted cuff 
electrode could work as well as the intracranially implanted electrode in 
the 1998 patient. As of 2009, the group is no longer active. 
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Figure 1.8: a) Schematic drawing illustrating the medial canthotomy approach of 
spiral optic nerve cuff implantation, negating the need for craniotomy and 
thereby greatly reducing the surgical and recovery time. The optic nerve cuff 
electrode was wrapped 2½ turns around the nerve and the cable was brought 
out underneath the globe. b) Coronal section of a CT head scan showing the 
cable leaving from underneath the globe, before running subcutaneously to the 
stimulator box embedded in the right parietal cranium (not shown). (Image 
modified from (Brelén et al., 2006)) 
a) Osaka University  
The Osaka University Group first implanted a 3-wire electrodes system 
(AV-DONE) to directly stimulate the optic nerve in a blind RP patient with 
no light perception in 2009 (Sakaguchi et al., 2009).  In this patient, 
phosphenes could be elicited by electric stimulation through each 
electrode and the phosphenes ranged in size from a match head to an 
apple. The phosphenes were also localised depending on the position of 
electrode used for stimulation, indicating that a useful visual prosthesis 
may be developed using more electrodes mapped to correct spatial 
orientation of the visual images.  
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More recently, a newer prototype composed of 7 wire stimulation 
electrodes, one return electrode, one manipulation rod and a cylindrical 
silicone board has been developed (see Figure 1.9). This device has 
been implanted in rabbits’ eyes to explore the surgical techniques 
(Sakaguchi et al., 2012). To implant the device, it was first inserted into a 
vitrectomised eye via a 7mm pars plana sclerostomy using a trocar. The 
device was then manipulated with vitreoretinal forceps in the vitreous 
cavity and it was shown that the 7 wire electrodes could be inserted intra-
papillarily into the optic disc head in one single move. Electrical 
stimulation via the electrodes of this implant showed evoked potentials 
(EEPs) at the visual cortex. The smooth experimental surgical 
implantation of this new device is an encouraging step towards human 
trials.  
 
Figure 1.9: Photograph of the newer AV-DONE optic nerve prosthesis 
prototype. It consisted of 7 wire stimulating electrodes, one return electrode, 
one manipulation rod and a cylindrical silicone board (2.0 mm in diameter). The 
arrow points to the stimulating electrode, while the arrowhead indicates the 
manipulation rod. During the implantation surgery, the 7 wire electrodes were 
inserted intra-papillarily into the optic disc head after vitrectomy. This device has 
been implanted in rabbits’ eyes to explore the surgical techniques. (Image from 
(Sakaguchi et al., 2012)).   
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c) C-Sight (Chinese Project for Sight) Group 
Set up in 2004, the C-Sight Group at Jiao-Tong University at Shanghai 
developed a 13-channel, platiniridium penetrating microelectrode array to 
optimise contact and localisation with the optic nerve (see Figure 1.10). A 
micro-camera was designed to be implanted into the lens capsule 
(powered by a solar panel in front of the iris) to provide coupling of 
camera movement to eye movements. Both the micro-camera and the 
cuff electrode were connected to an external image-processing unit. 
Experiments have been carried out in rabbits and cats to determine the 
best stimulation position of electrodes on the optic nerve (“Special 
Senses,” n.d.). 
  
Figure 1.10: Photograph of the 13-channel, platiniridium penetrating 
microelectrodes for the optic nerve prosthesis, developed by the C-Sight Group 
at Jiao-Tong University at Shanghai (Image from (Chai et al., 2008)).  
1.2.4 Retinal Prosthesis 
While the development of thalamic prostheses is still in the animal experimental 
stage, and that of the cortical and optic nerve prostheses are in early acute 
human studies phase, research into the development of retinal prostheses has 
made the most progress.  
There are many reasons for this and they can be best summarised as:  
a) greater accessibility at lower surgical risk than the intracranial visual 
pathways;  
b) straightforward monitoring of the device by direct visualisation; and  
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c) potentially predictable and reproducible retinotopy by applying 
stimulation at a pre-processing site. 
With the advent of modern vitreoretinal surgical techniques, access to the retina 
and the subsequent implantation of stimulating electrodes are comparatively 
easier than other sites of implantation. This is exemplified by the widespread 
implantation of the Argus® II System in many countries by many different 
surgeons over a relatively short period, at a level of surgical morbidity 
acceptable to regulators (Humayun et al., 2012; Rizzo et al., 2014). Despite the 
relative accessibility and safety discussed here, implantation still requires 
advanced vitreoretinal surgical skills. Complications and problems were also 
easily identified during the Argus® II phase I/II clinical trials due to the ability to 
directly visualise the device (Humayun et al., 2012).  
Two other advantages of a retinal prosthesis are: predictable retinotopy, and 
stimulation of the visual system at a site before significant processing of the 
signal has occurred. Brindley and Lewin (1968b) have demonstrated that 
although stimulation of cortical electrodes gave rise to phosphenes in locations 
in agreement with the classic Holmes’ retinotopic map of the visual cortex 
(Holmes, 1945), many of the phosphenes were complex and non-discrete in 
nature. This was thought to be due to the fact that there was significant 
processing and integration carried out in the pre-cortical visual pathway. This 
was borne out with the discovery of organisational processing in the retina, as 
demonstrated by the antagonistic centre-surround responses of the retinal 
ganglion cell (RGC) receptive fields to light stimuli, as previously discussed in 
Section 1.1.1. Furthermore, as there are approximately 120 million 
photoreceptors and only 1.5 million ganglion cells, many photoreceptors 
converge onto a single bipolar cell especially at the periphery, with further 
convergence taking place from the bipolar cells to RGCs (Kolb, 2003).  In 
contrast, within the macular region of the retina, the ratio of photoreceptor: 
bipolar cell: RGC approaches 1: 1: 1, with minimal convergence. It is thus 
envisaged that focal electrical stimulating patterns with a multi-electrode array in 
the macular region would more likely manifest retinotopic correlations along the 
visual pathway. There is, however, a particular limitation to this rationale, due to 
the arcuate displacement of axons and the piling up of ganglion cell bodies 
when approaching the fovea, if epiretinal stimulation is carried out. 
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The retina being a viable site for electrical stimulation to generate phosphene 
perception was first demonstrated by contact lens electrode stimulation in RP 
patients (Potts et al., 1968; Potts and Inoue, 1970; 1969; Zrenner et al., 2011). 
Currently, there are two main anatomical approaches to stimulating the retina: 
the epiretinal approach – whereby the multi-electrode array is placed on the 
retinal surface in direct contact with the nerve fibre layer; and secondly the 
subretinal approach – whereby the array is placed underneath the retina and is 
in closest contact with the bipolar cells. Both approaches have achieved reliable 
phosphene activation and have shown comparable functional improvements in 
human clinical trials.  
The Argus® II retinal prosthesis system uses the epiretinal approach, as do the 
2 German consortium groups who developed EPI-RET3 (Menzel-Severing et 
al., 2012; Wilke et al., 2011) and Intelligent Retinal Implant System (IRIS) 
(Besch et al., 2008; Velikay-Parel et al., 2009; 2013). The subretinal approach 
is used in the Artificial Silicon Retina (ASR) developed by the Optobionics 
(Chow et al., 2005; “Neuroscience for Kids: the visual pathway Interesting 
information on what can happen if there's any damage | Teaching: Physics - 
Vision | Pinterest | Pathways…,” n.d.; Wurtz and Kandel, 2013), and the alpha-
IMS device (Stingl et al., 2013b; Wilke et al., 2011) developed by the German 
group headed by Professor E. Zrenner. The alpha-IMS obtained the CE mark in 
2013.  
As the functional outcomes of the Argus® II retinal prosthesis system is the 
main theme of this thesis, a detailed introduction and analysis of the system will 
be discussed in the following chapters. The other retinal prosthesis systems 
currently available clinically or undergoing human clinical trials are briefly 
outlined as follows: 
a) EPI-RET3, EpiRet GmbH 
Research into the development of EPI-RET3 started in 1995 as part of 
the German EPI-RET implant project. Subsequently, the implants came 
under the development of EpiRet GmbH, a German company founded in 
2007. At present, 11 different partners from industry and universities are 
involved in the development of the third generation implant, the EPI-
RET3. The EPI-RET3 consists of an external unit (with a video-camera 
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and an external coil mounted onto a glasses frame), and an internal unit 
(see Figure 1.11).  
 
Figure 1.11: Schematic drawing of the EPI-RET3 system. Visual images 
captured by an external video camera are relayed to an external processing unit 
and transmitted back to an external transmitter coil situated at the side of the 
glasses frame. By RF telemetry, the external coil transmits the visual data and 
power to the internal receiver coil situated within the capsular bag. The final 
step of information rely consists of conversion of RF into electric pulses to 
stimulate the retina via the microelectrode array. (Image from (Roessler et al., 
2009)) 
The internal unit of the EPI-RET3 implant has a micro-coil buried in a 
flexible substrate and all the electronic components are integrated into a 
compact package similar in dimension to that of an intraocular lens 
(Mokwa et al., 2008; Roessler et al., 2009). This compact internal unit is 
then inserted into the capsular bag or sulcus area like an intraocular lens, 
which is further stabilised by 2 trans-scleral 10/0 sutures. Once in situ, 
the electrode array (consisting of 25 electrodes connected to the micro-
coil via a flexible cable) pierces through the posterior capsule to exit the  
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capsular bag and extends to rest on the retinal surface, where it is 
stabilised on the epiretinal surface by gold tacks (see Figure 1.12).   
 
Figure 1.12 An illustration of the Epi-Ret3 internal unit with magnified views of 
the receiver module composed of microcircuits and a micro-coil (left), and that 
of the stimulating electrode array (right). The 3 C-shaped opening close to the 
electrode array is for insertion of retinal tacks to stabilise the electrode array 
onto the retinal surface. The total length of the system is 40 mm. (Image from 
(Roessler et al., 2011)) 
A distinct advantage of this design is that all the components of the 
internal unit are intraocular, without any trans-scleral wire connections 
between the intraocular electrode array and the usually more superficially 
located internal coil and circuitry (as seen in Argus® II retinal prosthetic 
system). This potentially minimises the risk of conjunctival erosion and 
infection, and is dubbed the “wireless retinal implant system”. 
The first clinical trial for the EPI-RET3 retinal prosthesis started in 2007, 
when 6 patients registered as legally blind from RP were temporarily 
implanted with the device for 4 weeks before it was removed. The 
patients were tested with the implants activated on day 7, 14, and 27 
post-operatively. All the patients reported perceiving phosphenes such 
as dots, arcs or lines and the required stimulation threshold were found 
to be low (Menzel-Severing et al., 2012; Stingl et al., 2013a).  
b) IRIS® II, Pixium Vision 
The earliest prototype of this device was manufactured by a Swiss 
company founded in 1998, the IMI Intelligent Medical Implant AG (Hornig 
et al., 2007a). It has an external unit consisting of a video camera, 
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processing unit and external coil, and an internal unit consisting of the 
receiver internal coil, processing circuitry and stimulating electrode array, 
which is attached to the epiretinal surface by a Titanium tack. The 
electrodes are made of polyimide with gold tracks. 
A unique feature of this system is that it has a built-in “learning algorithm” 
in its image processing. “Learning” is achieved by fixing some of the filter 
parameters while changing others as images are presented to the test 
subject. Each time, the subject has to choose if one image is better than 
the other with the changing parameters. Simulations on normally sighted 
people have shown that after about 80 iterations of preferential choice, 
the presented image object can be recognised. In this way, fine-tuning of 
the parameters by each subject is simplified (Eckmiller et al., 2005).  
From 2005 to 2006, a 50-electrode system was temporarily (up to 13 
weeks) implanted into 4 patients in a clinical trial. The patients were able 
to discern simple lines and spots, as well as detect horizontal 
movements (Hornig et al., 2007b). 
In 2007, a multi-centre clinical trial (ClinicalTrials.gov Identifier: 
NCT00427180) began for the implantation of the IRIS (Intelligent Retinal 
Implant System) into RP patients. This was a 61-electrode prototype 
system with visual field of up to 40p. The 4-month report of the first IRIS 
patient was published in 2009, whereby the patient reported reliable 
visual percepts with stimulation (Velikay-Parel et al., 2009). In 2010, 
further report showed that the electrodes in IRIS have stable thresholds 
with prolonged active stimulation (Velikay-Parel et al., 2010).  
Lately, development of IRIS has been taken over by Pixium Vision, a 
French company. The next generation prototype, known as IRIS® II 
consisting of 150 electrodes, has recently started phase I clinical trial 
(ClinicalTrials.gov Identifier: NCT02670980) in multiple centres across 
Europe, and obtained CE mark in July 2016. 
c) Artificial Silicon Retina (ASR), Optobionics 
The Artificial Silicone Retina (ASR) is the first ever retinal prosthesis to 
be devised and patented in the 1980s by the Optobionics Corportaions. 
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This device is essentially a silicone microchip with microphotodiode-
array, 25 µm in thickness and 2 mm in diameter. It is composed of 5000 
micro-photodiodes (each linked to its individual electrode), and has been 
shown to be capable of converting light electromagnetic waves into 
electric impulses (photovoltaic) to stimulate the retinal ganglion cells in 
cats when inserted subretinally, akin to the natural function of the 
photoreceptors (Chow et al., 2001). 
Figure 1.13: Montage of Artificial Silicon Retina (ASR) with different 
magnifications. Fundus photograph of ASR in subretinal space (top left, 23X), 
explanted ASR device (top right, 25X), light micrograph of individual ASR pixels 
(bottom left, 500X), high-angle SEM of pixels (bottom right, 1650X) (Image from 
(Chow et al., 2010)). 
The first human clinical trial was carried out between 2000 and 2001 on 6 
patients legally blind from retinitis pigmentosa. While the implants had 
good safety profile with no reported adverse event for up to 18 months in 
all the 6 patients , the visual outcome and the proposed beneficial effects 
were more controversial. Three out of the 6 patients showed an  
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improvement in visual acuity as measured by the EDTRS chart, but only 
one patient had an improvement in the automated visual field test. There 
were also unexpected areas of visual improvement distant to the implant 
site. The authors attributed this observation to the protective or rescue 
effects of the neurotrophic factors released by the retina as a result of 
electric stimulation from the implant, a hypothesis that is supported by 
evidence from a study performed on Royal College of Surgeons rats 
(Pardue et al., 2006). However, it has subsequently been shown that 
photovoltaic energy from microphotodiodes alone was insufficient to 
activate the dystrophic retinal cells in humans to transmit useful visual 
information (Zrenner et al., 1999). Nevertheless, further implantations of 
the ASR were carried out in human subjects in 2010 to study the 
neurotrophic effect and the long term outcomes of the device . 
d) Alpha-IMS, Retina Implant AG 
Unlike the epiretinal prostheses described above which receive visual 
input from an external video-camera system, the alpha-IMS implant (and 
similarly in ASR) receives visual input directly. By strategically placing a 
light-sensitive, photovoltaic micro-photodiode array (MPDA) subretinally 
(preferably at the macula), the micro-photodiodes convert 
electromagnetic light waves directly into electrical energy, thereby 
directly replacing the function of photoreceptors. In terms of image 
generation, the alpha–IMS makes use of the patient’s own optical system 
within the eye, which naturally focuses light onto the retina as images.  
However, one serious limitation of using a photodiode based system was 
already shown in ASR (Chow et al., 2005; 2003). These photodiodes 
were not as efficient as natural photoreceptors at converting 
electromagnetic light waves into electric impulses, and as such could not 
generate adequate electrical charges to elicit action potentials to 
stimulate the remaining visual system. To overcome this problem in the 
design of their prototype, Zrenner et al. at Retina Implant AG supplied 
each photodiode with an external electrical power connection, so that the 
signals generated by the photovoltaic micro-photodiode array could be 
amplified at the individual photodiode level (Zrenner et al., 2011; 1999). 
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The first generation of Retinal Implant AG devices were temporarily 
implanted in 11 subjects in 2005 in a clinical trial (clinicaltrials.gov 
identifier: NCT00515814) (Wilke et al., 2011). The device consisted of a 
16 electrode-array for direct electrical stimulation of the retina, as well as 
the photovoltaic microphotodiode array (MPDA). The implant was placed 
subretinally and powered externally by a percutaneous wire, which exited 
in the retro-auricular region of the subject as a connection plug (Besch et 
al., 2008). Out of the 11 subjects, 3 subjects did not report any visual 
perception with electrical stimulation. This was due to local non-perfusion 
of the retina in 2 subjects, and device failure in 1 subject. For the 
remaining 8 subjects, 5 subjects could discern simple patterns such as 
lines and letters, and 4 of whom could detect direction of motion. Two 
subjects could also read large letters (Wilke et al., 2011). Although visual 
function improvement was demonstrated, the implant was removed from 
all the subjects after a few weeks as per protocol (except in one subject 
who declined removal) and no long-term durability data is available from 
this trial (Besch et al., 2008; Nakauchi et al., 2006). 
Subsequently, a second-generation device featuring some design 
improvement, termed the alpha-IMS, has been developed. The alpha-
IMS consists of an internal and an external unit. The internal unit has 3 
components (see Figure 1.13):  
a) a subretinal portion (ideally placed subfoveally), 
b) an extraocular portion (through the episclera and lateral orbital wall); 
c) a subcutaneous portion (from the lateral orbit to retroauricular region). 
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Figure 1.14: Illustration showing the internal unit of the alpha-IMS implant. It 
consists of a 3×3 mm microchip (magnified in bottom image). Within the 
microchip, there are 1,500 microphotodiodes (further magnified view in bottom 
right), each of which is connected to an electrode for signal amplification. 
(Image modified from (Stingl et al., 2013c)) 
The subretinal portion of the device is composed of 1500 MPDA each 
connected to an amplifier and its own Titanium nitride electrode. Each 
microphotodiode functions independently from its neighbours like a pixel, 
and the amplification is determined by the intensity of the light received 
by the microphotodiode. Ideally, the 3x3 mm microchip implant would be 
placed subfoveally or as close to fovea as possible to allow optimal 
stimulation of the MPDA by the incoming light, giving a visual field of 
11°x 11°.  
The extraocular portion of the device consists of a silicone cable 
connecting the MPDA to the internal coil, and has a rather tortuous 
course. It first leaves the eye transchoroidally to reach the lateral orbital 
rim, before tunnelling underneath the temporalis muscle  (the 
subcutaneous portion) in the subperiosteal space to reach the retro-
auricular space where it ends as an internal coil buried subdermally (see 
Figure 1.14).  
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Figure 1.15: Schematic drawing of the course of the extraocular and 
subcutaneous portion of the Alpha-IMS implant. (Imaged modified from (Stingl 
et al., 2013c)) 
 
The secondary coil acts as a bridge of connection between the internal 
unit and the external unit. The external unit of the alpha-IMS device 
essentially consists of an external power source which terminates in a 
primary coil (see Figure 1.15).  
 
Figure 1.16: The external unit of alpha-IMS retinal implant. It consists of an 
external power supply, which terminates as the primary coil. (Image from 
(“alpha-IMS of Retina Implant AG,” n.d.)) 
By holding the primary coil to the retroauricular region, it becomes 
magnetically attached to and held in place by the internal coil. The 
external power supply is then transmitted across the primary coil to the 
secondary coil by electromagnetic induction. This induced electric energy 
in turn amplifies the MPDA and activates the retina (see Figure 1.16). 
 Page 57 
 
Figure 1.17: Photograph showing the primary coil of the alpha-IMS retinal 
prosthesis being held in place magetically by the subdemral secondary coil in 
the retro-auricular region. External electrical power is transfered from the 
primary coil to the secondary coil by electromagnetic induction to amplify the 
electric signals generated by the microphotodiode array. 
A multi-centre phase II clinical trial with alpha-IMS started in May 2010 
(ClinicalTrials Identifier: NCT01024803), with the ophthalmology 
department of the John Radcliffe Hospital at Oxford and King’s College 
Hospital in London amongst the trial centres. The first patient in the UK 
received the implant in March 2012. A preliminary report of the first 10 
patients showed favourable results. One patient had irrevocable 
functional loss due to damage to the inner retina. Of the remaining 9 
patients, 7 could localise light and 5 could detect motion (with angular 
speed of up to 35 degrees/s). Six subjects had measurable gratings 
acuity (up to 3.3 cycles / degree), while 2 had measurable visual acuity 
with Landolt C-ring (equivalent to Snellen visual acuity of 20/546 or 1.43 
logMAR). In addition, 4 subjects showed statistically significant 
improvement in the recognition and localisation of objects (p < 0.05). 
Three of the subjects were also able to read large letters in an 
alternative-force-choice test (Stingl et al., 2013c; Zrenner et al., 2011). 
A further 12-month interim report on 29 patients showed that 21 patients 
had improvement in performing activities of daily living and in mobility. 
There were also initial significant improvement (p < 0.05, Wilcoxon test) 
in detection, localisation and recognition of geometric shapes with the 
device switched on versus off at 3 months post-operative visit. 
Unfortunately, this improvement was not sustained and the difference in 
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performance no longer achieves statistical significant (p > 0.05) at the 6 
months post-operative visit. Four of the patients could not perceive the 
light with the subretinal implant due to reasons including: intra-operative 
optic nerve trauma, post-operative retinal oedema, retinal ischaemia over 
the area of the MPDA and technical failure of the device. On the other 
hand, 4 patients were able to perform standardised visual acuity testing 
using contrast reversal Landolt C- rings, and achieved equivalent acuities 
of 20/2000, 20/2000, 20/606 and 20/546 at the 3 months post-operative 
visit (Stingl et al., 2015). The alpha-IMS received its CE marking in July 
2013. 
A summary of all the various visual prostheses currently available for clinical 
use or undergoing human clinical trials is shown in Table 1.1. A comparison of 
all the above-mentioned retinal prostheses in terms of their stimulation 
approach (epiretinal versus subretinal), clinical trial outcomes, visual function 
assessment and long-term biocompatibility in human clinical trials is shown in 
Table 1.2.  
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1.3 Future Development & Other Treatment Modalities 
Prosthetic vision is a rapidly expanding field with multiple groups of researchers 
worldwide developing new devices to improve the quality of vision, as well as 
improving the safety and efficacy of data transmission in long-term use. 
Moreover, different ways of neurotransmission (other than electric stimulation) 
have also been explored. In the following sections, we will look at a few 
prominent research groups whose devices are likely to impact the field in the 
near future, as well as groups developing other treatment strategies for the 
treatment of end-stage retinal degeneration.  
1.3.1 Bionic Vision Australia Group 
The Bionic Vision Australia is a consortium of researchers formed in March 
2010 after receiving a $42 million grant from the Australian Research Council in 
December 2009. Led by Professor Anthony Burkitt, the consortium brings 
together a multidisciplinary team with the aim to develop two different types of 
retinal prostheses: 
a) Wide-View device;  
b) High-Acuity device. 
a) The Wide-View Device 
The aim with Wide-View device was to improve the mobility and 
navigational function of the patients by improving their field of vision 
(“Wide-View device - Bionic Vision Australia,” n.d.). The ultimate goal is 
to produce a 98-channel electrode array, with the electrodes arranged in 
a unique hexagonal mosaic pattern. Each hexagonal unit is a “stimulating 
unit” composed of 7 electrodes: a central stimulating electrode 
surrounded by 6 guarding electrodes. The main function of the guarding 
electrodes is to contain the charge spread of the central stimulating 
electrode, therefore reduce inference between stimulating units.  Any of 
the seven electrodes in one hexagon can be serially employed as a 
stimulating electrode and all other surrounding electrodes form the new 
guarding electrodes. This hexagonal stimulation technique has been 
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shown to produce discrete, localised retinal activation as recorded at the 
visual cortex of cat retina (Wong et al., 2007). Encouraged by the results 
from the Seoul National University group (see section 1.3.2), the Bionic 
Vision Australia researchers have chosen to place their implants supra-
choroidally (Wong et al., 2008). 
On 3rd September 2012, the first prototype (consisting of 24 electrodes) 
of this device was successfully activated in the first patient, who received 
surgical implantation of the device a month prior. The clinical trial 
completed recruitment in October 2014, with a total of 3 patients. During 
the 2-year study, the supra-choroidal implants were reported to be stable 
with no clinical sign of movement or migration, as well as being safe with 
no unexpected device-related serious adverse events. The group also 
reported improvement in the patients’ ability to see light and shapes, as 
well as navigation. Further psychophysical testing and analysis 
performed on these patients will allow improvement of the design and 
processing algorithm (“Bionic Vision Australia successfully completes 
clinical trial of retinal implant in retinitis pigmentosa : Bionic Vision 
Australia,” n.d.). 
b) The High-Acuity Device 
In contrast, the High-Acuity device aims to provide functional central 
vision to assist with tasks such as face recognition and reading large 
print. It is composed of a 1024 electrode array made of diamond material 
and is to be inserted epiretinally (“High-Acuity device - Bionic Vision 
Australia,” n.d.).  
As of 31st December 2016, Bionic Vision Australia has ceased operations, and 
the technologies developed thus far by the group are being commercialised by 
Bionic Vision Technologies Pty Ltd (BVT) (see www.bionicvis.com). 
1.3.2 Suprachoroidal Implant – Seoul National University Group 
The Seoul National University researchers first developed a pillar shaped 108-
channel electrode array which are 40µm in height with a mushroom-shaped 
heads (Kim et al., 2008).These electrode arrays were implanted 
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suprachoroidally in rabbit eyes and successfully stimulated rabbit retina to show 
proof of concept. More recently, they have developed a 7-channel polyimide 
electrode system for long term implantation to assess safety and 
biocompatibility and have established polyimide is safe for long term 
implantation (Zhou et al., 2008). The main advantage of a suprachroidally 
placed device is the theoretical superior safety profile for electrical stimulation, 
as no neural tissue is in direct contract with the electrodes.  As a result, the safe 
electrical stimulation charge for a suprachoroidal device is deemed to be 3 
times that of a retinal device (Nakauchi et al., 2006).  
1.3.3 Photosensitive Suprachoroidal Implant – NIDEK Co. Ltd & 
 Osaka University 
The Japanese ophthalmic equipment company teamed up with the University of 
Osaka and the Nara Institute of Science and Technology to develop a 
suprachoroidal transretinal stimulation device in 2001.  
The implant technology employs several chips, each with 9 electrodes mounted 
onto a flexible polyimide substrate. A 576-channel electrode array would entail 
64 chips mounted onto a flexible polyimide substrate (Ohta et al., 2007). A more 
recent improvement on the device involves incorporation of a light-sensing 
circuit within the chips, to guide the stimulus properties, comparable to the use 
of multiphotodiode array in Retina Implant AG company’s alpha-IMS implants. 
In vivo experiments in rabbits have been carried out and showed feasibility of 
transretinal stimulation to elicit visual responses. However, further development 
in encapsulation and long-term stability of the device have to be established 
before clinical application (Tokuda et al., 2009) 
1.3.4  Biohybrid Implant 
Apart from various advances in developing ever-increasing number of 
electrodes to improve the visual resolution of the prostheses, the Institute of 
Physical and Chemical Research (RIKEN) in Nagoya, Japan, has developed a 
biohybrid implant, in which the nerve cells were cultured directly onto a silicon 
chip. The nerve cells were treated with growth factors and the chip was then 
implanted either epiretinal or subretinally in animal models. The nerve cells 
were encouraged to grow towards the CNS and form synaptic connections with 
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the adjacent retinal layers, interfaced with an electro-conductive polymer as 
electrodes. As of 2009, the RIKEN team are working towards improving the 
conductivity of the polymers and biocompatibility tests and no long term data is 
yet available (Yagi, 2009). 
1.3.5 OUReP™ (Okayama University-type Retinal Prosthesis) 
Developed by the Okayama University in Japan, the dye-coupling photo-electric 
subretinal prosthesis involves incorporation of the 2-[2-[4-
(dibutylamino)phenyl]ethenyl]-3-carboxymethylbenzothiazolium bromide dye on 
a polyethylene film, and this has been shown to produce adequate electrical 
charge to evoke neural responses in the retinal cells of chick embryos from light 
waves, compared with photodiodes alone (Dobelle, 2000; 1998; Dobelle et al., 
1979; Henderson et al., 1979; Uji et al., 2005; 2006). Preliminary results of 
subretinal implantation into rats have shown that tissue reactions like apoptosis 
were negligible with only slight glial response after 1 month. Subsequent 
subretinal implantation into Royal College of Surgeons rats showed reduction of 
retinal cell apoptosis at 5 months after implantation, and maintenance of visual 
behaviour in these rats at 2 months after implantation, compared with controls 
(Alamusi et al., 2015). The dye itself was also shown to have neuroprotective 
effects, preventing retinal cell apoptosis in RCS rats with intravitreal injections 
(Liu et al., 2017). 
1.3.6 Thalamus (Lateral Geniculate Nucleus) Implant 
As the first major relay station of the visual pathway where the majority of the 
ganglion cell nerve fibres synapse, the lateral geniculate nucleus (LGN) offers 
an attractive site for electrical stimulation. It has the advantage of having a large 
surface area whereby neurones from the macular regions congregate and have 
a high retinal area to thalamus area ratio, allowing for placement of large 
number of electrodes to optimise visual resolution. The magnocellular and 
parvocellular pathways are also segregated in the LGN, allowing for separate 
stimulation of the different pathways for extraction and processing of different 
visual information. However, as the LGN is situated behind the optic chiasm in 
the visual pathway, relaying of visual images are separated along the vertical 
midline, with each LGN receiving visual information from the contralateral 
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vertical hemi-field from both eyes. A functioning LGN-stimulating prosthesis 
would therefore require bilateral stimulation to achieve a holistic visual 
presentation. There are 2 major groups currently carrying out research in this 
field: the Massachusetts General Hospital group lead by John Pezaris, and the 
Neurocomputing and Neurorobotics Reasearch Group at the Complutense 
University of Madrid in Spain. 
Pezaris et al. have shown in macaque monkeys that LGN stimulation can give 
rise to reproducible phosphenes localised in space, as exhibited by the 
consistent saccades made by the monkeys in response to electrical stimuli, 
using surgical implantation techniques similar to deep brain stimulation (DBS) 
implants in the treatment of patients with Parkinson’s disease (Pezaris and 
Eskandar, 2009; Pezaris and Reid, 2007). Panetsos et al. carried out further 
investigations mapping LGN stimulation to cortical responses at the visual 
cortex (V1) of rats and rabbits(Panetsos et al., 2009; 2011). 
Future development in containing the charge spread of electrodes within the 
LGN to improve visual resolution and establishing safety for bilateral 
implantation and stimulation of the thalamus are some of the hurdles to 
overcome before clinical trials on human subjects could be carried out. 
1.3.7 Optogenetic Retinal Prosthesis 
Researchers have genetically modified the remaining undamaged retinal cells 
(e.g. bipolar cells and ganglion cells layers) from rd1 mice by transfecting them 
with lentivirus carrying genes expressing photosensitive proteins (e.g. a 
microbial opsin channelrhodopsin ChR2), thereby rendering the remainder 
retina photosensitive (Deisseroth, 2011). This technique, known as optogenetic 
technology, is a rapidly expanding field, with more opsins becoming available. 
The first experiments showed non-specific transfection, with both ON-and OFF- 
bipolar and ganglion cell systems expressing ChR2 equally. Such non-specific 
expression could not give rise to useful visual information.  
Nirenberg et al. recently published a study whereby the visual images captured 
by video camera were first processed by applying a neural code through an 
encoder, to generate signals that would be recognisable to the brain. These 
signals were then transformed into laser light pulses to activate the 
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optogentically treated, ChR2-expressing rd1 mice retina (Nirenberg and 
Pandarinath, 2012). Promising results showed that once the visual images were 
processed with the neural code, the visual behaviours (i.e. optomotor tracking) 
of the rd1 mice improved, implying that optogenetic retina was capable of 
accurately transmitting the processed image signals to the brain. Apart from 
establishing the optogenetic technique as a viable method of retinal activation 
and signal transmission, the paper also illustrated the importance of a robust, 
accurate neural code to process the visual images for accurate visual 
interpretation, which will be discussed further in chapter 8. 
1.3.8 Gene Therapy & Stem Cell Therapy 
With the advent of cell biotechnology and increasing understanding of the 
disease pathogenesis, gene therapy and stem cell therapy have made 
substantial progress over the past 2 decades (MacLaren et al., 2016). In gene 
therapy, the aim is to transfer genes encoding therapeutic proteins into the 
affected tissues by means of viral transfection. Stem cell therapy, on the other 
hand, offers replacement of lost or damaged tissues with new cells or tissues 
generated from stem cells. 
In patients with some forms of RP and other retinal degenerative diseases such 
as choroideremia and Leber’s congenital amaurosis, whereby the causative 
genetic defects are known, targeted gene therapy appears to be a reasonable 
approach. Indeed clinical trial for RPE65-associated Leber’s congenital 
amaurosis commenced in 2007, and showed robust safety as well as functional 
improvement (Jacobson et al., 2012). More recently, clinical trials of gene 
therapy for choroideremia (MacLaren et al., 2014) and MerTK-associated RP 
(Ghazi et al., 2016) are also under the way and preliminary results showed 
good safety profiles. 
While gene therapy offers an attractive treatment option early on in the disease 
to prevent photoreceptor and hence visual loss, it is unsuitable in patients with 
advanced disease where substantial atrophy of photoreceptors, RPE and 
choriocapillaries has already occurred. In these patients, stem cell therapy 
offers the potential to replace the lost tissue and to some extent, function. At 
present, research into stem cell-derived RPE transplantation and clinical trials in 
this area have gained the most ground. The first stem cell-derived RPE 
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transplantation clinical trial involved injection of embryonic stem cell-derived 
RPE into subretinal space in patients with Stargardt disease (ABCA4 mutation) 
and atrophic AMD (Schwartz et al., 2012; 2015). More recently, a clinical trial 
involving subretinal implantation of embryonic stem cell-derived RPE patch has 
begun in Moorfields Eye Hospital, in partnership with Pfizer Inc. (“New trial for 
wet AMD,” n.d.). Lately, a Japanese research group has reported success with 
transplanting a sheet of RPE generated from induced pluripotent stem cell 
(iPSC), in to a patient with wet AMD. The iPSC was derived from the patient’s 
own skin fibroblast. Although the vision of the patient did not improve, it 
remained stable and the transplanted RPE sheets remained intact at 1 year 
(Mandai et al., 2017). Success in tissue transplantation using iPSC opens up an 
exciting arena in transplantation medicine, by reducing issues such as immune 
rejection, tissue supply and ethical concerns using embryonic-derived stem 
cells. 
Given the pluripotent nature of stem cells, with increasing understanding and 
further research in the field, transplantation of other retinal cells such as 
photoreceptors or even the entire retina, may be feasible in the foreseeable 
future. 
1.4 Aims of the thesis 
The commencement of this PhD coincided with the granting of regulatory 
approval for Argus® II retinal prosthesis to be used as a humanitarian device. 
This approval was firstly obtained in the European Economics Areas (CE mark 
in March 2011), and later on in the USA (FDA approval in February 2013). With 
increasing numbers of patients receiving the implant worldwide, data on long-
term clinical and functional outcomes become of paramount importance for 
clinicians to understand the impact of the device and advise potential patients. 
The aims of this thesis are: 
1. To examine the long-term clinical and functional outcomes in an early 
cohort of subjects implanted with the Argus® II system, from the original 
feasibility study (Clinical Trials Identifier: NCT01490827). 
2. To elucidate the characteristics of the artificial vision that is perceived 
and its long-term repeatability and reproducibility in individual subjects.  
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3. To report on the safety of performing MRI brain scans in patients fitted 
with the Argus® II retinal prosthesis system. 
4. To explore the feasibility of real-time neuroimaging using functional near 
infra-red spectroscopy (fNIRS), to monitor visual cortex activities with 
retinal stimulation in this early cohort of Argus® II subjects. 
1.5 Overview of the thesis 
Following on from this introduction, Chapter 2 provides the background to 
Argus® II retinal prosthesis system by reviewing the literature on its proof of 
concept, development, design, case selection, surgical implantation and safety 
profile.  
Chapter 3 describes a prospective study of 11 Argus® II subjects, which looked 
at their ability to identify 2D geometric shapes presented in high contrast (i.e. 
white shapes against black screen) with the use of the device. A further 
prospective study from a subset of 7 subjects was then performed to investigate 
whether this 2D shape identification could be translated into identification of 3D 
objects. 
Previously published data showed that Argus® II subjects were able to locate 
and point to white squares (against a black background) presented on touch 
screens more accurately with the prosthetic system switched on versus off 
(Ahuja et al., 2011). Following on from this 2D target localisation study, Chapter 
4 describes a prospective study of 5 Argus® II subjects, looking at whether the 
Argus® II device could also facilitate localisation and prehension of an object in 
3D, using a 3D motion tracking system. 
As a wide range of performance levels was observed amongst this early cohort 
of Argus® II subjects, particularly for form recognition tasks (i.e. shapes and 
objects recognition), further investigation into the nature of prosthetic vision as 
perceived by individual subjects was warranted. Chapter 5 describes a 
prospective study of 6 Argus® II subjects, whereby the phosphenes elicited by 
fixed stimulating parameters were depicted by individual subjects, and their 
characteristics were analysed and compared for shapes, sizes, consistency and 
reproducibility. Inter-stimuli intervals ranging from 20 minutes apart, down to 1 
second were tested in each subject to investigate temporal resolution of the 
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phosphenes. 
Chapter 6 describes a retrospective study of 3 Argus® II subjects who 
underwent MRI brain scan (for unrelated medical reasons). Implant stability and 
function before and after the scan were compared to assess the safety and 
effect of MRI brain scan on the Argus® II subjects.  
Due to concerns with interference of signals from radiofrequency telemetry in 
the Argus® II system, functional MRI was deemed unsuitable for investigating 
cortical activities in Argus® II patients, despite initial demonstration of good 
safety with performing MRI brain scans in these patients in chapter 6. We 
therefore looked into the feasibility of capturing real-time primary visual cortex 
activities with retinal stimulation in these patients using a novel technique, 
functional near-infrared spectroscopy (fNIRS) in Chapter 7. We investigated the 
patterns of cortical activation in 6 subjects under 3 different stimulation 
conditions. We concluded that fNIRS is a useful neuroimaging tool in these 
patients, which could open up the arena of future neuroscience research into 
cross-modal plasticity in visual prostheses. 
The findings described in Chapters 3 to 7 and their significances are then 
brought together in the final concluding Chapter 8. 
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2.1 Introduction to Argus® II Retinal Prosthesis 
The Argus® II Retinal Prosthesis system (Second Sight Medical Products Inc., 
Sylmar, California, USA) is a commercially available device that restores a very 
low level of vision to patients with profound vision loss from outer retinal 
dystrophies. It has become the most widely used and most successful retinal 
prosthesis currently available in terms of regulatory approval. Since obtaining 
the CE mark in 2011 and FDA approval as a humanitarian device in 2013, 
commercial implantation has begun in many countries worldwide. Use of the 
device has been predominantly for patients with profound vision loss from 
retinitis pigmentosa and to a lesser extent, choroideremia as well as a planned 
cohort with extensive geographic atrophy from age-related macular 
degeneration (ClinicalTrails.gov Identifier: NCT02227498).  
The cost of the Argus® II retinal prosthesis system is approximately $150,000 
US dollars, with additional cost in surgical implantation and training with the use 
of the device (“The Argus II Retinal Prosthesis (‘Bionic Eye’) Receives Medicare 
Approval - VisionAware Blog - VisionAware,” n.d.). Based on a multi-state 
transition Markov model, the cost effectiveness of the Argus® II system has 
been estimated to have a incremental cost effectiveness ratio (ICER) of 
€14,603 Euros/QALY (Vaidya et al., 2014). This falls below the published 
societal willingness to pay of EuroZone countries, and hence is deemed a cost-
effective intervention compared to current standard of care of RP patients. To 
date, more than 200 devices have been implanted in 40 centres worldwide and 
the number is likely to increase. The content of this chapter has been published 
as a review article (Luo and daCruz, 2016). 
2.2 Components of the Argus® II Retinal Prosthesis 
Although termed a retinal prosthesis and popularly known as the ‘bionic eye’, 
devices such as the Argus® II are effectively photoreceptor replacements. As 
such, they are limited in their ability to replace retinal function in totality. The 
success of a retinal prosthesis depends on how well it is able to replace the 
functions of the degenerated or absent photoreceptors, namely: a) efficient 
capture of visual images in the form of light from the outside world; b) 
transduction of the captured light into meaningful neurological signals; and c) 
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subsequent activation of the residual inner retina (bipolar cells and RGCs), from 
where visual information can be relayed by the optic nerve to the visual cortex. 
To achieve these goals, the Argus® II retinal prosthesis system employed 3 
external components and 3 internal components. The 3 external components 
are:  (see Figure 2.1) 
1. A glasses mounted video-camera – for real-time image capture. 
2. A portable computer (the Visual Processing Unit, VPU) – for processing 
of the captured scenes and translation into electrical stimulating 
parameters conveying spatial-temporal information. 
3. An external coil (built into the side arm of the glasses) – for wireless 
transmission of the processed data from the VPU and electrical power to 
the internal components using RF telemetry.  
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Figure 2.1: Photograph of a patient fitted with the Argus® II retinal prosthesis 
system. The external components consisted of a spectacle-mounted video-
camera, a portable computer (the Video Processing Unit, VPU), and an external 
coil. The VPU enables real-time processing of the captured scenes and 
translation into electrical stimulating parameters conveying spatial-temporal 
information. The external coil allows for wireless transmission of the processed 
data from the VPU and electrical power to the internal components using 
radiofrequency (RF) telemetry. (Image from (Luo and daCruz, 2016)) 
The 3 internal components are: (see Figure 2.2) 
1. An internal coil – as a wireless receiver of RF telemetry, converting radio 
waves back to electromagnetic waves to recover both data and electrical 
power. 
2. An inbuilt Application-Specific-Internal-Circuit (ASIC) – for generating 
appropriate electrical pulses in accordance with the stimulating 
parameter data recovered from the internal coil, which are then relayed 
to the multi-electrode array.  
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3. A 60-channel microelectrode (6 x 10) epiretinal array – consisting of 60 
platinum electrodes (diameter = 200µm) spaced 200µm apart, 
embedded in a thin film of polyimide. Each microelectrode is connected 
to the ASIC in a parallel circuit via a metallised polymer connecting 
cable, such that each electrode can be activated independently 
according to the stimulating parameters. The array comes into direct 
contact with the retinal surface, allowing injection of electrical charges 
locally to stimulate the underlying retinal tissues (see Figure 2.3). 
 
Figure 2.2: An illustration of the internal components of the Argus® II retinal 
prosthesis system. These are: an internal coil, an inbuilt Application-
Specific-Internal-Circuit (ASIC) housed in the hermatic casing, and a 60-
channel stimulating electrode array (all labelled). The internal coil acts as a 
wireless receiver of RF telemetry, converting radio waves back to 
electromagnetic waves to recover both data and electrical power. The ASIC 
generates the appropriate electrical pulses according to the data received, 
which are then relayed to the electrode array where direct stimulation of the 
retinal surface takes place. (Reproduced with permission from Second Sight 
Medical Products Inc. and from (Luo and daCruz, 2016)) 
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Figure 2.3: Colour fundus photograph of the microeletrode array with 60 
platinum electrodes, implanted in a patient with choroideremia. The array rests 
on the retinal surface in direct contact with the retina, to allow efficient 
stimulation of the underlying retinal tissues. The array is held in place with a 
spring adjusted titanium tack that passes through retina, choroid and the sclera. 
(Image from (Luo and daCruz, 2016; Milam et al., 1998)) 
2.3 Choice of Candidates for Implantation  
All current retinal prostheses (including the Argus® II Retinal Prosthesis) work 
by electrically eliciting patterned focal responses in the residual inner retina. 
Ideal candidates for treatment would therefore have conditions where the outer 
retina (i.e. photoreceptors and / or retinal pigment epithelium) has been 
destroyed by any mechanism, while the inner retina (e.g. bipolar cells, RGCs, 
horizontal cells and amacrine cells) remains relatively intact. The largest single 
group of disorders that manifests this combination of outer retinal loss with 
relative inner retina preservation is RP (Hartong et al., 2006; Milam et al., 1998).  
RP denotes a group of hereditary outer retinal dystrophies, affecting around 1 in 
3000 live births and more than a million people worldwide (Grover et al., 1999; 
Hartong et al., 2006). Affected individuals suffer from progressive visual loss 
which can be profound (0.5% with no light perception and 25% with ≤ 20/200 
vision in both eyes) (Grover et al., 1999; Santos, 1997; Stone, 1992). Post 
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mortem histological studies of eyes of patients with moderate to severe RP 
have shown that even though all cellular layers of the retina underwent 
degeneration and cell loss with disease progression, the bipolar cell layer and 
the RGC layer remained relatively unaffected, with 78% and 30% preservation 
respectively, even in cases of severe RP (Guadagni et al., 2015; Santos, 1997; 
Stone, 1992). Treatment options for RP, other than for the associated cataract, 
epiretinal membrane and macular oedema, are limited (Guadagni et al., 2015; 
Humayun et al., 2012).  As such, they represent a currently untreatable group of 
patients who may benefit from retinal prosthesis treatment.  
Owing to the exploratory nature of the study, the recruitment criteria for entry 
into the Argus® II phase I / II clinical trial was RP patients with logMAR 2.9 
(bare light perception) vision or worse (Humayun et al., 2012; Machemer et al., 
1971; 1972). If visual loss in the eyes was asymmetrical, the worse-seeing eye 
was chosen as the study eye to minimise potential harm to the patient.  
2.4 Surgical Implantation 
Surgical implantation of the Argus® II Retinal Prosthesis involves the standard 
vitreoretinal surgery techniques of pars plana vitrectomy (Friedman, 1958; 
Machemer et al., 1972; 1971; Schepens and Okamura, 1957) and scleral 
buckling procedures (Friedman, 1958; Luo and daCruz, 2016; Schepens and 
Okamura, 1957). If the patient is phakic, lensectomy is usually performed from 
the outset, as subsequent cataract formation would render clinical monitoring 
difficult.  
A standard 3-port pars plana vitrectomy is first performed, with removal of the 
posterior hyaloid face to prevent future development of an epiretinal membrane. 
Any pre-existing epiretinal membrane is removed at the time of surgery in order 
to optimise electrical contact between the microelectrodes and the retinal 
surface. A 360˚ conjunctival peritomy is performed to allow isolation of all 4 recti 
muscles in preparation for placing the encircling band carrying the extraocular 
portion of the device. 
The internal coil and ASIC are sealed in protective hermetic cases, which have 
a concave under surface, conforming to the curvature of the globe. These are 
placed flush on bare sclera surface and sutured onto the sclera, usually in the 
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supero-temporal quadrant of the globe, at a pre-determined distance from the 
limbus (approximately 5mm) depending on the axial length of the globe (see 
Figure 2.4). A 5mm pars plana sclerotomy in the supero-temporal quadrant 
allows introduction of the microelectrode array into the vitreous cavity (see 
Figure 2.5) – this is the only intraocular portion of the device. With appropriate 
scleral placement of the extraocular part of the device, the microelectrode array 
would rest naturally on the retinal surface at the posterior pole with minimal 
tension. Gentle manipulation of the array position is possible to optimise 
placement in the macular region. Once the array position is satisfactory, a 
spring-tensioned, titanium retinal tack is inserted at the heel of the array, to 
ensure close apposition of the array and the retinal surface (see Figure 2.6). 
The sclerotomy is then sutured close around the traversing cable connecting 
the array to the ASIC to avoid scleral leakage and hypotony. 
 
Figure 2.4: Intra-operative photograph of the ASIC in a hermetic casing being 
sutured onto the sclera 5mm from the limbus. (Still image captured from 
surgical video, courtesy of Stanislao Rizzo with permission and from (Luo and 
daCruz, 2016)) 
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Figure 2.5: Intra-operative photographs showing the insertion of the 
microelectrode array into the vitreous cavity via a 5mm pars plana sclerotomy. 
(Still image captured from surgical video, courtesy of Stanislao Rizzo with 
permission, and from (Luo and daCruz, 2016)) 
 Page 79 
Figure 2.6: Intra-operative photographs showing the Titanium tack being passed 
through the heel of the microelectrode array and then through the retina choroid 
and sclera, thereby fixing the array to the retinal surface. (Still image captured 
from surgical video, courtesy of Stanislao Rizzo with permission, and from (Luo 
and daCruz, 2016; S. Rizzo et al., 2014)) 
The internal coil and ASIC cases on the sclera are further stabilised by a 
silicone encircling band, which passes under each of the 4 recti muscles around 
the globe before being gently tightened and held with a Watzke’s sleeve. 
Finally, an allograft (e.g. Tutoplast®) or autologous fascia-lata patch is sutured 
over the hermetic cases before the conjunctival closure over the device. 
Surgical time generally falls between 1.5 – 4 hours, as reported in a single 
centre post-marketing study (Humayun et al., 2012; S. Rizzo et al., 2014). This 
is remarkably shorter than the initial surgical time reported during the phase I 
feasibility trial, whereby the median surgical time was 4 hours and 4 minutes 
(range from 1 hour 53 minutes to 8 hours 32 minutes)(Humayun et al., 2012). In 
this interim report, it was explained that there was a single case with very 
prolonged surgical time. It was due to the fact that the subject had previously 
undergone multiple surgeries on the implanted eye, resulting in extensive 
fibrosis of conjunctiva and reinsertion of the previously disinserted lateral retus 
muscle was also required intra-operatively. In summary, surgical implantation of 
Argus® II retinal prosthesis can be performed within reasonable time frame by 
surgeons with standard vitreoretinal surgical skills. 
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2.5 Safety Profile  
Given that the aim of the Argus® II programme was to develop a commercially 
available retinal prosthesis, the safety of chronic implantation was central to the 
early clinical studies. The interim report of a 6-month to 2.7-year follow-up of the 
first 30 Argus® II patients showed a good initial safety profile, with 21 patients 
(70%) manifesting no severe adverse events (SAEs) during this period 
(Humayun et al., 2012). Of the 9 patients who experienced SAEs, the 
commonest complication was conjunctival erosion or dehiscence (5 patients). 
All except one of them were satisfactorily treated with re-suturing. This patient 
suffered from recurrent conjunctival erosion, hypotony with 360˚ choroidal 
effusions and retinal detachment, resulting in subsequent explantation of the 
device. The retinal detachment was successfully treated post-explantation with 
silicone oil tamponade and the patient’s intraocular pressure returned to normal 
without further sequelae. Other SAEs included: 2 cases of retinal detachment 
(including the above-mentioned patient), 2 cases of hypotony with choroidal 
effusions (including the above-mentioned patient), 3 cases of culture-negative 
presumed endophthalmitis and 2 cases of retinal tack dislocation requiring re-
tacking. Except for the one patient who underwent eventual explantation, all of 
the other patients’ SAEs were treated successfully either surgically or medically 
(e.g. intravitreal antibiotics for endophthalmitis), and they retained good 
functional use of their device during the follow-up period. Most of the SAEs 
(82%) occurred within the first 6 months, with 70% occurring within the first 3 
months. After some protocol adjustment halfway through the trial including 
device design improvement, surgical modifications, and the addition of a 
prophylactic intra-vitreal antibiotic injection at the end of surgical implantation, 
the rate of SAEs reduced significantly, and there were no further cases of 
endophthalmitis in the second half of the study (i.e. the last 15 cases) 
(Humayun et al., 2012; S. Rizzo et al., 2014).  
More recently, a report of the 12-month follow-up outcome of 6 patients who 
received the implant in a single centre performed by a single surgeon was 
published (Humayun et al., 1994; S. Rizzo et al., 2014). There were no SAEs 
such as wound dehiscence, endophthalmitis or retinal detachment that required 
further surgery. There was one patient with post-operative elevation of 
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intraocular pressure that was managed medically, and one patient with 
moderate choroidal detachment, which resolved spontaneously. These 
outcomes are markedly better than the safety profile observed during the 
clinical trial phase of the Argus® II Retinal Prosthesis. 
2.6 History of Development 
Research into the possibility of retinal prosthetic vision began in the early 1990s 
with Mark Humayun, Robert Greenberg and Eugene de Juan at Johns Hopkins 
University. They first demonstrated that focal electrical stimulation with a 
platinum electrode could elicit localised retinal responses in isolated animal 
retinas (Humayun et al., 1994; 2005; 2003; Yanai et al., 2003) (discussed in 
detail in section 2.7.1). The group subsequently moved to the University of 
Southern California (USC), and started a collaboration with the Second Sight 
company that would eventually lead to the development of the Argus I and 
Argus® II retinal prostheses. 
2.6.1 Argus I System 
The prototype retinal prosthesis, the Argus I, began its phase I clinical trial 
involving 6 patients in 2002 (Horsager et al., 2009; Humayun et al., 2005; 2003; 
Yanai et al., 2003). The main differences between the first generation device 
and the Argus® II device are: 
1. The stimulating array of Argus I consisted of 16 microelectrodes (4 x 4 
configuration), of either 260µm or 520µm in diameter, or both sizes 
alternating in a checkerboard pattern, with a centre-to-centre inter-
electrode separation of 800µm (see Figure 2.7 inset) (Horsager et al., 
2009; Zrenner et al., 2011). 
2. In the Argus I system, the hermetic casing containing the internal coil and 
ASIC was placed subcutaneously in the temporal bone recess, with the 
connecting cable leaving the periorbital space via a lateral canthotomy 
and tunnelled along the temporal bone subcutaneously to reach the 
temporal recess (see Figure 2.7). This approach was similar to that of the 
cochlear implant and the alpha-IMS subretinal implant (Brummer and 
Turner, 1977; Brummer et al., 1983; Zrenner et al., 2011), and required 
dissection of the temporal region with the assistance of maxillofacial / 
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otolaryngology expertise and extended surgical time. As such, this 
approach has been revised in the subsequent Argus® II design to 
simplify the implantation. 
3. In the Argus I system the external coil is situated over the temporal bone, 
held magnetically to the subcutaneous internal coil. 
Initial results from this clinical trial with a follow-up period of up to 33 months 
supported safety and long term functioning of the device. A wide range of 
electrode thresholds were observed both within and across the subjects, but 
many electrodes were able to elicit visual percepts within the safety charge 
density limit (Brummer and Turner, 1977; Brummer et al., 1983; Caspi et al., 
2009).  
Variability in the performances across the subjects was also noted, but was 
generally encouraging with the subjects being able to enumerate and localise 
high contrast objects with greater accuracy than by chance. Two subjects were 
also able to orientate shape (in the form of letter ‘L’) and identify 3 common 
objects (i.e. plate, cup and knife) with greater accuracy than by chance. 
Furthermore, using high contrast square wave gratings, one subject was able to 
differentiate the orientation of the gratings in 4 directions (vertical, horizontal, 
diagonal to right, diagonal to left) significantly better than by chance. The best 
level of resolution achievable was equivalent to logMAR 2.21 vision, in keeping 
with the theoretical resolution possible with the 4 x 4 array (Caspi et al., 2009; 
Horsager et al., 2009). The ability to carry out these tasks supported the notion 
that the subjects are capable of interpreting patterned electrical stimulation. 
Based on these results, the next generation retinal prosthesis – the Argus® II – 
with 60 microelectrodes, was developed.  
 Page 83 
 
Figure 2.7: An illustration of the Argus I retinal implant in situ showing: (A) a 
video-camera mounted in glasses frame; (B) the external coil for wireless RF 
telemetry transmission held magnetically to the underlying subcutaneous 
internal coil; (C) the hermetic casing containing the internal coil and ASIC 
embedded subcutaneously in the temporal bone recess, with the connecting 
cable leaving the periorbital space via a lateral cantotomy and tunnelled along 
the temporal bone subcutanelously to reach the temporal recess; (D) multi-
electrode array implanted intraocularly on the epiretinal surface. The inset 
shows the multi-electrode array consisting of 16 electrodes  (4 x 4 
configuration). The electrodes are alternating 260µm and 520µm in diameter in 
a checkerboard pattern. The centre-to-centre inter-electrode separation is 
800µm. (Modified and reproduced with permission from (Horsager et al., 2009; 
Humayun et al., 2003) and (Humayun et al., 2003; Luo and daCruz, 2016; 
Sekirnjak et al., 2009), and from (Humayun et al., 1994; Luo and daCruz, 2016; 
2014; Rose and Robblee, 1990)) 
2.7 Proof of Concept 
The development of the Argus® II Retinal Prosthesis, as with all retinal 
prostheses, was based on the following assumptions: 
1. The inner retina (RGCs with / without bipolar cells) of end-stage RP 
patients remains functionally intact allowing transmission of information 
along the visual pathway to the visual cortex. 
2. The residual inner retina can be activated focally with localised electrical 
stimulation to elicit discrete phosphenes without causing damage or 
toxicity to the retina. 
3. Retinotopy is relatively preserved in the residual inner retina and along 
the visual pathway, such that simultaneous multi-focal stimulations would 
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form geometric patterns of phosphenes in accordance with retinotopic 
locations. 
4. The elicited geometric patterns of phosphenes can be relayed in a 
spatio-temporally correct manner along the visual pathway and 
interpreted by the primary visual cortex as recognisable visual patterns. 
5. Limited pixels can still provide useful visual function. 
The evidence for the first premise has already been discussed in section 2.3. 
The rest of this section will therefore focus on animal and human studies that 
support the remaining concepts. 
2.7.1 Focal Retinal Stimulation 
Animal Studies 
Safety of Retinal Stimulation 
To establish whether focal electrical stimulation of the inner retina could be 
achieved using microelectrodes and stimulating parameters within the 
established safety density charge limits (Humayun et al., 1994; Jensen et al., 
2003a; Rose and Robblee, 1990) carried out a series of experiments: on the 
retinas of bullfrogs in an eye cup preparation; on a normal retina from an intact 
rabbit eye under terminal anaesthesia; and on rabbit eyes with the outer retinal 
function abolished by intravenous sodium iodate infusion. Using a pair of 
epiretinal platinum electrodes of 200µm in diameter separated by 200µm (the 
same diameter as that of the final Argus® II device) the authors demonstrated 
that the thresholds for activating these 3 retinal preparations were: 2.98µC/cm2, 
8.92µC/cm2 and 11.0µC/cm2 for bullfrog, normal rabbit retina and rabbit retina 
with abolished outer retinal function respectively. Even though stimulation of the 
retinal tissue with outer retinal dysfunction required higher stimulating charge 
density, all of them were within the predetermined safety limit for long term 
retina stimulation with platinum electrodes (limit = 50 - 150µC/cm2) (Jensen et 
al., 2003b; Rose and Robblee, 1990). Similar responses have also been 
achieved by electrically stimulating transgenic P23H-1 rats’ retinas, which had 
lost responses to light stimuli secondary to photoreceptor degeneration (Lilly et 
al., 1955; Sekirnjak et al., 2009). 
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Localisation of Retinal Responses 
Humayun et al. (1994) demonstrated that the retinal responses elicited were 
localised to the area of electrical stimulation, as the recording electrode only 
detected activity when it was placed in between the stimulating electrode and 
the optic disc, but not when it was distal to the stimulating electrode-optic disc 
path (e.g. when it was placed nasal to the optic disc while the stimulating 
electrode was placed in the temporal retina). This indicated that the RGC 
responses elicited by electrical stimulation are only recordable from axons close 
to the point of stimulation, but not from axons of cells residing far away from the 
electrical stimuli. However, this study did not examine axons from distal cells 
that passed through the area of stimulation. Overall it at least showed probable 
gross retinotopic localisation of retinal responses, allowing for the possibility of 
simultaneous multi-focal stimulation to form geometric patterns, which could 
then potentially give rise to pixelated vision.  
The issue of the inadvertent activation of bypassing axons from RGCs distal to 
the point of stimulation remains one of concern for creating discrete 
phosphenes. This potential problem exists due to the layering of axons in the 
macula region and the arcuate displacement of nerve fibres away from the 
fovea to minimise the visual obstruction of light falling on the central high-
density photoreceptors. Stimulation of the RGC axon fibres, instead of the cell 
body (soma), would theoretically convey the perception of peripheral retinal 
activation, rather than a retinotopically correct pattern of photoreceptor 
activation. This may be more problematic with epiretinal electrodes, which are 
anatomically closer to the nerve fibre layer (hence the axon fibres), than the 
RGC soma. Furthermore, with a diameter of 200µm, each electrode 
encompasses the equivalent area of hundreds of photoreceptors (see Figure 
2.8), further reducing the achievable resolution. 
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Figure 2.8: Adaptive optics (Imagine Eyes – rtx1™) retinal image of a healthy 
subject, taken at 3 degrees temporal to fixation. Individual cone photoreceptors 
can be seen as discrete dots. Within this macular region, the ratio of 
photoreceptors: bipolar cells: retinal ganglion cells approaches 1:1:1, allowing 
maximal visual resolution. In comparison, the 4 white circles are representative 
of the retinal surface areas covered by the Argus® II retinal prosthesis 
microelectrodes, with a diameter of 200µm each, drawn to scale. Activation of 
one microelectrode would therefore result in equivalent simultaneous activation 
of hundreds of photoreceptors. The resolution achievable is thus limited. 
(Reproduced with permission from (Greenberg et al., 1999; Luo and daCruz, 
2014)) 
With the assumption that selective activation of localised RGCs will lead to 
production of discrete phosphenes, further work has been carried out to 
determine the nature of retinal activation with epiretinal electrodes, and to 
explore methods of focal retinal stimulation (e.g. by varying stimulating 
parameters and / or reducing the stimulating electrode size). Using isolated 
rabbit retinas and ultra fine electrodes (2µm), (Jensen et al., 2003a; Nanduri, 
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2011) set out to investigate the differences in the thresholds of stimulating RGC 
axons versus cell bodies. They discovered that the electrical threshold of 
activation was lowest with mono-polar cathode stimulation applied directly over 
the RGC soma (assuming the soma is located within its light receptive field), 
and that the threshold increased as the stimulation moved further away from the 
soma. With cathode stimulation, the RGC soma threshold was about half of that 
of the axon. However, this difference was not observed when anode stimulation 
was applied, which showed similar thresholds for both RGC soma and axon 
activation. In addition, application of cadmium chloride, a synaptic blocker, did 
not abolish the retinal responses, suggesting that the responses may originate 
in the RGC, rather than from bipolar cells.  
In a separate study by the same group using mono-polar cathode stimulation, 
the authors found that with smaller electrode sizes (5µm in diameter), and 
shorter stimulating durations (0.1ms pulses), the threshold for directly activating 
RGC was much lower (37 times lower) than that required to activate the RGC 
indirectly via synaptic transmission. Even with a 125µm electrode and 2ms 
stimulating pulse, the average threshold for direct RGC activation was still half 
of that of trans-synaptic RGC activation (Jensen et al., 2003b; Sekirnjak, 2006; 
Sekirnjak et al., 2008). While the results from Jensen et al.’s group pointed 
towards a potential way of selective RGC soma activation, the conical 
configuration of the needle-shaped stimulating electrode and the mono-polar 
cathode stimulation were very different from the intended multi-electrode array 
design (which has a disciform planar configuration), and the safer charge-
balanced biphasic stimulation (which reduces the Faradaic reaction at the 
electrode-tissue interface, hence minimising tissue damage) (Abramian et al., 
2010; 2011; Lilly et al., 1955; Lovell et al., 2005; Sekirnjak et al., 2008). 
However, despite the fact that both Jensen et al. and (Behrend et al., 2011; 
Greenberg et al., 1999; Jepson et al., 2013) computer modelling demonstrated 
lower thresholds for RGC soma compared with the axons, other evidence 
suggests that the RGC axons appear to be the preferred site of activation 
(Horsager et al., 2009; Nanduri, 2011; Twyford et al., 2014). As such, whether it 
is the RGC soma or axon that is preferentially stimulated by the Argus® II 
device in vivo, remains ambiguous. 
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Multielectrode Array Stimulation 
To expand the study on other animal retinas and test out settings and 
configurations which were similar to the intended retinal prosthesis design, 
Sekirnjak et al. (2008) carried out experiments on the retinas of rats, guinea 
pigs and later, macaque monkeys (which bear close resemblance to human 
retinas). They used multi-electrode arrays with micro-electrodes of 6µm – 25µm 
in diameter and charge-balanced biphasic stimulations to investigate retinal 
responses (Addi et al., 2008; Guo et al., 2014; Sekirnjak, 2006; Sekirnjak et al., 
2008). The threshold charge densities from their experiments were typically 
100µC/cm2, which were within the established safety limit. Addition of various 
synaptic blockers did not abolish the retinal responses, again indicating that the 
responses were of RGC origin.  
Focal Retinal Stimulation 
In a subset of macaque monkey RGCs, the parasol cells (both ON and OFF) 
were further stimulated with 9 – 15µm electrodes (comparable to the size of 
individual RGC somas) (Palanker et al., 2004; Sekirnjak et al., 2008). It was 
shown that these parasol cells responded to a single electrical pulse with a 
single evoked response at sub-millisecond latency (~ 0.2ms), and that the 
response was confined within the activated cell, without spreading to its 
neighbours (i.e. spatially specific). 
Further work on other ganglion cell types of macaque monkeys’ retinas were 
carried out by (Jepson et al., 2013; Mathieson et al., 2012), including ON and 
OFF midget cells and small bi-stratified ganglion cells as well as the ON and 
OFF parasol cells. All these ganglion cells could also be independently 
activated with sub-millisecond latency within established safety limits. Given 
that the parasol cells form a significant part of the magnocellular pathway, while 
midget cells form the parvocellular pathway, the authors postulated that 
epiretinal electrical stimulation has the potential to elicit signals of high temporal 
and spatial resolution in primate retinas using high-density multi-electrode 
arrays. Selective activation of ON and OFF RGCs has also been demonstrated 
in isolated rabbit retinas by (Humayun et al., 1999; Twyford et al., 2014), using 
a conical epiretinal electrode with a base diameter of 15µm (comparable to the 
surface area of a 40µm disc electrode), and high frequency electrical 
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stimulations (HFS) of 2kHz. They have shown that within the low magnitude 
range (20 – 60µA) of HFS, modulation of the amplitude elicited opposing 
spiking responses in ON and OFF RGCs, lending to the prospect of developing 
a retinal prosthesis capable of cell-type specific, selective activation in the future 
(Guo et al., 2014; Humayun et al., 1999). 
More recently, an Australian research group at the University of New South 
Wales has proposed the use of a complex epiretinal stimulating unit, whereby a 
central stimulating electrode is surrounded by 6 hexagonally-arranged return 
electrodes, which collectively return the delivered current (Abramian et al., 
2010; 2011; Lovell et al., 2005; Weiland et al., 1999). Electrical charge spread 
from single electrode stimulation has previously been demonstrated both by 
computer modelling and later experimentally in rabbit as well as salamander 
retinas (Behrend et al., 2011; J. F. Rizzo et al., 2003a; 2003b). This could be 
responsible for the clinical observation that some Argus I subjects reported 
phosphene sizes that were more than twice the physical size of the single 
stimulating electrode (Horsager et al., 2009; J. F. Rizzo et al., 2003a). The 
presence of electric currents in the return electrodes supported the notion of 
charge spread from the stimulating electrode. The hypothesis behind this 
arrangement of stimulating and return electrodes was that it might isolate a 
particular stimulating electrode from neighbouring active stimulating electrodes.  
This isolation of the stimulating electrode would theoretically minimise the effect 
of ‘cross-talking’ from charge leakages (Addi et al., 2008; Beebe and Rose, 
1988), improving the ‘focus’ of retinal stimulation. In this stimulating unit, each 
electrode was 50µm in diameter and could act both as a stimulating or returning 
electrode. In a multi-electrode array (with centre-to-centre electrode distance of 
200µm), this configuration allowed great flexibility in the stimulating pattern. 
Other methods of improving focal retinal stimulation have also been described, 
including minimising the distance between the stimulating element and the 
target cells (Palanker et al., 2004; Weiland et al., 2002), and the design of a 
bipolar stimulating / return pixel to minimise charge spread (Mathieson et al., 
2012; J. F. Rizzo et al., 2003b). 
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Human Studies 
Focal Epiretinal Stimulation 
Following experiments in vertebrate retinas, (Humayun et al., 1999; Nadig, 
1999; Walter and Heimann, 2000) carried out experiments in 5 blind volunteers 
(3 with RP; one with an unknown retinal degeneration since birth; and one with 
extensive AMD) to investigate the effect of focal epiretinal stimulation. Using 
handheld probes of bipolar platinum electrodes of 200µm in diameter, the 
authors performed intra-operative stimulations with the patients awake under 
local anaesthesia.  With a focal stimulation, all 5 patients reported perception of 
a transient phosphene, ranging from “pin” to “pea” in size. The location of each 
of the perceived phosphenes in space corresponded broadly to that predicted 
retinotopically by the position of retinal stimulation within the 4 quadrants of the 
macula, except in the patient who was blind since birth. This may have been 
due to the lack of development of retinotopic organisation at the visual cortex 
level from sensory deprivation. Simultaneous stimulation of 2 sites separated < 
1mm apart produced the perception of 2 separate phosphenes in one patient, 
while stimulation with an elongated piece of platinum wire gave rise to an 
elongated percept (“a pencil held at arm’s length”). These findings strongly 
supported the notion that focal electrical stimulations could elicit discrete 
phosphenes in a retinotopic manner in a diseased human retina with outer 
retinal degeneration. 
Formation of Pixelated Vision 
To explore whether multiple discrete phosphenes could be elicited 
simultaneously to form recognisable geometric patterns, further experiments 
were carried out by the same group of researchers using platinum multi-
electrode arrays of 3 x 3 and 5 x 5 configurations on 2 different blind RP 
patients (Chen et al., 2006; Güven et al., 2005; Humayun et al., 1999). Each 
electrode was 400µm in diameter with an inter-electrode separation of 200µm, 
and was embedded in a silicone matrix. The first patient with the 5 x 5 array 
perceived a horizontal line when a row of electrodes was activated, and a 
vertical line when a column of electrodes was activated. The phosphenes 
appeared to merge together such that a continuous line (rather than discrete 
linear dots) was seen. When the electrodes in 2 columns and 1 row in the form 
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of a “U” shape were stimulated, the patient reported an “H” shaped percept. In 
the second patient with the 3 x 3 array, when the 8 electrodes forming the 
perimeter of the array were activated, a “box” with an empty centre was 
described. Both patients reported visual percepts which appeared to correspond 
to the pattern of multi-electrode stimulation, indicating that visual percepts could 
be modified by the stimulation pattern to give rise to form vision. 
Stimulation Threshold and Associated Phosphenes  
To further elucidate the effect of outer retinal loss on electrically elicited visual 
percepts, (Walter et al., 2005; Weiland et al., 1999) carried out an experiment 
on 2 patients with normal retinas, prior to their eye exenteration for orbital 
cancer. Krypton and argon laser retinal ablations (each about 1 disc diameter in 
size) were applied to the infero-temporal macula and supero-temporal macula 
respectively. Krypton red destroyed photoreceptors, while argon green 
destroyed both the outer and inner retinal layers, leaving only RGC nuclei and 
axons. Charge balanced, biphasic stimulations with a platinum wire electrode 
(125µm in diameter) were applied to areas of normal retina as well as the 
krypton and argon laser-ablated areas. Supra-threshold stimuli applied to a 
normal retinal area elicited a large, dark percept, while stimulation of the 
krypton-ablated area elicited a discrete, small white dot and stimulation of the 
argon-ablated area elicited a linear, thread-like percept that was somewhat 
fainter. Both patients reported similar visual percepts when the same retinal 
areas were stimulated and these visual percepts were repeatable. 
(Humayun et al., 1996; J. F. Rizzo et al., 2003b; 2003a) from the Boston Retinal 
Implant Group also explored the feasibility of multi-focal epiretinal stimulation 
using iridium oxide electrodes, to give visual percepts of recognisable geometric 
shapes. Using arrays of variable electrode sizes (50µm, 100µm and 400µm in 
diameter), epiretinal stimulations were performed in 5 blind RP patients and 1 
patient with a normal healthy retina who was awaiting an exenteration 
procedure for orbital cancer. They (Greenberg et al., 1999; J. F. Rizzo et al., 
2003a) observed that in general, the stimulation thresholds were much lower in 
the normal retina compared to diseased RP retinas. For the 50µm electrodes, 
the threshold to produce phosphenes exceeded that of the established charge 
density limit (quoted from established literature to be 1mC/cm2 with cathodic 
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stimulation) (Beebe and Rose, 1988; Dagnelie and Stronks, 2014; Humayun et 
al., 2003; Stronks et al., 2013). Even with the 100µm and 400µm electrodes, 
only the normal retina thresholds were below the established charge density 
limit. Severely damaged retinas from RP appeared to have 4 – 19 times higher 
thresholds than normal retinas, which raised the concern for long-term electrical 
stimulation in severe RP patients. However in a later study, the iridium oxide 
safety charge limit was found to be higher than previously estimated, measuring 
up to 4mC/cm2 with a 0.2 ms stimulating pulse (Stronks et al., 2013; Weiland et 
al., 2002), suggesting that safe chronic stimulation was possible. 
In a follow-on study, contrary to Humayun et al. and Weiland et al.’s findings, 
(Brindley and Lewin, 1968; J. F. Rizzo et al., 2003b) showed that out of the 5 
blind RP patients, only 3 patients experienced perception of a single discrete 
phosphene with single electrode stimulation. Single electrode stimulations were 
carried out by either 100µm or 400µm electrodes. Of the 185 visual percepts 
elicited in the 3 patients, only 6 %, 35% and 85% of these phosphenes were 
perceived as small single dots. Other phosphenes were more complex in 
nature, such as a “line”, or a “cluster of 2 or 3 images”. Even in the patient with 
a normal retina, only 57% of single electrode stimulations yielded single discrete 
phosphenes. When simple geometric patterns of electrodes were stimulated 
(e.g. a line or letter ‘L” or “T”), out of 84 stimulations, the proportion of 
phosphenes matching the expected retinotopic representation was 55%, 21% 
and 29% respectively in the 3 RP patients, and 43% in the normal retina patient.  
When the same stimulating parameters were applied to the same electrodes at 
different times to test the reproducibility of phosphenes, the results were 
variable between the patients. One RP patient reported similar phosphenes in 2 
out of 2 trials, while the other 2 patients reported similar phosphenes in 19/23 
trials and 9/12 trials respectively. The patient with normal retina reported 
reproducibility in 9/11 trials. Notably in one RP patient, when 2 electrodes 
spaced 1860µm apart were stimulated simultaneously, one phosphene was 
reported 5 out of 6 times while two phosphenes were observed once. 
Subsequent sequential stimulation of one followed by 2 electrodes for 
comparison yielded a single brighter percept twice, a brighter and larger percept 
once, a larger percept once, and the sensation of “motion” once. 
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J. Rizzo et al. confirmed that single discrete phosphenes could be achieved with 
single electrode stimulations in some patients, but noted that there was 
considerable variability amongst the patients (later borne out in the chronic 
implantation and stimulation studies, see Chapters 3 – 5). The patterns of the 
phosphenes elicited were often not predictable from the patterns of electrode 
array stimulation.  
2.7.2 Cortical Responses from Electrically Stimulating Diseased 
 Retina 
A further requirement of a functional retinal prosthesis is the successful relay of 
the elicited electrical signals from the retina to the visual cortex. Several 
research groups have looked into the cortical responses to epiretinal electrical 
stimulation, using electrophysiology measurements in both animals and 
humans.  
Animal Studies 
Cortical activities from epiretinal stimulation were first demonstrated in rabbit 
retinas, using subcutaneously implanted / extradural electrodes over the visual 
cortex (Cha et al., 1992b; Nadig, 1999; Walter and Heimann, 2000). The cortical 
electrically-evoked potentials (EEPs) were comparable to that of visually-
evoked potentials (VEPs) in both wave forms and in responses to changes in 
stimulus strength and frequency, suggesting that EEPs also originated from 
focal retinal activation.  
Further demonstration of eliciting EEPs by focal electrical stimulation has been 
made in normal and rd1 mice, and normal and RCD1 dogs (Chen et al., 2006; 
Güven et al., 2005; Sommerhalder et al., 2006).  These two animal studies 
showed that EEP elicitation was also achievable in animal models of outer 
retinal degeneration. There was a distinct early response (latency < 10ms) and 
late response (latency > 50ms). Synaptic blockade using cadmium chloride 
(CaCl2) abolished the late responses, but not the early responses, indicating 
that the early responses were from direct activation of RGC. Epiretinal electrical 
stimulation thus elicited cortical responses both via direct activation of RGC and 
via trans-synaptic signal transmission. 
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With the aim of visualising neuronal activity changes in the visual cortex, 
(Sterling and ACM, 1971; Walter et al., 2005) performed direct optical imaging 
of the cortical surface following epiretinal stimulation in rabbits. With neuronal 
activation visualised as darkening of the cortical area, topographical changes in 
the area of activation could be seen to follow sequential pairs of epiretinal 
electrodes being activated. The cortical activation was temporally matched and 
appeared to follow the visuotopic organisation of the cortex. This confirmed that 
retinotopic stimulation gives rise to focal, visuotopically preserved patterns of 
cortical activation. 
Human Studies 
Apart from working on rd1 mice and RCD1 dogs, Chen et al. also performed 
measurements of EEP in one human with RP, using gold disc scalp electrodes 
over the occipital cortex. The epiretinal stimulation was carried out by an 
implantable epiretinal electrode array. Eight epiretinal electrodes were activated 
simultaneously, using supra-threshold currents. EEPs were recordable from the 
human RP patient on 2 separate occasions 3 weeks apart. On both occasions, 
EEPs were recorded with a latency of > 50ms. This was unexpected as 
previous works from (Dagnelie et al., 2007; Humayun et al., 1996) and 
computer modelling from (Greenberg et al., 1999; Wang et al., 2008) suggested 
RGC as the main site of electrical activation. The authors have commented that 
this may be due to the lack of sensitivity of scalp electrodes in detecting the 
early signal response. 
More recently, EEPs have been recorded in both Argus I and Argus® II patients 
(Dagnelie and Stronks, 2014; Humayun et al., 2003; Stronks et al., 2013; 
Terasawa et al., 2002). (Humayun, 2001; Stronks et al., 2013) reported EEP 
recordings from 4 Argus® II retinal implant patients. Despite using all available 
electrodes for stimulation for each patient to maximise the cortical response, the 
signal-noise ratios were still low, thus requiring prolonged recording time and 
more substantial signal processing than standard VEPs. Nevertheless, the 
authors were able to identify characteristic features in the waveform. In 
particular the second peak, P2, was identified as the most reproducible 
outcome measure as it correlated well with the patients’ subjective report of the 
phosphene elicited by the supra-threshold stimulus. However, although the 
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patients reported a decline in their perceived phosphene brightness over time 
with continuous stimulation, this was not reflected in the P2 recordings. 
Despite numerous animal and human studies providing objective evidence of 
cortical activation in response to epiretinal stimulation, little is understood about 
how these cortical activities reflect image processing and / or interpretation 
along the visual pathway and at the cortical level. Neither is the correlation 
between EEPs and visual function well understood. 
2.8 Simulation of Potential Visual Outcomes with 
 Retinal Prosthesis 
While physically replacing millions of photoreceptors with microelectrodes is not 
technically feasible, the actual number of microelectrodes required to restore 
functioning vision may be far lower. With the cortical implant, (Brindley and 
Lewin, 1968; Hayes et al., 2003; Humayun, 2001) first demonstrated the 
feasibility of partially restoring vision by the means of pixelated scenes – visual 
patterns made up of punctate spots of light (phosphenes). With this in mind, 
researchers set out to estimate the number of pixels (hence the number of 
functioning microelectrodes for focal retinal stimulation) theoretically required to 
provide useful function, using a combination of psychophysical experiments and 
computer simulations. For the purpose of practical application in Argus® II 
subjects, simulations were performed to establish the number of pixels required 
for 3 levels of visual tasks: navigational vision, facial and object recognition, and 
reading vision. 
2.8.1 Navigational Vision 
(Cha et al., 1992b; Thompson, 2003) used a monochromic monitor mounted on 
a pair of goggles for projecting scenes. The monitor was further covered by a 
perforated mask to create pixelated images. Seven normally sighted volunteers 
were asked to wear the goggles and navigate through a maze. The obstacles 
and the configuration of the maze were altered randomly for each trial in order 
to prevent route learning by the participants. They found that the field of view 
and the number of pixels were the two strongest determinants of navigational 
ability, and collectively accounted for 83.7% of the variance in walking speed. 
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Training and practice improved the performance of maze navigation (i.e. 
walking speed and number of contact with obstacles), and each subject 
required about 40 trials for the performance to be stabilised. The authors 
estimated that a minimum of 25 x 25 (625 in total) pixels projected centrally to 
the fovea, with a field of view of 30˚, was required for normal walking speed to 
navigate through the maze. (Brindley, 1964; Brindley and Lewin, 1968; 
Sommerhalder et al., 2006) also reported a very similar estimation of pixel 
requirements for navigation, recommending a visual field of 23˚ x 33˚ and a 
minimum of 500 pixels, while earlier work by (Sterling and ACM, 1971) indicated 
that a much lower number of 200 pixels might be adequate for recognition of 
small obstacles.  
To allow comparisons of several more feasible designs of electrode arrays in 
navigation and mobility performances, (Cha et al., 1992a; Dagnelie et al., 2007) 
looked at the differences in navigational performance with 3 different densities 
of simulated pixelated vision: 4 x 4, 6 x 10 and 16 x 16 pixels. The authors used 
a combination of real mobility navigation – whereby the normal sighted 
participants wore a prosthetic vision simulator to walk through a maze; and a 
virtual reality navigation – whereby the participants navigated through a virtual 
maze with a game controller, again only watching a simulated pixelated vision 
display. The authors found that with adequate practice, an experienced user 
could navigate with the same efficiency using 6 x 10 pixelated vision, as with 16 
x 16 vision. To further emulate the effect of phosphene “drop-outs” as 
encountered in the real-life use of the Argus® II Retinal Prosthesis System (due 
to poor electrode-retinal contact and / or unresponsiveness of the underlying 
retinal tissue to electrical stimulation within the safety charge density limit), the 
same group of researchers evaluated the effect of introducing random removal 
of pixels, and addition of background noise (i.e. random sparks, to mimic the 
spontaneous background photopsia experienced by many end-stage RP 
patients) in a virtual maze navigation (Hayes et al., 2003; Wang et al., 2008). 
The simulated prosthetic vision display was also “gaze-locked”, such that the 
presented scene did not vary with eye movement, to emulate the fact that the 
same area of retina was always stimulated by the electrode array, irrespective 
of eye movement. The authors concluded that a phosphene drop-out rate of 
30% significantly extended the time required to perform the virtual maze 
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navigation (by 40%), while addition of background noise and variation in 
luminance contrast did not significantly affect navigation. 
2.8.2 Object & Facial Recognition 
Object and facial recognition form an important aspect of visual function as well 
as playing a significant role in social interaction. Apart from the number of pixels 
as discussed previously, a second important factor in the rendition of prosthetic 
vision is the ability to perceive differences in image grey levels (i.e. luminance 
contrast). By varying the stimulating parameters (e.g. amplitude and frequency), 
the luminance contrast of different pixels can be adjusted, giving the perception 
of different grey levels. The greater the range of grey levels perceivable, the 
better the scene recognition (Dagnelie et al., 2006; Terasawa et al., 2002). 
(Humayun, 2001; Sommerhalder et al., 2003) set out to determine the pixel 
number and grey levels required for facial recognition. Using a head-mounted, 
customised Low Vision Enhancement System (LVES) display, simulated 
pixelated facial images were projected over the entire macular region of 8 
normally sighted volunteers. The dot size, spacing, drop-out rates, grid size 
(visual field) and number of grey levels were varied in the simulation, to emulate 
the 3 different array designs: 4 x 4 (covering a 7.3˚ x 7.3˚ visual angle), 6 x 10 
(covering a 11.3˚ x 19.3˚ visual angle) and 16 x16 array. While unsurprisingly 
the best performance was seen in the 25 x 25 array with 6 grey levels (over 
75% accuracy), reasonable facial recognition could be achieved with the 16 x 
16 array with a minimum visual field of 10˚, drop-out rate of less than 30% and 4 
grey levels. Recognition of common daily objects (e.g. cup, spoon, plate and 
pen) was only achievable with the 16 x 16 array, while the 6 x 10 array allowed 
description of the object shape, but not accurate identification (Hayes et al., 
2003; Humayun, 2001; Sommerhalder et al., 2004). 
(daCruz et al., 2013; Humayun et al., 2012; Thompson, 2003) tested a range of 
16 different simulation conditions with varying combinations of the following 
parameters: dot size, drop-out rate, gap width (i.e. inter-dot distance), grid 
(array) size, grey levels and image contrast. The performance with each 
condition was compared with that of a standard condition to assess the effect of 
varying these parameters. The standard condition settings were: 16 x 16 array, 
31.5 arc-min dot size, 4.5 arc-min gap size, 30% dot drop-out rate, and 6 grey 
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levels. While each of the parameters was shown to affect the recognition speed, 
image contrast in particular, had a great impact on performance. For high 
contrast images (i.e. darkest grey level = 0% luminance; brightest grey level = 
100% luminance), good facial recognition was achievable except when the 
simulated image was reduced to 70% random dot drop-out rate and 2 grey 
levels. For low contrast images (i.e. darkest grey level = 44% luminance; 
brightest grey level = 56% luminance), reasonable facial recognition was also 
possible with up to 70% dot drop-out rate, but a minimum of 4 grey levels and at 
least 17% of target image size was required. With more difficult images, the 
performance of the participants was shown to improve with practice. 
2.8.3 Reading vision 
As early as 1964, Brindley et al. estimated that 50 channels would permit 
recognition of one “printed or typed letter”, and that 600 channels would suffice 
for normal reading speed with the aid of automatic scanning (Brindley, 1964; 
Brindley and Lewin, 1968; Sommerhalder et al., 2004; 2003). This was 
supported by (J. F. Rizzo et al., 2003b; Sterling and ACM, 1971) and later on by 
(Cha et al., 1992a; Nanduri et al., 2011; 2012; 2008) who also looked into the 
factors affecting reading in phosphene-based pixelated vision. Using a 
phosphene simulator similar to that described in section 2.2.1, they estimated 
that 625 points (25 x 25 array, covering a 10˚ visual field) implanted within 1cm2 
of the area representing the fovea in the visual cortex would provide 20/30 
vision. 
While the earlier works were aimed at estimating reading vision provided by 
cortical implants, researchers at Johns Hopkins University set out to investigate 
the potential vision of 3 different retinal prosthesis arrays, namely 4 x 4, 6 x 10, 
and 16 x 16, using a head-mounted prosthetic vision simulator (as described in 
section 2.2.1) (Hayes et al., 2003; Pérez Fornos et al., 2012). They estimated 
that the potential visual acuity achievable with each of these arrays were 
20/1810, 20/1330, and 20/420 respectively. Reading was achievable in all 8 
participants with the 16 x 16 array and 36-point fonts, with 2 of them able to 
read 27-point fonts (equivalent of 20/450 reading acuity). With the 6 x 10 array, 
2 participants were able to read 72-point fonts with an average reading speed of 
1.02 words per minute. The reading speed could be vastly improved with good 
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text scanning technique, achieving a reading speed of 30 – 60 words per 
minute using the 16 x 16 array (Dagnelie et al., 2006). (Sommerhalder et al., 
2003) also estimated that as few as 300 pixels would be adequate for close to 
perfect reading of 4-letter words (>90% correctly read words) when presented 
within the central 10˚ of visual field, while 600 pixels distributed over a retinal 
surface of 3mm x 2mm would be required for reading of a full-page text 
(Sommerhalder et al., 2004). 
In summary, the above studies have shown theoretically that while more than 
600 pixels would allow near normal functioning such as reading and navigation, 
reasonable visual function could be achieved with far fewer pixels (16 x 16 
array, 4 grey levels and drop-out rate of less than 30%). The current Argus® II 
Retinal Prosthesis with 6 x 10 pixels would be predicted to provide reasonable 
navigational and some reading vision – as borne out by around 20% of patients 
from the Argus® II phase I / II clinical trials (daCruz et al., 2013; Humayun et al., 
2012). There is also evidence that training and practice by way of visual 
rehabilitation improve the performance of visual tasks (Sommerhalder et al., 
2004; 2003). However, there is still a substantial discrepancy between the 
predicted performance and the actual functional capability in all the Argus® II 
patients.  This is in part due to the fact that these pixelated vision simulations 
were based on the assumption that each phosphene was perceived as uniform, 
discrete dots, which appear and disappear in accordance with the duration of 
electrical stimuli. In reality, although many percepts were indeed reported as 
white / yellow dots, the shapes, forms and persistence of many phosphenes 
elicited from epiretinal electrical stimulation are much more complex and vary 
greatly within subjects. This will be discussed in detail in Chapter 5.  
As previously discussed, (J. F. Rizzo et al., 2003b) have observed that 
frequently, more than one phosphene of indiscriminate shape was described by 
subjects following single electrode stimulation. Furthermore, the same percept 
was not always described by the subject despite using identical stimulating 
parameters. This finding was also reported by (Nanduri et al., 2012; 2011; 
2008), who further demonstrated changes in phosphene shape, size and 
brightness with varying stimulating frequency and amplitude. Additionally, 
phosphene perception has been found to have poor temporal correlation with 
the duration of the electrical stimuli. They were frequently reported to last less 
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than 2 seconds, despite persistent electrical stimulation. There is also a wide 
inter-subject variability (Pérez Fornos et al., 2012). Due to the number of factors 
involved and the variability in perception within and between subjects, the actual 
number of pixels required to produce useful vision has remained difficult to 
predict. 
2.9 Conclusions 
In summary, early animal and human studies have demonstrated the ability of 
focal retinal stimulation to elicit discrete phosphenes using epiretinal electrodes. 
Experiments with prosthetic vision simulators showed that reasonable 
navigational and reading (of 72-points font letters) vision could potentially be 
achieved with a 6 x 10 epiretinal electrode array, such as one employed by the 
Argus® II retinal prosthesis system. 
Since the commencement of the phase I/II clinical trial in 2006, the Argus® II 
system has succeeded in being well tolerated with acceptable safety profile, 
resulting in the granting of the CE mark and FDA approval. However, the true 
impact of the system in the subjects’ lives remains unknown. 
In the following chapters (chapters 3 and 4), we set out to investigate the real-
life performance of target recognition and localisation in a cohort of chronically 
implanted subjects. To explain the variation in the visual performance observed 
amongst the subjects, we further explored the fundamental difference in the 
prosthetic vision as perceived by each subject in chapter 5.  
As a commercial device, clinical safety of not only the device implantation itself, 
but also the compatibility with other common clinical investigative procedures is 
an important aspect of clinical outcome. As such, in chapter 6, we reported on 
the safety of Magnetic Resonance Imaging (MRI) brain scans in 3 Argus® II 
subjects who underwent the scans. 
Collectively, we aim to give a report on selected aspects of long-term clinical 
and functional outcomes in real-life settings in Argus® II retinal prosthesis 
subjects in this thesis. 
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Chapter 3 
 
Form Vision 
(Shapes & Objects Recognition) 
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3.1 Introduction 
Despite a plethora of theoretical predictions and extensive animal testing, 
confirmation of successful stimulation of the inner retina with matching 
perceptions by the patients has only become possible since the commencement 
of long-term human trials of retinal prostheses. The Argus I trial began in 2002 
and the international multi-centre phase II clinical trial of the Argus® II began in 
2007 (clinicaltrials.gov identifier: NCT00407602).  
As a result of the regulatory trials, the Argus® II retinal prosthesis system has 
been shown to function safely and reliably over long periods of time (Humayun 
et al., 2012; Zhou et al., 2013). The visual performance, however, has been 
variable among the subjects, ranging from reading of large letters in high-
performing subjects (daCruz et al., 2013), to reliable perception of light only in 
others. Out of the 30 subjects enrolled in the phase II trial, 50.0% were able to 
identify direction of motion significantly better with device switched on versus off 
at 5 years after implantation; while 38.1% also had measurable gratings acuity 
of logMAR 2.9 or better {daCruz:2016kx}. 
The ability to differentiate visual forms with the view to recognising objects and 
elements in real-life relies on 2 assumptions:  
a) patterned electrode stimulations are able to reproducibly elicit 
distinguishable, discrete phosphenes; and  
b) the phosphenes are represented in a retinotopic manner to convey 
spatial form.  
In this study we set out to investigate the feasibility of using the Argus® II 
implant to enable subjects to differentiate form, firstly by assessing their 
recognition of two-dimensional (2D) geometric shapes presented on a LCD 
screen, followed by recognition of three-dimensional (3D) objects from real-life. 
We hypothesised that the use of Argus® II retinal prosthesis would improve the 
subject’s ability to identify a range of geometric shapes than without the device. 
We also hypothesised that the performance in 2D shapes recognition could be 
translated into 3D objects recognition.  
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The experiments were performed in 2 parts and discussed under the following 2 
headings: 
1. Two-Dimensional screen-based Shapes Recognition Study; and  
2. Three-Dimensional Objects Recognition Study. 
3.2 Patients & Methods 
Eleven subjects with RP implanted with the Argus® II retinal prosthesis system 
as part of the Second Sight phase I/II feasibility study (clinicaltrials.gov 
identifier: NCT00407602) were recruited from 4 centres in Europe. This study 
was approved by the institutional review board or ethics committee of each of 
the centres involved, and followed the tenets of the Declaration of Helsinki. 
Informed consent was obtained from all the subjects. 
The Shapes Recognition Study was performed in 11 subjects who were 
available for regular training and psychophysical testing in the 4 European 
centres, namely London and Manchester in the UK, Paris, and Geneva. The 
subsequent Objects Recognition Study was performed in a subset of 7 of these 
11 subjects based in the 2 UK centres. The subjects from the centres in Europe 
were not included due to difficulties in the logistics of patient accessibility and 
distance. Of the 8 UK-based subjects, only 7 subjects participated in the 
Objects Recognition Study, as one subject (Subject ID: 52-002) has since 
immigrated outside of the UK. All of the subjects received appropriate training 
with the general use of the Argus® II device as well as training specific to the 
tasks prior to testing. 
3.2.1 Shapes Recognition Study (2D) 
3.2.1.1 Materials 
Test I: Solid Shapes 
Eight geometrically distinct solid shapes were selected for this testing, namely: 
circle, semi-circle, triangle, square, cross, rectangle, pentagon and hexagon 
(see Figure 3.1). The shape optotypes were created using PowerPoint 
(Microsoft®, Redmond, Washington, USA) for presentation on a 15-inch flat 
LCD screen with the screen resolution set to 1024×768 pixels, against a black 
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background.
 
Figure 3.1: Eight geometric Solid Shapes chosen for the Shapes Recognition 
Study. During the Solid Shapes testing, each subject was presented with each 
of the 8 white solid shapes (top panel) in 5 different sizes (see Figure 3.2) in 
random order. Each image was presented once during the testing (i.e. 40 
presentations per testing). This was then repeated with presentation of grey 
solid shapes (bottom panel), also in 5 different sizes. The subject was allowed 
up to 1 minute to identify each presented shape. The testing was performed 
with the Argus® II device switched on and then repeated with the device off. 
(Image modified from (Luo and daCruz, 2016)) 
Two shades (white or grey) in 5 different sizes (XL = 22.6 cm, L = 14.3 cm, M = 
9.0 cm, S = 5.6 cm, XS = 3.6 cm; see Figure 3.2) were created for each 
optotype. 
 
Figure 3.2: The five different sizes of each geometric shape created for the 
Shapes Recognition Study. The white solid triangles are shown here in XL 
(22.6cm), L (14.3cm), M (9.0cm), S (5.6cm) and XS (3.6cm) sizes. During the 
testing, the subjects were presented with each of the 8 chosen geometric 
shapes in the any of these sizes in random order. 
The use of white and grey shades allowed us to determine the effect of contrast 
on performance. By varying the optotype size presented, we prevented the use 
of size (rather than shape) as a discriminator for optotype recognition. 
Test II: Outlined Shapes 
The outlined forms of these 8 geometric shapes (see Figure 3.3) were also 
created in both white and grey, and in 5 different sizes as above, for 
presentation against a black background on LCD screen. 
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Figure 3.3: The eight Outlined Shapes chosen for the Shapes Recognition 
Study. During the Outlined Shapes testing, as with the Solid Shapes testing, 
each subject was presented with each of the 8 white outlined shapes (top 
panel) in 5 different sizes (see Figure 3.2) in random order. Each image was 
presented once during the testing (i.e. 40 presentations per testing). This was 
then repeated with presentation of grey outlined shapes (bottom panel), also in 
5 different sizes. The subject was allowed up to 1 minute to identify each 
presented shape. The testing was performed with the Argus® II device switched 
on and then repeated with the device off. (Image modified from (Luo and 
daCruz, 2016)) 
3.2.1.2 Pre-test Training 
A standardised pre-test training was carried out with the Argus® II retinal 
prosthetic device switched on. Each subject was presented with each of the 8 
shapes in the largest size (XL = 22.6 cm) sequentially in a darkened room. 
During the training, with each presented image, the subject was first instructed 
to carry out “macro-scans” with the video-camera glasses across the entire 
screen to determine the overall size of the image. Once the size was 
determined, the subject was asked to carry out “micro-scans” to trace along the 
edge of the presented image to determine its geometric shape. If the shape of 
the image could not be identified, the subject was guided to trace along the 
edge of the image until one could identify the shape. A further 8 randomly 
chosen shapes of mixed sizes and shapes were then presented once to the 
subject, to allow familiarisation with shapes presented in different sizes. All of 
the shapes were presented in white against black background during the 
training. 
3.2.1.3 Test Conditions & Controls 
The experiment was performed in a darkened room, with the LCD screen set at 
eye level, 30 cm in front of seated subjects. 
During the testing, the subjects were presented with each of the 8 geometric 
solid shapes in both white and grey shades and in all 5 sizes in random order. 
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Each image of the same shade was presented once during the testing (i.e. 40 
presentations per testing). Randomisation was provided by the MatLab® 
program (MatLab®, Mathworks, Natick, Massachusetts, USA). The subject was 
given up to 1 minute to identify each presented shape. At the end of the minute, 
the image would disappear from the screen and a response was requested 
(forced choice). Subjects were expected to guess if they did not feel they could 
identify the shape. Standardised instructions were given to all the subjects at 
the beginning of each experiment. The experiment was performed with the 
Argus® II retinal prosthetic device switched on and then repeated with the 
device switched off, in order to act as an internal negative control.  
The entire experiment was then repeated with the 8 outlined shapes under the 
same settings and conditions as described for the solid shapes. 
3.2.2 Objects Recognition Study (3D) 
3.2.2.1 Materials 
Test I: Solid Objects 
As part of designing this experiment, the 7 participating subjects were 
interviewed to establish the 8 objects they would most like to be able to identify 
in their daily environment. The chosen objects were: a teapot, a mug, a plate, a 
salt and pepper cruet set, a bunch of keys, a mobile phone, a remote control 
and a wallet (see Figure 3.4). These objects were chosen as they represented a 
group of objects likely to be found together in a home setting, e.g. on a coffee 
table. As such, visual discrimination would be helpful.  
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Figure 3.4: Eight objects from real-life chosen for the Objects Recognition 
Study. During the testing, the subjects were presented with each of the 8 solid 
white objects in random order, with each object presented twice (i.e. 16 
presentations) per testing. The subject was allowed up to 30 seconds to identify 
the object. The testing was performed with the Argus® II device set to one of 
the following 3 conditions: device switched on, device switched on but with 
signals scrambled (i.e. scrambled mode) and device switched off. (Image 
modified from (Luo and daCruz, 2016)) 
Test II: Outlined Objects  
In order to elucidate the effect of accentuating the outlines of the objects in their 
recognition, the body of each object was partially covered with cutout black 
cardboard to create an edge effect. These outlined objects were also presented 
for testing as the second part of the Objects Recognition Study (see Figure 3.5). 
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Figure 3.5: Eight objects from real-life covered with cutout black boards so as to 
accentuate their outlines in Objects Recognition Study. During the testing, as 
with the Solid Objects testing, the subjects were presented with each of the 8 
outlined objects in random order, with each object presented twice (i.e. 16 
presentations) per testing. The subject was allowed up to 30 seconds to identify 
the object. The testing was performed with the Argus® II device set to one of 
the following 3 conditions: device switched on, device switched on but with 
signals scrambled (i.e. scrambled mode) and device switched off. (Image 
modified from (Luo and daCruz, 2016)) 
3.2.2.2 Pre-test Training 
A standardised pre-test training took place with the Argus® II retinal prosthetic 
device switched on, in a well-lit room to mimic real-life environment (see Test 
Conditions and Figure 3.6).  
The subject was presented with each of the 8 objects sequentially. For each 
object, the subject was first instructed to perform “macro-scans” across the 
worktop to determine the object’s size and whether it had height. This was 
followed by “micro-scans” to identify and follow the outlines of the object. The 
subject was then asked to touch the object to match his visual perception to the 
tactile information of the object. The distinctive visual features for the different 
objects were summarised to the subjects as below: 
• Small objects: mobile phone, remote control, wallet, set of keys 
- Small object with irregular shape:  a set of keys 
• Large objects: teapot, mug, plate 
- Large object without height:  plate 
- Large object with height: teapot or cup 
• Two separate objects: salt and pepper set. 
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3.2.2.3 Test Conditions & Controls 
The experiment was performed in a well-lit room to simulate the real-life 
environment. The worktop was covered with a black felt cloth to serve as a dark 
background, against which objects of white or highly reflective hues were 
presented to maximise contrast. Two black armrests were placed on either side 
of the presented object, about 50 cm apart, so as to help the subject locate the 
presented object (see Figure 3.6). The subjects were seated with the worktop at 
their waist level, and instructed to place their arms on the two armrests on the 
worktop. They were informed that the object for identification would be placed in 
between the two armrests. 
 
Figure 3.6: Two dark blocks (~50 cm apart) acting as armrests were placed on 
either side of the presented object during Objects Recognition Study. By placing 
their hands / arms on the armrests during the testing, the subjects could locate 
the presented object more easily. 
During the testing, the 8 solid objects were presented sequentially in random 
order, with each object presented twice (i.e. 16 presentations) per testing. The 
subject was allowed up to 30 seconds to identify the object, upon which time the 
object would be removed from the field of view of the subject, and an answer 
was required (forced choice).  
The experiments were performed with the Argus® II retinal prosthetic device set 
to one of the following 3 conditions: 
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1. Device on (standard mode); 
2. Device in scrambled mode (internal positive control, see below); and 
3. Device off (internal negative controls). 
Signal-Scrambling Mode of Argus® II Retinal Prosthesis 
Signal-scrambling mode (hereinafter referred to as scrambled mode) allows 
transmission of electrical impulses to the electrode array, but the pattern of 
array activation is systemically altered such that it no longer reflects spatial 
form, essentially turning the Argus® II into a light detection device (Caspi et al., 
2009; daCruz et al., 2013). For example, if the subject were looking at a white 
line on a black background in standard mode, a line of electrodes would be 
activated. However, in scrambled mode, the same number of electrodes would 
be activated in random positions across the array without any resemblance of 
linearity (see Figure 3.7).  If the subject were using the Argus® II as a light 
detection device and inferring form vision, then there would be no difference in 
outcome between standard and scrambled mode. Conversely, any difference in 
the performance with the device in standard mode versus scrambled mode 
would therefore reflect the degree of perception of spatial information originating 
from the device, rather than inference of form from head scanning.  
 
Figure 3.7: A diagrammatic illustration of the difference between the electrode 
array activation patterns under the standard and scrambled modes (as labelled) 
when the camera is viewing a square box. In scrambled mode, the spatial 
correspondence between a point’s real position and the stimulation position on 
the array has been randomised. In this way, the patient does not receive spatial 
information but does receive non-spatial light detection information. (Image 
modified from (daCruz et al., 2013)) 
Two sets of experiments were performed with the Argus® II device under 
condition 1 and 2, while one set of experiment was performed under condition 3 
for each subject. Both the order of objects presented and the conditions under 
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which the testing was performed were randomised using the random number 
sequence generated by the Research Randomizer website 
(https://www.randomizer.org). The subjects were masked to the device setting 
conditions. 
The experiment was repeated with the 8 outlined objects under the same 
settings and conditions as described for the solid objects. 
3.2.3 Statistical Analysis 
All of the statistical analyses and graphical presentations were performed using 
SPSS program (IBM® SPSS® Statistics version 22). Non-parametric tests were 
chosen for the analysis, as normality of the distribution of the results could not 
be assumed given the small sample size. 
3.3 Result 
3.3.1 Subjects and Implant 
Gender, age at diagnosis and implantation, and the number of electrodes 
activated and functioning at the time these tests were performed for each 
subject are as shown in Table 3.1. Some subjects have considerably less 
number of electrodes activated (namely 51-003, 52-002, 61-001 and 72-002) 
compared with other subjects. In these subjects, many of their microelectrodes 
were disabled at the first post-operative threshold testing, either because the 
threshold level to elicit visual percepts exceeded that of the safe density charge 
limit; or stimulation caused physical discomfort to the subject.   
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Subject ID Sex Age at 
Diagnosis 
(Years) 
Age at 
Surgery 
(Years) 
Number of 
Working 
Electrodes 
51-003 M 19 72 28 
51-005 M 7 55 60 
51-006 M 46 66 56 
51-007 M 28 63 56 
51-009 F 11 45 60 
52-001 M 30 50 60 
52-002 M 16 65 29 
52-003 M 25 60 37 
61-001 M 3 53 11 
61-003 M 34 57 51 
72-002 M 15 60 29 
Table 3.1: Demographics of the 11 Argus® II subjects who participated in 
Shapes Recognition Study. 51-003, 51-005, 51-006, 51-007, 51-009, 52-001 
and 52-003 also participated in the Objects Recognition Study. M = Male, F = 
Female.  
3.3.2 Shapes Recognition Study 
Test I: Solid Shapes 
The median (interquartile range) percentage of correct identification of white 
solid shapes was 22.5 (15.0 – 32.5)% with the Argus® II device on, and 12.5 
(12.5 – 15.0)% with the device off (P = 0.033, Wilcoxon signed rank test). 
For grey solid shapes, the median (interquartile range) percentage of correct 
identification was 17.5 (12.5 – 35.0)% with the device on, and 12.5 (10.0 – 
15.0)% with the device off (P = 0.032, Wilcoxon signed rank test). 
With the Argus® II device on, there is no statistically significant difference in the 
identification of white solid shapes compared to grey solid shapes (P = 0.65, 
Wilcoxon signed rank test).  
Overall, the median (interquartile range) percentage of correct identification of 
all solid shapes was 20.0 (14.4 – 33.1)% with the Argus® II device on, and 12.5 
(10.0 – 15.0)% with the device off (P = 0.002, Wilcoxon signed rank test, see 
Figure 3.8). 
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Figure 3.8: Box and Whisker plot showing the median and interquartile range of 
the mean % of correct identification of solid shapes with the Argus® II retinal 
prosthesis device switched on and off as labelled. (+ denotes the outliers) 
Test II: Outlined Shapes 
The median (interquartile range) percentage of correct identification of white 
outlined shapes was 33.8 (27.5 – 51.3)% with the Argus® II device on, and 13.8 
(11.3 – 17.5)% with the device off (P = 0.003, Wilcoxon signed rank test). 
For grey outlined shapes, the median (interquartile range) percentage of correct 
identification was 32.5 (18.8 – 38.8)% with the device on, and 13.8 (12.5 – 
15.0)% with the device off (P = 0.006, Wilcoxon signed rank test). 
With the Argus® II device on, the subjects were able to correctly identify white 
outlined shapes significantly better than grey outlined shapes (P = 0.018, 
Wilcoxon signed rank test). 
Collectively for all outlined shapes, the median (interquartile range) percentage 
of correct identification was 33.1 (26.6 – 48.1)% with the device on, and 13.8 
(12.2 – 15.3)% with the device off (P < 0.001, Wilcoxon signed rank test, see 
Figure 3.9).  
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Figure 3.9: Box and Whisker plot showing the median and interquartile range of 
the mean % of correct identification of outlined shapes with the Argus® II retinal 
prosthesis device switched on and off as labelled. (+ denotes the outliers) 
In addition, the greater accuracy of identifying outlined shapes (median 33.1%) 
versus solid shapes (median 20.0%) with the device on was statistically 
significant (P < 0.001, Wilcoxon signed rank test). 
3.3.3 Objects Recognition Study 
Test I: Solid Objects 
The median (interquartile range) percentage of correct identification of solid 
objects was 31.25 (25.00 – 45.31)% with the device on, 25.00 (18.75 – 31.25)% 
with the device in scrambled mode, and 12.50 (6.25 – 18.75)% with the device 
off (P = 0.016, Friedman’s test, see Figure 3.10). For identifying solid objects, 
while the subjects performed significantly better with the device on versus off (P 
= 0.016, Wilcoxon signed rank test), there is no statistical significance in the 
performance with the device on versus with the device in scrambled mode (P = 
0.193, Wilcoxon signed rank test). 
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Figure 3.10: Box and Whisker plot showing the median and interquartile range 
of the mean % of correct identification of solid objects with the Argus® II retinal 
prosthesis device switched on, device on and in scrambled mode and off as 
labelled. (+ denotes outliers) 
Test II: Outlined Objects 
The median (interquartile range) percentage of correct identification of outlined 
objects was 43.75 (34.38 – 50.00)% with the device on, 18.75 (10.94 – 25.00)% 
with the device in scrambled mode, and 6.25 (0.00 – 12.5)% with the device off 
(P = 0.006, Friedman’s test, Figure 3.11). 
For identifying outlined objects, the difference in the performance with the 
device on versus with the device in scrambled mode, and with the device on 
versus device off are both statistically significant (P = 0.002, and 0.012 
respectively, Wilcoxon signed rank test). 
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Figure 3.11: Box and Whisker plot showing the median and interquartile range 
of the mean % of correct identification of outlined objects with the Argus® II 
retinal prosthesis device switched on, switched on in scrambled mode and off 
as labelled. (+ denotes outliers) 
The subjects were also able to identify outlined objects with greater accuracy 
(median 43.75%) than with solid objects (median 31.25%) with the device (P = 
0.015, Wilcoxon signed rank test). 
3.4 Discussion  
The Argus® II retinal prosthesis system has allowed subjects who are blind due 
to RP to perform certain visual tasks not possible with their native vision. 
Despite published outcomes for improved motion detection (Dorn et al., 2013; 
Humayun et al., 2012; Zhou et al., 2013), spatial-motor co-ordination (Ahuja et 
al., 2011; daCruz et al., 2013), grating visual acuity (daCruz et al., 2016; 
Humayun et al., 2012) and large letter recognition (daCruz et al., 2013; Luo and 
daCruz, 2016), it remains unclear as to whether these abilities could be of 
assistance to the subjects’ day-to-day living.  In this study we endeavoured to 
look at aspects of form perception in both artificial (shapes recognition) and 
practical (objects recognition) ways with the artificial vision provided by the 
Argus® II retinal prosthesis, in order to begin to examine the use of artificial 
vision in real-life. 
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From our study, the Argus® II retinal prosthesis enabled the subjects to identify 
2D geometric shapes on screen with greater accuracy (Figure 3.8) than with 
their native vision. This accuracy could be improved by presenting the shapes 
as schematic outlines instead of in solid forms (Figure 3.9, P < 0.001, Wilcoxon 
signed rank test). When presented with real-life objects, a similar phenomenon 
was observed. The subjects were able to identify a range of common objects 
better with the assistance of the retinal prosthesis (Figure 3.10), with greater 
accuracy achieved when objects with accentuated outlines were presented 
(Figure 3.11, P = 0.015, Wilcoxon signed rank test). 
It is interesting to note that the change in contrast (i.e. white versus grey) did 
not affect the identification of solid shapes, but identification of outlined shapes 
was improved by greater contrast (P = 0.018, Wilcoxon signed rank test). 
Meanwhile, scrambling of the retinal prosthesis signals (i.e. scrambled mode) 
significantly reduced the accuracy of identifying outlined objects (P = 0.015, 
Wilcoxon signed rank test), while the effect on solid object identification was not 
significant. This discrepancy in performance could be due to the fact that when 
viewing a solid form (whether in 2D or in 3D), the homogenous surface gave 
rise to a large reflectance, which resulted in eliciting a visual percept of 
substantial size and intensity that reflect the overall surface area of the viewed 
shape / object, at the expense of spatial resolution. Under this circumstance, 
the Argus® II device effectively functioned as a reflectance detector instead of 
detecting form (as in scrambled mode), and factors such as the overall 
reflectance and size of the target played a major role in its identification, rather 
than its spatial form. 
At present, most of the published data on the visual functions of Argus® II 
retinal prosthesis were based on simulated visual tasks displayed on screens, 
performed under controlled artificial settings (Barry et al., 2012; Caspi et al., 
2009; daCruz et al., 2012; Dorn et al., 2013; Luo and daCruz, 2016). To 
determine if these screen-based outcomes could be predictive of performance 
in a more realistic setting, we looked at the correlation between the subjects’ 
identification of white outlined shapes on screen and that of real-life outlined 
objects. As shown in Figure 3.12, there is a general positive trend, although the 
sample size is too small to determine the strength of this correlation.  
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Figure 3.12: Scatter plot showing the correlation between the performance of 
white outlined shapes identification versus outlined objects identification in 7 
subjects, using the Argus® II device. There is a general positive trend, however 
the sample size is too small to assess the strength of this correlation (Pearson’s 
correlation, r = 0.65). 
As seen in other Argus® II studies (Barry et al., 2012; Caspi et al., 2009; 
daCruz et al., 2012; Dorn et al., 2013; Luo and daCruz, 2016), there is 
considerable variation in the performance of the 11 subjects, as evident in the 
wide interquartile range of median percentages of correct identification of 
shapes / objects. Explanation for this have included age, duration of blindness, 
the type of genetic defect as well as variable retinal circuitry remodelling in 
degenerative diseases (Jones et al., 2012; Luo and daCruz, 2016; Marc et al., 
2007; 2003). A further factor may be due to variations in the temporal profile of 
perception as detailed by Fornos et al. (Caspi et al., 2009; daCruz et al., 2013; 
Pérez Fornos et al., 2012). Despite this variability, overall there is a strong 
indication that highlighting the outlines of objects will enhance their 
identification, and will aid the patients in their home environment. 
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Owing to the small sample size, repeatability of the results could not be 
adequately addressed. Another limitation with this study is that the subjects 
were given up to 30 seconds in the Objects Recognition Study to identify the 
presented object. It therefore remains debatable whether visual identification 
within this time frame could be directly translated into daily use. To gain a more 
comprehensive and realistic view of integrating the device into daily life use, 
further assessment with the subjects in their own home environment would be 
useful.  
With the current cohort of Argus® II subjects, we have observed a few high 
performing subjects, who could correctly identify up to 75% of the presented 
objects. In a similar study with letter / word reading in 21 Argus® II subjects, 
multiple regression analysis showed that the number of electrodes activated 
and the age of the subject at the time of implantation showed the greatest 
contribution to performance difference (daCruz et al., 2013), with the age at 
implantation being the only statistically significant factor. This may reflect the 
presence of healthier residual inner retina at the time of implantation. 
With greater understanding of the factors affecting device performance (Ahuja 
and Behrend, 2013), and further investigations into the correlation between 
subject performance and genotype-phenotype, we would be able to formulate 
more stringent selection criteria for future patients to offer more accurate 
prediction of performance and maximise their benefits from the device. 
In conclusion, the Argus® II retinal prosthesis system allowed subjects blind 
from outer retinal degeneration to better identify a range of shapes and common 
daily life objects in a controlled setting. The ability to do so varies greatly from 
subject to subject and we are currently unable to predict the outcome for 
individual subjects. Recognition of shapes and objects appeared to be improved 
by enhancing their schematic outlines, suggesting that the usefulness of the 
Argus® II may be enhanced in real-life situations by simple modification of the 
objects. Given the growing availability and use of the Argus® II devices 
worldwide, evidence of how the system could be used more effectively in real-
life could help improve rehabilitation and training for the future.  
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Target Localisation 
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4.1 Introduction 
One of the main criticisms of the use of an external camera for image capture in 
a retinal prosthesis system is the dissociation between the visual scene 
captured by the camera (which is always directed straight ahead), and that of 
the subject’s eye position. In a normally sighted person, the sense of an object’s 
location within one’s visual field is directly correlated with the position of the 
image on the retina and its displacement from the fovea relative to head 
position.  The latter is communicated as part of the proprioceptive information 
that is co-ordinated by the vestibular and other sensory systems. As such, 
complex proprioceptive skills such as hand-eye co-ordination are often 
developed in relation to one’s eye position. In an Argus® II subject, the image 
captured by the external camera is always projected onto a fixed area of the 
retina determined by the placement of the electrode array. Such misalignment 
between the camera position and the patient’s eye could interfere with the 
patient’s perception of spatial localisation, as has been previously suggested 
(Sabbah et al., 2014). 
In terms of resolving the head and eye position, however, it has been shown 
that the Argus® II subjects in the clinical trials have developed an effective 
compensatory mechanism, whereby they keep their gaze (eye position) straight 
ahead at all times while using the device, and move their head (rather than 
eyes) to change the direction of gaze. With this technique, 96% of the 27 
Argus® II subjects were able to localise and point to bright squares on a touch 
screen with higher accuracy than without the device (Ahuja et al., 2011). 
Prehension, the act of reaching out and grasping a visually identified object, is 
an important milestone in our motor skills development during infancy 
(Halverson, 1943). It forms a basic way for us to explore and interact with our 
environment, and is a task we carry out many times a day in our daily life. 
Visual inputs are crucial in first directing the trajectory of the reaching hand, 
then allow for adaptive changes to be made to shape the reaching hand in 
accordance with the perceived characteristics of the target object (e.g. shape, 
texture, weight), to achieve a firm and stable grasp of the object (Halverson, 
1943; Hohlstein, 1982). 
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In this study, we set out to explore if the aiming and pointing performance with 
the Argus® II device, as exemplified by the two-dimensional target localisation 
under laboratory setting (Ahuja et al., 2011), could be translated into real-life 
practical applications of object localisation and prehension in the three-
dimensional space. Secondly, we wanted to examine whether enhanced 
visualisation of their fingers would improve the subjects’ performance in 
prehension. We hypothesised that effective visualisation of one’s reaching 
fingers in three-dimensional space would improve the proprioception of the 
subject, which would in turn aid in the accuracy of object prehension. The 
outcome of this study has been published (Luo et al., 2015). 
4.2 Materials & Methods 
This is a prospective, internally controlled, interventional case series from a 
single centre. The current study was approved by the local ethics committee as 
part of the Argus II phase I/II feasibility study and respected the tenets of the 
Declaration of Helsinki. Informed consent was obtained from all the subjects. 
4.2.1 Patient Eligibility 
Five (out of a total of 7) subjects who received the Argus® II retinal prosthesis 
system implant as part of the Second Sight phase I / II feasibility study at 
Moorfields Eye Hospital between 2008 – 2010 were recruited (clinicaltrials.gov 
identifier: NCT00407602). All subjects were blind (logMAR 2.9 bare light 
perception or worse in both eyes) from RP or choroideremia and their 
demographics are as shown in Table 4.1. Two subjects were excluded from this 
study as one of them was medically unwell and under treatment from an 
unrelated neoplastic condition at the time of the study, while the other one 
declined to participate in the study. All the subjects had received visual 
rehabilitation training provided by the Second Sight Inc. with the general use of 
the device prior to testing. 
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Subject ID Sex Age at Diagnosis 
(Years) 
Age at Surgery 
(Years) 
Number of Active 
Electrodes 
51-003 M 19 72 28 
51-005 M 7 55 60 
51-006 M 46 66 56 
51-007 M 28 63 53 
51-009 F 11 45 60 
Table 4.1: Demographics of the 5 Argus® II subjects who participated in the 
Object Localisation Study.  
4.2.2 The ProReflex® Motion Capture System 
The ProReflex® Motion Capture system (Qualisys, Sweden) (qualisys.com, 
n.d.) consists of specialised infrared (IR) motion detection cameras and the 
Qualisys Track Manager (QTM) software for motion data analysis. Each camera 
consists of a group of flashing IR light emitting diodes (LEDs) situated external 
to the camera lens, and an image sensor. During motion capture, IR retro-
reflective markers are attached to the areas of interest. The IR light emitted by 
the camera LEDs is reflected back from the reflective markers and detected by 
the camera lens and image sensor. The QTM software calculates the central 
point and size of each marker signal in real-time, thus giving marker position 
and hence the movement trajectory of the marker over time.  
4.2.3 The Flashing Beacon Finger Marker 
All of the Argus® II subjects were able to reliably perceive flashes of light with 
the device. To enhance the visualisation of the subjects’ own fingers in space, 
we devised a bright beacon consisting of 2 x 5-Watt LED lights of ~5mm in 
diameter, with adjustable brightness intensity and flashing frequency. The 
beacon was attached over the nail of the index finger of each subject’s 
dominant hand used in the prehension task (see below), and both the intensity 
and frequency of the beacon were adjusted individually until the subject 
reported reliable and persistent visualisation of the flashing beacon with the 
Argus® II device. The pulsating nature of this beacon allowed the subjects to 
distinguish between this signal and signal from other non-pulsating objects (i.e. 
the LEGO® blocks used for the prehension task). None of the subjects reported 
visualisation of the flashing beacon without the use of the device. 
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4.2.4 Test Conditions & Setting 
A 60 cm x 70 cm tabletop covered in black felt cloth in a uniformly illuminated 
room served as our worktop. A doorknob (also covered in black felt) was placed 
at middle of one border of the worktop, to act as a pre-determined starting point 
for the prehension task (described below). The target object for prehension was 
a white cuboid made of 2 x 2 LEGO® blocks (3.1cm x 3.1cm) x 6 layers in 
height (5.7 cm), giving a total volume of 54.78cm3. White LEGO® blocks were 
chosen to maximise the contrast against the black worktop.  
Three of the specialised ProReflex® infrared cameras were triangulated around 
the table at a height of approximately 1.5 meters above the table, to enable a 3 
dimensional (3D) recording of all movements within the worktop area. 
Three lightweight IR retro-reflective markers of approximately 7mm in diameter 
were placed on the subject’s dominant hand, as determined using the 
Edinburgh handedness questionnaire,(Oldfield, 1971) for recording its 
movement in 3D. One marker was attached to the wrist using a Velcro strap 
and two were placed on the subject’s opposing distal borders of the thumbnail 
and index fingernail. The target object was also marked with an IR retro-
reflective marker. Movements of the IR retro-reflective markers were tracked by 
the ProReflex® Motion Capture system as described above and recorded 
directly by a personal computer based system (see Figure 4.1 and 
supplementary video). 
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Figure 4.1: Prehension of objects in 3D space. (A) An Argus® II subject carrying 
out prehension tasks. (B) The time taken and the trajectory of the prehensile 
hand during prehension tasks were captured using ProReflex® Motion Capture 
system, Qualisys, Sweden. IR-reflective markers were attached to the wrist 
(lilac sphere), thumb (blue sphere) and forefinger (green sphere) of the subject, 
and to the target object (yellow sphere). During prehension, movements of 
these markers in 3D with time were captured by 3 IR cameras, which surveyed 
the scene. The accuracy of the prehension tasks could then be analysed. 
4.2.5 Prehension Task 
The subjects were seated during the task such that the worktop was at their 
waist level, and the doorknob was situated at their sagittal midline, along the 
table border closest to them. 
At the beginning of the task, the subject’s dominant hand (with IR retro-
reflective markers and flashing beacon attached as described above) was 
positioned at the pre-determined start point (as designated by the doorknob). 
During each task, the subject was instructed to locate the target object (i.e. the 
white LEGO® cuboid) on the worktop, reach out and grasp the object with their 
dominant hand, place the object to one side before returning their hand to the 
start point. The subject had up to 30 seconds to complete each task, after which 
time, the motion recording would stop automatically and any further movement 
would not be captured and analysed. The placement of the target object was 
varied in an random order (as generated by a computerised randomiser) 
(“Research Randomizer: Free Random Sampling and Random Assignment,” 
n.d.) in one of the following 4 locations with one repeat, resulting in a total of 8 
trials per set of prehension task. The 4 locations were (see Figure 4.2): 
• Location 1: near (~20cm away) and to the right of the sagittal midline; 
• Location 2: near (~20cm away) and to the left of the sagittal midline; 
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• Location 3: far (~40cm away) and to the right of the sagittal midline; 
• Location 4: far (~40 cm away) and to the left of the sagittal midline of the 
subject. 
 
Figure 4.2: Schematic drawing of the prehension task setup showing the 
subject's position in relation to the worktop table. The target object (i.e. the 
white LEGO® cuboid) would be placed in one of the 4 locations in random order 
during the task. (Image from (Luo et al., 2015)) 
Each subject was asked to carry out the task under the following conditions: 
• Argus® II device switched on, finger marker beacon switched on; 2 sets 
of tasks were performed (16 trials in total) per subject. 
• Argus® II device switched on, finger marker beacon switched off; 2 sets 
of tasks were performed (16 trials in total) per subject. 
• Argus® II device switched off, finger marker beacon switched on; 2 sets 
of tasks were performed (16 trials in total) per subject. 
• Argus® II device switched off, finger marker beacon switched off; 1 set of 
tasks was performed (8 trials in total) per subject. 
The subject was masked to the settings of the Argus® II retinal device and 
finger marker beacon, and the order in which the above conditions were carried 
out were also randomised. 
4.2.6 Motion Data Analysis 
Each IR retro-reflective marker (located on the target object as well as the 
subject’s dominant hand) generated x, y, z co-ordinate outputs for each 30-
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second recording. These data were analysed using a purpose written script 
(Matlab 8.0.0.783 R2012b, The Mathworks Inc, Massachusetts, U.S.A).  
To analyse the accuracy of prehension, the First Hand Stop (FHS) was marked 
manually for each of the 30-second recordings by two independent observers. 
The FHS was defined as the hand position at which the trajectory of the 
subject’s moving hand first showed a sudden change in velocity (i.e. a reduction 
in speed and / or a change in direction of movement). This would represent 
where the subject perceived the location of the target object to be, and reached 
out his / her hand accordingly.  
4.2.7 Statistical Analysis 
All of the statistical analysis and graphical representations were performed 
using SPSS program (IBM® SPSS® Statistics version 22). Non-parametric 
tests were chosen for the analysis, as normality of the distribution of the results 
could not be assumed given the small sample size.  
4.3 Results 
4.3.1 Success of Prehension 
The percentage of successful prehension ± standard deviation was: 71.3 ± 
27.1% with the Argus® II device switched on and the finger marker switched on; 
77.5 ± 24.5% with the device on and the finger marker off; 0.0 ± 0.0% with the 
device off and finger marker on, and 0.00 ± 0.00% with the device off and finger 
marker off. The difference in performance between finger marker on and finger 
marker off is not significant, whether the prosthesis was switched on (P = 0.546) 
or switched off (P = 1; Wilcoxon signed rank test). 
Since the finger marker beacon setting did not appear to affect the performance 
of prehension task, the data for all the performance with the Argus® II device 
switched on and switched off were amalgamated respectively for further 
analysis. 
Collectively, the percentage of successful prehension ± standard deviation for 
all performances with the Argus® II device switched on was 74.4 ± 23.4% and 
0.0 ± 0.0% with the device switched off (P = 0.04, Wilcoxon Signed Rank test). 
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The performance of successful prehension for each subject was shown in Table 
4.2.  
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Subject Prosthesis Setting 
On Off 
Prehension 
initiated 
(%) 
(n = 32) 
Successful 
prehension 
after 
initiation 
(%) 
Mean ± 
S.D. FHS - 
Target 
Distance 
(mm) 
Prehension 
initiated 
(%) 
(n = 16 ) 
Successful 
prehension 
after 
initiation 
(%) 
Mean ± 
S.D. FHS - 
Target 
Distance 
(mm) 
51-003 21 (66%) 14/21  
(66.7%) 
140.0 ± 
140.7 
0 (0%) NA NA 
51-005 29 (91%) 27/29  
(93.1%) 
67.9 ± 25.3 0 (0%) NA NA 
51-006 19 (59%) 18/19  
(94.7%) 
57.3 ± 21.8 0 (0%) NA NA 
51-007 32 (100%) 32/32 
(100%) 
52.4 ± 27.5 0 (0%) NA NA 
51-009 31 (97%) 28/31 
(90.3%) 
145.2 ± 
66.8 
0 (0%) NA NA 
Table 4.2: Percentage of prehension initiation and percentage of successful 
prehension with the retinal prosthesis switched on versus switched off for each 
subject. Where prehension was initiated, the mean ± standard deviation 
distance (mm) of First Hand Stop (FHS) to the target object for each subject’s 
performance was shown. N = total number of trials. (Image from (Luo et al., 
2015)) 
4.3.2 Accuracy of Prehension 
The distribution of FHS relative to the target object for each prehension task is 
presented graphically for each subject in Figure 4.3. The location of the target 
object was assigned the co-ordinates of (0, 0), while the designated starting 
point was assigned the arbitrary co-ordinates of (2000, 2000). The relative 
displacement of the FHS in the x and y axis from the target object was 
calculated and plotted accordingly.  
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Scatter plots showing the relative (x, y) co-ordinates of the First Hand Stop 
(FHS) to the target object for the prehension tasks for 51-003. An open circle 'O' 
denotes the FHS with prosthesis switched on; a cross 'X' denotes the FHS with 
the prosthesis switched off.  
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Scatter plots showing the relative (x, y) co-ordinates of the First Hand Stop 
(FHS) to the target object for the prehension tasks for 51-005. An open circle 'O' 
denotes the FHS with prosthesis switched on; a cross 'X' denotes the FHS with 
the prosthesis switched off.  
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Scatter plots showing the relative (x, y) co-ordinates of the First Hand Stop 
(FHS) to the target object for the prehension tasks for 51-006. An open circle 'O' 
denotes the FHS with prosthesis switched on; a cross 'X' denotes the FHS with 
the prosthesis switched off.  
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Scatter plots showing the relative (x, y) co-ordinates of the First Hand Stop 
(FHS) to the target object for the prehension tasks for 51-007. An open circle 'O' 
denotes the FHS with prosthesis switched on; a cross 'X' denotes the FHS with 
the prosthesis switched off.  
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Scatter plots showing the relative (x, y) co-ordinates of the First Hand Stop 
(FHS) to the target object for the prehension tasks for 51-009. An open circle 'O' 
denotes the FHS with prosthesis switched on; a cross 'X' denotes the FHS with 
the prosthesis switched off.  
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Figure 4.3: Scatter plots showing the relative (x, y) co-ordinates of the First 
Hand Stop (FHS) to the target object for the prehension tasks for each subject. 
An open circle 'O' denotes the FHS when the prehension was performed with 
the prosthesis switched on; a cross 'X' denotes the FHS when the task was 
performed with the prosthesis switched off. The FHS was defined as the hand 
position at which the trajectory of the subject’s moving hand first showed a 
sudden change in velocity (i.e. a sudden reduction in speed and / or a change 
in direction of movement). The FHS represented where the subject perceived 
the target object to be and placed his / her hand accordingly. The closer the 
FHS was to the target object location, the greater the accuracy of the spatial 
localisation. The location of the target object was assigned the co-ordinates of 
(0, 0), while the designated starting point (i.e. at the doorknob) was assigned 
the arbitrary co-ordinates of (2000, 2000). The relative displacement of the FHS 
in the x and y axis from the target object was calculated and plotted accordingly. 
The closer the FHS was to the target object location, the greater the accuracy of 
the spatial and corresponding proprioceptive localization. When the subject 
failed to visually locate the target object during the allowed time, no attempt of 
prehension was initiated and the subject’s hand remained at the designated 
start point (i.e. at the artificial doorknob).  
When the Argus® II retinal prosthesis was switched off, none of the subjects 
were able to visually locate the target object. Their dominant hand therefore 
remained at the designated start point and the corresponding FHS – target 
object distance was therefore conceptually infinitely large. This is shown in 
Figure 4.3, where all the cross-points (denoting hand positions with prosthesis 
switched off) were seen at the (2000, 2000) co-ordinates, the assigned start 
point, for all the subjects. 
With the prosthesis switched on, prehension was attempted (indicating visual 
localization of the target object by the subjects) on 82.5% (range 59 – 100%) of 
the trials. Once prehension was initiated, the subjects were able to successfully 
reach and grasp the object on 89.0% (range 66.7 – 100%) of the trials. 
The mean ± standard deviation distance (mm) of FHS to the target object for all 
the attempted prehension was 92.2 ± 78.4 mm. The performance for each 
subject was as tabulated in Table 4.2. Graphically, most of the open-circle-
points (denoting hand positions with the prosthesis switched on) were seen 
clustered around the target object location (0, 0). 
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4.4 Discussion 
The precision of prehension evolves in a systematic manner, from primitive 
squeeze, hand and palm grasp, to the superior and precise digital grasp 
(Halverson, 1943). While our adult subjects would have acquired the fine motor 
skills of prehension in their childhood, decades of blindness have deprived them 
of the visual inputs required to perform this important functional task.  
Visualisation of the target object was the first step in target object prehension. 
Our study has shown that the Argus® II retinal prosthesis enabled the subjects 
to visually locate the object, and subsequently achieve prehension otherwise 
not possible without the device (74.4 ± 23.4% versus 0.0%, P = 0.043, Wilcoxon 
signed rank test). Similar to the findings of Ahuja et al.(Ahuja et al., 2009), it 
appears that the Argus® II subjects were able to use the visual information they 
have received from the prosthesis with proprioceptive information to locate an 
object in 3D space with some degree of accuracy.  
The use of a flashing beacon finger marker to improve direct visualisation of the 
subject’s own finger did not contribute to any improvement in the performance 
of prehension. The successful completion of prehension without constant finger 
visualisation demonstrated that proprioceptive cues alone were adequate to 
achieve reaching and object contact (Clifton et al., 1993), and that the subjects 
retained good proprioception despite decades of blindness.  
It is interesting to note that most of the patients performed well in this task, and 
the two high-performers in the form discrimination / recognition tasks (see 
Chapter 3) did not show superior performance. There was also no statistical 
difference in the performance of object prehension with the Argus® II system in 
standard mode versus scrambled mode (Kotecha et al., 2014), as would be 
expected from the nature of the task.  These results indicate that it remains 
possible for Argus® II subjects to co-ordinate head / neck proprioception and 
image location on the retina relative to head position, to develop hand-camera 
co-ordination to complete accurate target localisation and prehension tasks. 
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Phosphene Characterisation 
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5.1 Introduction 
Despite its growing clinical use since entering the commercial market in Europe 
(2011) and worldwide (2013), data describing the features of artificial vision 
perceived by the users of the Argus® II retinal prosthesis remain scarce in the 
published literature (Humayun et al., 1996; 1999; 2003; Rizzo et al., 2003b). 
The idea of developing useful vision by epiretinal electrical stimulation hinges 
on the premise that stimulation with a single electrode gives rise to a discrete 
focal percept in a retinotopic manner. Simultaneous stimulation with multiple 
electrodes therefore theoretically leads to perception of a pattern in 
concordance with the pattern defined by the stimulating electrodes (Humayun et 
al., 1999).  
However in earlier studies, as discussed in detail in Chapter 2 (Section 2.7.1 
Human Studies), Rizzo et al. have called into question the consistency and 
reproducibility of phosphenes elicited by patterned epiretinal microelectrode 
stimulation (Rizzo et al., 2003b). In a study involving 5 end-stage RP patients 
and one patient with normal retina, only 48% of the single-electrode stimulations 
and 32% of the multi-electrode stimulations elicited visual percepts that 
matched the electrical stimulation patterns. Of the single-electrode stimulations, 
3 subjects reported “a line” on some occasions, while “clusters of 2 or 3 images” 
were seen on other occasions. In particular, the authors reported that only 66% 
(out of 99 stimulations) of the elicited visual percepts were reproducible in 3 RP 
patients on 2 separate trials despite using the same stimulating parameters to 
activate the same electrodes. Such inconsistencies in the form and 
reproducibility of phosphenes would seriously undermine the formation of 
pixelated vision. Furthermore, as shown in Chapter 3, there is a wide variation 
in the performance level of form discrimination / recognition tasks by our cohort 
of chronically implanted Argus® II subjects. The reason for such performance 
variation is still poorly understood. 
In this study, we set out to investigate the consistency and reproducibility of 
phosphenes elicited in the same cohort of subjects chronically implanted with 
the Argus® II system. All of the subjects described have had the device 
implanted and functioning for over 5 years at the time of the study. The outcome 
of this study has been published (Luo et al., 2016). 
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5.2 Method 
5.2.1 Subject Inclusion / Exclusion Criteria 
This is a single-centre prospective study. All but one of the 7 subjects from 
Moorfields Eye Hospital NHS Foundation Trust implanted with the Argus® II 
retinal prosthesis system as part of the phase I/II clinical trial (clinicaltrials.gov 
Identifier: NCT00407602) took part in the study (n = 6). The one subject was 
excluded as his device ceased to function after developing retinal detachment 
and a thick epiretinal membrane as a result of a fall. The participating subjects’ 
demographic features and operation dates are shown in Table 5.1. The study 
was approved by the local ethics committee, and adhered to the tenets of the 
Declaration of Helsinki. 
Subject ID Diagnosis Year of Operation Age at Time of 
Operation (yrs) 
51-001 Retinitis Pigmentosa 2008 70 
51-003 Retinitis Pigmentosa 2008 72 
51-005 Retinitis Pigmentosa 2009 55 
51-006 Choroideremia 2009 66 
51-007 Retinitis Pigmentosa 2009 63 
51-009 Retinitis Pigmentosa 2009 45 
Table 5.1: Demographics and operation dates of the Argus® II subjects who 
participated in the Phosphene characterisation Study. (Table from (Luo et al., 
2016)) 
5.2.2 Selection of Stimulating Electrodes & Parameters 
For each subject, a cluster of 4 electrodes (hereinafter referred to as a quad) 
closest to the fovea, which were functioning with thresholds within the safety 
charge density limit, was selected for stimulation, and the elicited phosphenes 
characterised for the purpose of this study (see Figure 5.1).   
An estimated location of the fovea was made on the fundus photograph (taken 
at the outset of the study) and was used for each subject as a reference point, 
measuring 15.5 ± 1.1° from the centre of the optic disc horizontally, and -1.5 ± 
0.9° vertically (Rohrschneider, 2004). The foveal position was estimated as 
there were no remaining classical anatomical or structural features of the 
normal fovea on colour photographs, fluorescein angiograms or OCT scans due 
to severe end-stage RP.  
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Figure 5.1: A redfree fundus photograph of one subject (ID: 51-007) with the 
Argus® II retinal implant in situ. The designated four electrodes (i.e. quad) for 
stimulation are indicated as those enclosed in the white square. The foveal 
location is estimated to be 15.5° temporal and 1.5° inferior to the centre of the 
optic disc. The quad-fovea relation is calculated from the estimated fovea 
location, to the centre of the stimulated quad. (Image from (Luo et al., 2016)) 
Once the designated quad was chosen, the stimulating current for each subject 
was arbitrarily set to be 100µA above the threshold (measured within the last 6 
months) initially, and then adjusted according to the strength of response and 
comfort level reported by the subject. We aimed to elicit a clear, definite visual 
percept without causing any discomfort or physical “tingling” sensation for each 
subject.  Default settings for the Argus® II retinal prosthesis system Clinical 
Fitting System (CFS) employed for device fitting and standard testing were 
likewise used for this study, which generate cathodic-first, charge-balanced 
biphasic square waves to avoid tissue damage from charge build up. These 
default waveform parameters were: phase width of 0.46ms, inter-phase duration 
of 0s, and total stimulation duration of 250ms at the frequency of 20Hz (“Argus® 
II Retinal Prosthesis System,” n.d.). Swept source OCT (DRI OCT-1 Atlantis, 
TOPCON®) imaging through the chosen quad for each subject was performed, 
to assess the contact between the stimulating electrodes and the retinal surface 
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(see Figure 5.2).  
The position of each electrode in the 6 x 10 array is designated alphabetically 
by row (A to E), and numerically by column (1 to 10) as shown in Figure 5.1. 
The selected quad, quad-retina relation, quad threshold, and stimulating current 
for each subject were as shown in Table 5.2.  
Subject 
ID 
Quad Quad-
Retina 
Relation 
(on OCT) 
Threshold 
(µA) 
Stimulating 
Current 
(µA) 
Phosphene 
Features 
Phosphene 
Duration, t 
(s) 
51-001 C07C08 
D07D08 
In contact 
*no 
significant 
ERM 
137 277 White filled-
in circle 
0.5 < t < 1 
51-003 A07A08 
B07B08 
In contact 
*no 
significant 
ERM 
250 350 Electric 
blue filled-in 
circle 
t < 0.5 
51-005 E05E06 
F05F06 
In contact 
*no 
significant 
ERM 
137 237 Bluish-grey 
vertical line, 
with fizzy 
vertical 
edges 
t < 0.5 
51-006 A07A08 
B07B08 
Quad-
retina 
separation 
= 377 µm; 
no ERM 
visible  
371 552 Yellow “7” 
shape 
0.5 < t < 1 
51-007 E07E08 
F07F08 
In contact 
*no 
significant 
ERM 
24 124 Orange 
filled-in ring 
which 
ripples out 
0.5 < t < 1 
51-009 E07E08 
F07F08 
In contact 
*no 
significant 
ERM 
97 124 Orange 
horizontal 
lines x 2, 
with fizzy 
brightness 
in between 
the lines 
0.5 < t < 1 
Table 5.2: Phosphene features described by each chronically implanted Argus® 
II retinal prosthesis subject, from stimulating the designated quad with the 
above parameters.  (Table from (Luo et al., 2016)) 
* In images where the electrode array is in direct contact with the retinal 
surface, owing to the artefact caused by the acoustic shadow of the array, it is 
difficult to ascertain the presence, if any, of mild epiretinal membrane.   
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Swept source OCT (DRI OCT-1 Atlantis, TOPCON®) imaging through the 
chosen quad for 51-001. 
 Page 143 
 
Swept source OCT (DRI OCT-1 Atlantis, TOPCON®) imaging through the 
chosen quad for 51-003. 
 
 Page 144 
 
Swept source OCT (DRI OCT-1 Atlantis, TOPCON®) imaging through the 
chosen quad for 51-005. 
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Swept source OCT (DRI OCT-1 Atlantis, TOPCON®) imaging through the 
chosen quad for 51-006. 
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Swept source OCT (DRI OCT-1 Atlantis, TOPCON®) imaging through the 
chosen quad for 51-007. 
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Swept source OCT (DRI OCT-1 Atlantis, TOPCON®) imaging through the 
chosen quad for 51-009. 
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Figure 5.2: Swept source OCT (DRI OCT-1 Atlantis, TOPCON®) imaging 
through the chosen quad for each Argus® II subject. This allows assessment of 
the contact between the stimulating quad electrodes and the retinal surface. 
The quad was in direct contact with the retinal surface in 5 subjects, while in 
subject 51-006, there was a 377µm separation. 
5.2.3 Phosphenes Depiction 
To record the phosphenes perceived by each subject, we constructed a wall 
covered with smooth-surface black mats. The subjects were first asked to stand 
up and stretch out both arms fully to touch the black wall, so that their shoulders 
were square facing the wall. The standing position of each subject was then 
adjusted so that the distance between the front of their eyes and the wall 
equalled to 30cm. Next, the subjects were asked to point with the index finger of 
both hands simultaneously on the black wall, to where they believed the centre 
of their visual field was, while keeping their head and eyes pointing straight 
ahead. A stack of white A4 sized papers (in landscape layout) was then placed 
underneath the index fingers of each subject and pinned to the wall, so that the 
index fingers were pointing at the centre of the top sheet of paper (i.e. the 
centre of the paper was approximating the proclaimed centre of each subject’s 
visual field). A drawing pin with a protruding cylindrical head was then inserted 
at the point where their index fingers contacted with the wall, so as to mark the 
location of the proclaimed visual field centre.  
During the experiment, the subjects were asked to position themselves 
according to the set up above, hold on to the pre-placed drawing pin head and 
adjust their head and eye position until they felt the centre of their visual field 
was in alignment with the drawing pin. With each quad stimulation, the subjects 
were instructed to keep their non-dominant hand on the drawing pin as a point 
of reference, while drawing on the paper the outline of the phosphene they 
perceived in relation to their visual field centre with a marker pen. A fresh sheet 
of paper was used for each phosphene depiction (see Figure 5.3). 
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Figure 5.3: Colour photograph showing an Argus® II subject depicting the 
phosphene he perceived from the selected quad stimulation. The subject was 
positioned with his shoulders square facing the wall and with the eye to wall 
distance of 30 cm. The protruding blue drawing pin was positioned at the visual 
field centre as indicated by the subject. Before commencing each quad 
stimulation, the subject was first asked to hold on to the drawing pin with his 
non-dominant hand, and adjust his head and eye position until he felt his visual 
field centre was in alignment with the drawing pin. When the quad was 
stimulated, he was instructed to keep his non-dominant hand on the drawing pin 
as a point of reference, while drawing on the paper the outline of the phosphene 
perceived in relation to the visual field centre with a marker pen. A fresh sheet 
of paper was used for each phosphene depiction. (Image from (Luo et al., 
2016)) 
5.2.4 Experiment Design 
We set out to test the consistency and reproducibility of phosphenes within 
each subject when the selected quad was stimulated using the same settings, 
but at different time intervals between the stimulations. The experiments were 
divided into those with long inter-stimuli intervals and short inter-stimuli 
intervals.  
For the long intervals experiments, the subjects were asked to draw the 
perceived phosphenes at baseline, and then at subsequent time points whereby 
the inter-stimuli intervals were: 20 minutes, 10 minutes, 5 minutes, 2.5 minutes 
and 1 minute.  For the short intervals experiments, the phosphenes were 
depicted at baseline, as well as at following stimulations with these inter-stimuli 
intervals: 30 seconds, 20 seconds, 10 seconds, 5 seconds, 2 seconds and 1 
second. Due to built-in safety features in the Argus® II system proprietary 
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software and delay in the radio frequency link transmission between the 
external and internal coil of the device, we could not reduce the inter-stimuli 
interval below 1 second. Each set of long intervals experiments and short 
intervals experiments was repeated once on the same day (4 sets of 
experiments per visit). This was then repeated on a separate visit between 1 
week and 1 month later. In total, each subject yielded 4 sets of data for the long 
intervals experiments, as well as 4 sets of data for the short intervals 
experiments, obtained over 2 separate visits. The aim of long inter-stimuli 
intervals experiments was to assess the reproducibility of the phosphenes over 
different time periods, while the short inter-stimuli intervals experiments allowed 
us to evaluate the temporal resolution of the phosphenes up to 1Hz 
stimulations. 
5.2.5 Data Analysis 
All the phosphene drawings were scanned in full size and stored as digital 
images for further computer processing and analysis. 
To assess the consistency and reproducibility of the depictions, we compared 
the phosphene drawings for variability in: a) shape, b) size and c) location within 
each subject.  
a) Shape Comparison 
Adobe® Creative Suite® 5 Photoshop® was employed for the initial image 
processing. All the scanned phosphene drawings for each set of stimulations 
were imported as individual layers in the program, and superimposed at the 
point of subjective visual field centre (i.e. the point marked with the drawing pin). 
The colour of each phosphene drawing was altered to reflect the inter-stimuli 
interval of the stimulation that elicited the phosphene. Such superimposition 
allowed us to display and qualitatively compare the shapes of the drawings 
across different stimulation intervals, as well as across different sets of 
experiments simultaneously. 
b) Size Comparison 
To compare the variations in size of the phosphene drawings, we employed the 
“scale tool” in the GNU Image Manipulation Program (GIMP) software version 
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2.8. The “scale tool” automatically forms a closest-fit rectangle with the 
maximum horizontal and vertical dimension of any selected image. By selecting 
individual phosphene drawings, we were able to calculate and compare the 
changes in the diagonal length of the closest-fit rectangles across the different 
drawings, which indirectly reflected the changes in drawing size (see Figure 
5.4). 
 
Figure 5.4: A screen shot showing the “scale tool” function of the GNU Image 
Manipulation Program (GIMP) software version 2.8. The “scale tool” 
automatically forms a closest-fit rectangle with the maximum horizontal and 
vertical dimension of any selected image, as exemplified by the closest-fit 
rectangle of a phosphene depicted by subject 51-009 after a long inter-stimuli 
interval stimulation. By selecting individual phosphene drawings, we were able 
to calculate and compare the changes in the diagonal length of the closest-fit 
rectangles across the different drawings, which indirectly reflected the changes 
in drawing size. The black dot denotes the subjective visual field centre. 
c) Location Analysis & Comparison 
Analyses on phosphene locations were performed in 2 ways. Firstly, we set out 
to show the variability of these locations within each set of experiments. 
Secondly, we were interested to find out whether the locations of depicted 
phosphenes matched the retinotopic orientation of the stimulated quad for each 
subject.  
To facilitate location analyses, we calculated the centroid for each of the 
phosphene drawings using a Python plug-in in the GNU Image Manipulation 
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Program (GIMP) software version 2.8. (“Light and shadow centroids | GIMP 
Plugin Registry,” n.d.) Within each set of experiments (containing phosphene 
drawings of different inter-stimuli interval stimulations), the centroid of all the 
phosphene centroid points was then calculated. This set centroid represented 
the average location of the perceived phosphenes for that set of stimulations 
(see Figure 5.5).  
 
Figure 5.5: This composite image shows phosphenes depicted by subject 51-
009 during an experiment of long inter-stimuli intervals stimulations. The colours 
of the drawings reflected the specific inter-stimuli intervals that elicited the 
phosphenes. The centroid of each phosphene drawing is shown as a solid circle 
of the same colour. The visual field centre is shown as the black dot. The set 
centroid (i.e. the average location of all the phosphene centroid points) is 
shown as a white circle and marked with an arrow. (Image (Luo et al., 2016)) 
To assess the variability in phosphene locations, the distance between each 
phosphene centroid and the set centroid point was measured for each set of 
experiments. These variations in the distances could then be compared across 
different sets of experiments within each subject as well as amongst different 
subjects. The location of all the 8 set centroid points for each subject relative to 
the subjective visual field centre could also be compared, to show intra-subject 
variability across the different sets of experiments. 
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To further simplify the analysis, a summary centroid location for all the 8 sets of 
experiment for each subject (hereinafter referred to as ‘final centroid’, later 
explained in Figure 5.7) was calculated. This final centroid location was used to 
compare with the expected phosphene location calculated from the quad-fovea 
relation of each subject’s the fundus photographs (see Figure 5.1), to assess 
retinotopic agreement.  
5.3 Results 
5.3.1 Shape Comparison 
Each subject reported consistently seeing phosphenes of the same colour and 
shape irrespective of the inter-stimuli intervals. However, across the subjects, 
there is great variability in the shapes and sizes of the phosphenes perceived 
(see Figure 5.6). The features of the phosphenes as described by each subject 
are summarised in Table 5.2.  
 Page 154 
Figure 5.6: The phosphene drawings for the first set (out of 4 sets) of long inter-
stimuli interval stimulations (left hand panels), and that of the short inter-stimuli 
interval stimulations (right hand panels), are displayed for each of the Argus® II 
subjects. The colour of each phosphene drawing reflects the inter-stimuli 
interval of the stimulation that elicited the depicted phosphene, rather than the 
actual colour perceived by the subject. (Image from (Luo et al., 2016)) 
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5.3.2 Size Comparison 
The mean ± standard deviation of the diagonal distance of the closest-fit 
rectangle for each set of phosphene drawings is shown in Table 5.3. Three 
subjects (51-005, 51-006 and 51-009) drew phosphenes of significantly different 
size during long inter-stimuli interval stimulations (P = 0.005, 0.005 and 0.01 
respectively, Friedman’s test), while one subject (51-007) drew phosphenes 
significantly different in size during short interval stimulations (P = 0.01). For the 
remaining 2 subjects, phosphene depictions for both long and short inter-stimuli 
interval stimulations were consistent with no statistically significant size 
variation. Independently of the drawings, all of the subjects reported that they 
perceived phosphenes of similar sizes with their given quad stimulations. 
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Subject ID 
Diagonal Distance of Closest-fit Rectangle for Phosphene, 
mm 
51-001 51-003 51-005 51-006 51-007 51-009 
Long 
Interval1 
27.98 ± 
6.28 
84.24 ± 
14.94 
58.53 ± 
25.34 
58.53 ± 
25.34  
102.20 
± 21.73 
36.89 ± 
9.11 
Long 
Interval2 
27.42 ± 
5.90 
93.73 ± 
11.18 
46.09 ± 
11.03 
46.09 ± 
11.02 
115.17 
± 15.85 
28.62 ± 
4.94 
Long 
Interval3 
25.90 ± 
7.81 
103.69 
± 5.51 
29.92 ± 
9.81 
29.92 ± 
9.81 
105.47 
± 19.52 
51.99 ± 
13.10 
Long 
Interval4 
25.90 ± 
7.81 
102.88 
± 4.72 
32.46 ± 
5.02 
32.46 ± 
5.02 
111.43 
± 18.80 
29.72 ± 
5.26 
Friedman’s 
Test, P = 
0.18 0.22 *0.005 *0.005 0.71 *0.01 
Short 
Interval1 
21.16 ± 
4.51 
82.73 ± 
7.80 
26.88 ± 
4.43 
26.88 ± 
4.43 
93.97 ± 
10.49 
30.67 ± 
3.09 
Short 
Interval2 
18.03 ± 
7.70 
84.12 ± 
6.56 
24.83 ± 
4.60 
24.83 ± 
4.60 
96.42 ± 
9.41 
26.81 ± 
4.01 
Short 
Interval3 
25.67 ± 
6.42 
100.28 
± 11.99 
20.86 ± 
7.42 
20.86 ± 
7.42 
90.93 ± 
13.29 
30.87 ± 
4.22 
Short 
Interval4 
20.68 ± 
3.66 
84.95 ± 
5.54 
23.85 ± 
4.06 
23.85 ± 
4.64 
76.30 ± 
12.58 
30.49 ± 
3.28 
Friedman’s 
Test, P = 
0.48 0.17 0.74 0.07 *0.01 0.18 
Table 5.3:  A comparison of phosphene size variation depicted by Argus® II 
subjects. This table shows the mean ± standard deviation (in millimetres) of the 
diagonal distance of the closest-fit rectangle for each set of phosphene 
drawings. Friedman’s analysis of variance showed statistically significant 
difference in the drawing size for long inter-stimuli interval stimulations in 3 
subjects, and in short inter-stimuli interval stimulations in 1 subject (marked with 
asterisk, *). (Table from (Luo et al., 2016)) 
5.3.3 Location Analysis & Comparison 
a) Location Variability  
Variability in the phosphene locations was first evaluated in terms of changes in 
the mean ± standard deviation of the distance between the set centroid point 
and the individual phosphene centroids within the set (see Table 5.4).  
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Subject ID 
Mean ± S.D. Phosphene Centroid-Set Centroid Distance 
mm 
51-001 51-003 51-005 51-006 51-007 51-009 
Long 
Interval1 
30.7 ± 
11.5 
13.0 ± 
3.43 
19.1 ± 
18.8 
8.3 ± 
5.9 
6.4 ± 
2.7 8.9 ± 3.9 
Long 
Interval2 
27.0 ± 
20.6 
9.0 ± 
7.0 
25.2 ± 
17.4 
9.4 ± 
7.2 
6.3 ± 
2.1 
14.2 ± 
6.4 
Long 
Interval3 
27.5 ± 
13.7 
9.4 ± 
5.6 
20.5 ± 
9.9 
19.8 ± 
9.24 
6.0 ± 
2.3 
15.2 ± 
6.3 
Long 
Interval4 
27.5 ± 
6.4 
8.3 ± 
3.9 
13.3 ± 
5.1 
10.2 ± 
6.5 
9.0 ± 
1.5 
12.6 ± 
5.6 
Short 
Interval1 
22.7 ± 
14.6 
10.2 ± 
7.3 
12.3 ± 
8.2 
14.0 ± 
5.8 
8.1 ± 
5.4 
11.3 ± 
5.0 
Short 
Interval2 
28.4 ± 
17.4 
8.6 ± 
2.7 
16.8 ± 
5.9 
12.7 ± 
8.4 
11.2 ± 
6.8 
10.5 ± 
6.5 
Short 
Interval3 
36.1 ± 
21.5 
12.4 ± 
6.2 
18.1 ± 
9.6 
13.0 ± 
9.4 
7.9 ± 
4.4 
11.5 ± 
6.3 
Short 
Interval4 
39.8 ± 
15.5 
10.5 ± 
8.0 
14.6 ± 
7.3 
14.8 ± 
8.1 
16.8 ± 
7.5 
11.6 ± 
7.5 
Table 5.4: Intra-subject variability of the phosphene locations (represented by 
phosphene centroids) depicted by each of the Argus® II subjects. The mean (± 
standard deviation) distance of the individual phosphene centroids to the set 
centroid for all sets of experiments are shown. (Table from (Luo et al., 2016)) 
The changes in the position of the phosphenes across different sets of 
experiments are shown as set centroid distribution relative to each subject’s 
visual field centre (see Figure 5.7 and Table 5.5). 
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Figure 5.7: Diagrams showing the centroids of the phosphenes depicted by 
each of the chronically implanted Argus® II retinal prosthesis subjects. The set 
centroids (white circles) and the final centroid point (centroid of the set 
centroids, denoted as a red circle) are shown relative to each subject’s visual 
field centre (black dot). (Image from (Luo et al., 2016)) 
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Subject ID 51-001 51-003 51-005 51-006 51-007 51-009 
Set 
Centroid: 
Long 
Interval1 
36.6 mm 
S(T) 
20.0 mm 
IT 
25.9 mm 
IT 
14.5 mm 
SN 
9.3 mm 
IN 
38.7 mm 
IT 
Set 
Centroid: 
Long 
Interval2 
17.7 mm 
(I)T 
9.2 mm 
ST 
42.9 mm 
IT 
22.3 mm 
SN 
7.0 mm 
IN 
28.2 mm 
IT 
Set 
Centroid: 
Long 
Interval3 
25.7 mm 
ST 
0.00 mm 
O 
35.5 mm 
IT 
19.3 mm 
ST 
9.6 mm 
IN 
68.0 mm 
(I)T 
Set 
Centroid: 
Long 
Interval4 
23.9 mm 
(S)T 
6.9 mm 
IT 
24.4 mm 
(I)T 
24.6 mm 
SN 
6.1 mm 
IN 
36.6 mm 
IT 
Set 
Centroid: 
Short 
Interval1 
25.9 mm 
(S)T 
15.1 mm 
IT 
37.2 mm 
IT 
33.0 mm 
ST 
5.8 mm 
I 
46.6 mm 
(I)T 
Set 
Centroid: 
Short 
Interval2 
22.9 mm 
ST 
11.9 mm 
IT 
46.0 mm 
IT 
55.3 mm 
ST 
11.2 mm 
IT 
46.9 mm 
IT 
Set 
Centroid: 
Short 
Interval3 
41.2 mm 
S(N) 
24.8 mm 
IT 
30.3 mm 
IT 
56.2 mm 
IT 
2.0 mm 
ST 
48.9 mm 
(I)T 
Set 
Centroid: 
Short 
Interval4 
51.4 mm 
ST 
10.6 mm 
IT 
24.8 mm 
ST 
55.5 mm 
IT 
36.2 mm 
T 
54.5 mm 
T 
Final 
Centroid 
24.8 mm 
ST 
10.9 mm 
IT 
31.5 mm 
IT 
21.4 mm 
ST 
6.1 mm 
IT 
45.4 mm 
IT 
Table 5.5: This table shows the distance and relative location of the set centroid 
to Argus® II subject’s visual field centre. ST = superotemporal to, IT = 
inferotemporal to, SN = superonasal to, IT = inferotemporal to, and O = the set 
centroid overlaps the visual field center. When the angle of deviation of the set 
centroid point is less than 10° from the horizontal or vertical line, the direction of 
deviation is bracketed. The final centroid was calculated to represent the 
summary position of all the set centroids for each subject. (Table from (Luo et 
al., 2016)) 
b) Retinotopic Agreement 
The quad-fovea location and the expected phosphene location for each subject 
are as shown in Table 5.6. Out of the 6 subjects, 4 subjects’ depicted 
phosphene locations fell in the same quadrant of the visual field as that of the 
expected phosphene location. Two subjects’ (51-001 and 51-005) depicted 
phosphenes in the same hemi-field (temporal and inferior respectively) as the 
expected locations.  
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Subject ID 001 003 005 006 
 
007 009 
Quad C07C08 
D07D08 
A07A08 
B07B08 
E05E06 
F05F06 
A07A08 
B07B08 
E07E08 
F07F08 
E07E08 
F07F08 
Quad-Fovea 
Distance 
1100µm 1000µm 1200µm 1300µm 1100µm 2400µm 
Quad Position 
Relative to 
Fovea  
SN SN ST IN SN SN 
Expected 
Phosphene 
Location in VF 
19.2 mm 
IT 
17.5mm 
IT 
21.0 mm 
IN 
22.7 mm 
ST 
19.2 mm 
IT 
42.16 mm 
IT 
Final Centroid 
Location in VF 
24.8 mm 
ST 
10.9 mm 
IT 
31.5 mm 
IT 
21.4 mm 
ST 
6.1 mm 
IT 
45.4 mm 
IT 
Table 5.6: This table shows the quad position relative to the estimated fovea 
location from fundus photograph for each subject. The expected phosphene 
location and the final centroid location relative to each subject’s visual field (VF) 
center are also shown. SN = superonasal; ST = superotemporal; IN = 
inferonasal; and IT = inferotemporal. (Table from (Luo et al., 2016)) 
5.4 Discussion 
With the establishment of good long term safety profiles (Ho et al., 2015; 
Humayun et al., 2012) and advances in biotechnology promising larger number 
of pixels in the future (Stronks and Dagnelie, 2014), high resolution pixelated 
vision from electrical retinal stimulations may become an important avenue for 
vision restoration. Despite the encouraging outcomes showing improved visual 
performance with the use of the device(daCruz et al., 2012; Garcia et al., 2014; 
Humayun et al., 2012; Luo and daCruz, 2016), understanding of the interaction 
between the stimulating parameters and the individual subjects’ visual percepts 
remains poor. Clearly the ability to produce consistent, controllable and 
retinotopically-defined phosphenes will remain central to improving prosthetic 
vision in the future.  
We chose the parafoveal quad as our focus for evaluation as physiologically, 
the photoreceptor: bipolar cells: ganglion cells ratio in this region approaches 1: 
1: 1. Direct electrical stimulation at this area would therefore theoretically be 
most predictable, giving rise to focal, dot-like phosphenes, whether the bipolar 
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cells and / or ganglion cells were the main target of electrical stimulation. 
Greater density of ganglion cells found in this region also allowed for lower 
stimulating currents to be used to elicit distinctive phosphenes reliably (i.e. 
lower threshold). Quad stimulation, rather than single electrode, was chosen as 
only 2 out of the 6 subjects had functioning single electrodes in the parafoveal 
region at the time of the study. 
Interestingly, our study has shown that irrespective of the variability in size and 
location of the drawn phosphenes, all our subjects reported perceiving 
phosphenes of the same shapes and similar sizes when using the same 
stimulating parameters. This consistency was seen across different inter-stimuli 
intervals (with temporal resolution down to 1 second) and was reproducible on 
separate occasions ranging from 1 week to 1 month apart. However, in spite of 
the good intra-subject consistency, each of the 6 subjects experienced 
phosphenes of totally different shapes and sizes. It is likely that the inter-subject 
variations reflect the variety of genetic diseases, the duration the degeneration 
has been present, the different proportions of surviving bipolar and ganglion cell 
types, and the variability in reconnections and remodelling within these severely 
diseased retinas. 
The wide variation in phosphene shape and size may in part explain the wide 
range of inter-subject performance levels observed when they performed tasks 
involving visual form differentiation, e.g. letter recognition, shapes and objects 
recognition (daCruz et al., 2012; Luo and daCruz, 2016). Indeed one subject 
(51-009) who consistently out-performed other subjects in all the vision form 
recognition tasks, depicted phosphene shapes closest to the stimulation pattern 
(i.e. 2 horizontal lines with filled in centre, simulating a box shape from the quad 
stimulation). It is also interesting to note that despite the inter-subject variability 
in perceived phosphenes, Argus® II subjects still performed statistically 
significantly better in visual form differentiation tasks with the device on than 
without. This may be attributable to the intra-subject consistency and 
reproducibility of the phosphenes elicited. Such consistency and reproducibility 
may allow each subject to learn and adapt to the prosthetic visual information 
(albeit crude and unlike natural vision), and use it to make consistent, simple 
decisions about form. This learning is evident in the improvement of 
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psychophysical and other visual tasks performance with training (Chader et al., 
2009; Stronks and Dagnelie, 2014).  
Sabbah et al. reported that the perceived position of the phosphene is 
dependent on the direction of gaze (i.e. the eye position) of the Argus® II 
subject, and that misalignment of head and eye position occurred in all the 
subjects in their study (Sabbah et al., 2014). This would explain the variations in 
the location of the phosphene drawings in our study, even though the subjects 
were instructed to keep their head and eyes pointing straight ahead during the 
task. The largest deviation of the phosphene centroid location from the set 
centroid location was 39.8 ± 15.5 mm, indicating a disparity distance of about 5 
cm, viewed at 30 cm away (≈ 9.5˚). One subject (51-007) showed greater 
localisation consistency than the others (see Figure 5.7), and this is consistent  
with his superior performance in carrying out object prehension tasks (see 
Chapter 4) (Luo et al., 2015). This is also in keeping with Sabbah et al.’s 
conclusion that the Argus® II subjects are able to develop strategies to 
minimize the impact of head-eye misalignment. Our study also showed that 4 
out of the 6 subjects had phosphene locations in the expected visual field 
quadrant, as indicated by the relative quad-fovea location. These subjects may 
be better at keeping their head-eye alignment, such that their subjective visual 
field centre was in alignment with the estimated fovea location.  
In general, our study showed that stimulation of the same quad with the same 
stimulating parameters gave rise to consistently reproducible phosphenes for a 
given subject in a cohort of chronically implanted subjects more than 5 years 
after the initial surgery. This consistency is an encouraging basis for the 
construction of more complicated pixelated images. Given the vastly different 
shapes and sizes of the phosphenes perceived by individual subjects, future 
work into determining the suitable stimulating parameters for each electrode / 
quad stimulation may be required for each subject, to achieve the construction 
of useful pixelated prosthesis based vision.  
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MRI Brain Scan Safety 
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6.1 Introduction 
Magnetic resonance imaging (MRI) is a frequently used investigative tool. Of 
the 30 million MRIs performed annually in the USA(OECD, 2012), 22% are 
brain scans (“Market Research MRI products,” n.d.). With the increasing clinical 
use of the Argus® II retinal prosthesis following CE mark (March 2011) and 
FDA approval (February 2013), safety information on the use of MRI with the 
device will be useful.  
Weiland et al. (Weiland et al., 2012) addressed the safety aspects of performing 
MRI in Argus® II patients based on in-vitro experimental findings with 
phantoms. They concluded that MRI performed at 1.5 or 3-Tesla field strength 
(highest spatial gradient magnetic field of 720 gauss/cm) in the absence of the 
external components, would not be detrimental to the patient and the device.  
In this study, we reported 3 subjects chronically implanted with the Argus® II 
retinal prosthesis system, who underwent MRI brain scans for medical 
indications independent of the trial. To our knowledge, what is reported here 
represents the first experience of in-vivo MRI examinations performed with the 
Argus® II retinal implants in-situ. Some of the data from this study has been 
published (Luo et al., 2013). 
6.2 Materials & Methods 
This is a single-centre, retrospective case series. Three subjects chronically 
implanted with the Argus® II retinal prosthesis in the initial phase I/II feasibility 
study who underwent MRI brain scans for unrelated medical conditions were 
included. Argus® II device stability before and after the MRI brain scan was 
assessed both anatomically and functionally. The effect of the in situ Argus® II 
retinal implant on the diagnostic quality of the MRI brain scan image would also 
be evaluated. 
6.2.1 Anatomical Assessment 
As previously described in Chapter 2 (section 2.2, Figures 2.2 and 2.3), the 
internal components of the Argus® II retina consists of an internal coil, an ASIC 
enclosed in a hermetically sealed case and a 60-channel microelectrode (6 x 
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10) array which rests on the retinal surface and is held in place with a custom-
made, spring-tension, metallic tack (Second Sight Medical Products. Inc.). After 
surgical implantation, the only portion of the device that is directly visible is the 
epiretinal microelectrode array on the retinal surface. 
To assess the anatomical stability, 4 modalities of assessment were applied: 
a) Colour fundus photograghy 
b) Optical coherence tomography (Topcon 3D-OCT 2000) 
c) Electrode impedance measurements  
d) Clinical examination with slit lamp biomicroscopy 
The colour fundus photographs of the posterior pole were acquired before and 
after the MRI brain scan for en face comparison for each subject. OCT (Topcon 
3D-OCT 2000) scans of the epiretinal microelectrode array was also performed 
before and after the MRI brain scan to assess any axial movement of the 
epiretinal microelectrode array. Further more, the electrical contact of the 
microelectrode array with the retinal surface could be reflected in the individual 
electrode impedance measurements. These measurements before and after the 
MRI brain scan were also compared. Slit lamp biomicroscopy examinations 
were performed after the MRI brain scan to look for any extraocular sign of 
implant movement or extrusion through conjunctiva.  
6.2.2 Functional Assessment 
The function of the Argus® II device was assessed by monitoring changes in 
the thresholds of the microelectrode array after the MRI brain scan for each 
subject. It has been observed that in all chronically implanted Argus® II 
subjects, there is a range of intra-subject inter-testing variability. As such, the 
thresholds of the 60 electrodes were tested at two stimulating current levels, 
233µA and 677µA, and separated into 3 levels: a) low threshold (≤233µA), b) 
moderate threshold (≥233µA but ≤ 677µA), and c) high threshold (≥677µA). 
This allows comparison of proportional changes in threshold levels distribution 
with time within each subject. Any electrode that caused discomfort with 
stimulation was disabled during the testing.  
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6.3 Result 
The demographics of the participating subjects are as shown in Table 6.1. The 
study was approved by the local ethics committee for our centre and respected 
the tenets of the Declaration of Helsinki.  
Subject ID Diagnosis Year of 
Operation 
Age at Time of 
Operation (yrs) 
Date of MRI 
Brain Scan 
51-007 Retinitis 
Pigmentosa 
2009 63 September 2011 
51-001 Retinitis 
Pigmentosa 
2008 70 September 2012 
51-003 Retinitis 
Pigmentosa 
2008 72 February 2013  
Table 6.1: Demographics and MRI brain scan dates of the 3 Argus® II subjects 
who underwent MRI brain scans for unrelated medical conditions. 
6.3.1 Intraocular Implant Position & Function 
6.3.1.1 Case 1 (Subject 51-007) 
This Caucasian male received the Argus® II retinal prosthesis implant in 2009. 
He underwent 1.5- Tesla MRI brain scan in September 2011 for investigation of 
tinnitus. Colour fundus photographs of the posterior pole 3 months prior to and 
8 months after the MRI brain scan did not show gross rotational or other  
topographical change in implant position (see Figure 6.1). 
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Figure 6.1: A colour fundus photographs of the right eye of subject 51-007 who 
received Argus® II retinal prosthesis implant in 2009.  In the pre-MRI scan 
fundus photo (top image), the microelectrode array covers the majority of the 
macula region and is fixed to the retinal surface by the retinal tack to achieve 
retinal apposition. The post-MRI scan photo (bottom image) was taken 8 
months after the scan. The microelectrode array remains fixed by the retinal 
tack to the retinal surface, covering the same area of the macula as before. 
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There is no evidence of implant dislocation, rotation, or retinal detachment. 
(Image modified from (Luo et al., 2013)) 
OCT scan of the microelectrode array 3 months before and 8 months after the 
MRI brain scan also did not show any change in axial position, with the implant 
remaining in direct contact with the retinal surface both before and after the MRI 
brain scan (see Figure 6.2). There are no associated complications of implant 
dislocation or retinal detachment to date. The distribution of electrode 
impedance was comparable before and after the scan, suggesting no change in 
retinal contacts (see Figure 6.3).  
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Figure 6.2: OCT image (Topcon 3D-OCT 2000) of Argus® II implant in the right 
eye of subject 51-007 at 3 months before the MRI brain scan (top image), and 
at 8 months after the scan (bottom image). In the pre-MRI OCT, the under 
surface of the retinal implant is closely apposed to the retinal surface. The 
upper surface of the Argus II implant is seen as the upper-most bright reflective 
layer. The electrodes of the implant are seen casting vertical acoustic shadows 
over the retina. In the post-MRI OCT, the under surface of the electrode array 
remains closely apposed to the retinal surface. (Image from (Luo et al., 2013)) 
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Figure 6.3: Histogram of electrode impedance distribution for subject 51-007 
before and after MRI brain scan. (Image from (Luo et al., 2013)) 
With regards to implant function, serial threshold testing pre-MRI scan showed 
that there is a general trend of threshold increase with time, but there is no 
substantial change in the thresholds after the MRI scan in subject 51-007 (see 
Figure 6.4). This trend of gradual threshold increase with time has also been 
observed in the other 4 Argus® II subjects (51-003, 51-005, 51-006 and 51-009) 
from our unit who did not undergo MRI brain scan (controls). 
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MRI Brain Scan Subjects 
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Figure 6.4: Bar chart showing the proportional changes in electrode threshold 
distribution with time. The thresholds of the 60 electrodes were tested at two 
stimulating current levels, 233µA and 677µA, and separated into 3 levels: a) low 
threshold (≤233µA), b) moderate threshold (≥233µA but ≤ 677µA), and c) high 
threshold (≥677µA). During the testing, electrodes which caused discomfort with 
stimulation were disabled. The first 3 subjects (51-007, 51-001 and 51-003) 
underwent MRI brain scan. Their threshold testing performed after MRI brain 
scan is marked with asterisk (*), which took place 8 months after the scan for 
51-007 (36 months post-op), and at 1 month after the scan for both 51-001 (53 
months post-op) and 51-003 (57 months post-op). A similar trend of gradual 
increase in electrode threshold over time has been observed in all the subjects 
including the controls (51-002, 51-005, 51-006 and 51-009).§ Denotes episodes 
when the subject did not undertake electrode threshold measurement as it was 
optional on the protocol for those time points. (Image modified from (Luo et al., 
2013))  
6.3.1.2 Case 2 (Subject 51-001) 
This Caucasian male underwent Argus® II retinal prosthesis implantation in 
2008 and had a MRI brain scan in September 2012 at 1.5T for investigation of a 
base of tongue tumour. Fundus photographs, OCT and electrode 
measurements were performed 6 months prior to and at 1 month after the MRI 
brain scan. Topographically, there appears to be no change in the implant 
position, and no associated complications such as retinal detachment on the 
colour fundus photograph (see Figure 6.5). 
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Figure 6.5: Colour fundus photographs of the right eye of subject 51-001 who 
received Argus® II retinal prosthesis implant in 2008.  In the pre-MRI scan 
fundus photo (top image), the microelectrode array covers the superotemporal 
part of the macula. The post-MRI scan photo (bottom image) was taken 1 
month after the scan, with the microelectrode array covering the same area of 
the macula as before. (Image modified from (Luo et al., 2013)) 
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OCT scans showed an area of non-contact between the implant and the retinal 
surface, which pre-dates the MRI brain scan. This separation measured at a 
determined location (electrode D2) was 759µm before MRI brain scan, and 
remained stable post-scan, measuring 755µm (see Figure 6.6). This finding is 
supported by the similar distribution of the electrode impedance measurements 
(see Figure 6.7). 
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Figure 6.6: OCT image (Topcon 3D-OCT 2000) of Argus® II implant in the right 
eye of subject 51-001 at 6 months before the MRI brain scan (top image), and 
at 1 months after the scan (bottom image). In the pre-MRI OCT, the under 
surface of the retinal implant at electrode position D2 (second electrode of third 
row) was separated from the retinal surface by 759 microns.  In the post-MRI 
OCT, the distance of retinal implant separation from the retinal surface under 
the electrode remained similar at 755 microns, indicating minimal change in 
axial position in relation to retinal surface. (Image from (Luo et al., 2013)) 
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Figure 6.7: Histogram of electrode impedance distribution for subject 51-007 
before and after MRI brain scan. (Image from (Luo et al., 2013)) 
Functionally, the electrode thresholds were also comparable before and after 
MRI scan, whilst exhibiting the general trend of chronological threshold increase 
as seen in controls (see Figures 6.4). 
6.3.1.3 Case 3 (51-003) 
This Caucasian male received Argus® II retinal prosthesis implantation in 2008 
and underwent a MRI brain scan in September 2013 at 1.5T for investigation of 
a suspected cerebral vascular accident (CVA). 
Fundus photographs, OCT and electrode measurements were performed 6 
months prior to and at 1 month after the MRI brain scan. Similarly, there is no 
gross topographical change in the implant position as shown on the fundus 
photograph (see Figure 6.8). 
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Figure 6.8: Colour fundus photographs of the right eye of subject 51-003 who 
received Argus® II retinal prosthesis implant in 2008.  In the pre-MRI scan 
fundus photo (top image), the microelectrode array covers the superotemporal 
part of the macula. The post-MRI scan photo (bottom image) was taken 1 
month after the scan, with the microelectrode array covering the same area of 
the macula as before.  
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OCT scan of the microelectrode array 6 months before and 1 month after the 
MRI brain scan also did not show any change in axial position, with the implant 
remaining in direct contact with the retinal surface both before and after the MRI 
brain scan (see Figure 6.9).  
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Figure 6.9: OCT image (Topcon 3D-OCT 2000) of Argus® II implant in the right 
eye of subject 51-003 at 6 months before the MRI brain scan (top image), and 
at 1 months after the scan (bottom image). In the pre-MRI OCT, the under 
surface of the retinal implant is closely apposed to the retinal surface, which 
remains so in the post-MRI OCT. 
Electrode impedance measurements before and after the MRI brain scan 
showed a similar distribution, again indicating similar array-retina contact before 
and after the scan (see Figure 6.10). 
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Figure 6.10: Histogram of electrode impedance distribution for subject 51-003 
before and after MRI brain scan. 
Functionally, as seen in the previous 2 subjects, the electrode thresholds were 
comparable before and after MRI scan, whilst exhibiting the general trend of 
chronological threshold increase as seen in controls (see Figures 6.4). 
Extraocular Implant Assessment and Subjective Reports 
Extraocular implant position and stability was assessed by slit lamp 
bimicroscopy clinical examination. There was no evidence of implant movement 
or extrusion through the conjunctiva in any of the 3 patients. The hermetically 
sealed case housing the receiving coil electronics remained unchanged in 
position under the subconjunctival fibrous capsule.  
All 3 patients were able to carry out visual rehabilitation tasks as before the MRI 
scan, and did not report any subjective change in device functionality after the 
scan. 
6.3.2 Effect of Argus® II Retinal Prosthesis on MRI  
The MRI examinations were retrospectively evaluated by a consultant neuro-
radiologist to assess the diagnostic quality of the imaging and related 
paramagnetic artifact generated from the prosthesis. The Argus® II implant 
produced local moderate paramagnetic artifacts at 1.5 Tesla field-strength 
measured maximally at 29mm x 37mm x 40mm (AP x TR x SI) (Weiland et al., 
2012). This precluded clear visualisation of intra-orbital contents immediately 
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adjacent to the implant causing loss of signal return and anatomical distortion, 
but interpretation of other orbital and retro-orbital structures outside of this area 
was unaffected and diagnostic (see Figure 6.11). 
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Figure 6.11: Magnetic Resonance Imaging at 1.5-Tesla with the Argus® II 
retinal implants in the right eye of a patient, on a) axial T2-weighted, b) coronal 
T1-weighted and c) sagittal T1-weigthed acquisitions. The measurements are 
the maximal dimensions of the artifact (in millimeters) in the anterior-posterior 
(AP), transverse (TR) and superior-inferior (SI) planes. (Image from (Luo et al., 
2013)) 
6.4 Conclusion 
In this study, we reported on 3 patients who underwent MRI brain scan at 1.5T 
with Argus® II retinal prosthesis in-situ. There appears to be no detrimental 
effect to the patients and their implant function with the scan. The implant 
position remained stable in all 3 patients after the MRI brain scan, as assessed 
topographically by colour fundus photography, axially by OCT scan, and 
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electrically by electrode impedance measurements. The device function also 
remained robust after the MRI brain scan, as shown objectively with the 
electrode threshold measurement, as well as from the patients’ subjective 
reports. 
The Argus® II implant produces an artifact of around 50mm x 50mm in size 
which would prevent visualisation of structures within the orbit, but visualisation 
of surrounding tissues outside these areas are unaffected. Further 
investigations into other safety issues such as the potential of generating 
electrical outputs to the retina during MRI scanning, with a greater number of 
samples would be required to fully determine the safety of MRI brain scan in 
Argus® II patients. 
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Chapter 7 
 
Functional Near Infra-red 
Spectroscopy (fNIRS) 
Imaging of Primary Visual 
Cortical Activation 
  
 Page 187 
7.1 Introduction 
In the previous chapters, we have demonstrated that the Argus® II retinal 
prosthesis system is capable of improving the visual function in extremely low 
vision patients who suffered from end stage outer retina diseases. However this 
visual improvement, particularly in terms of form vision(daCruz et al., 2013; Luo 
and daCruz, 2016) (see chapter 3), is highly variable amongst the subjects. 
This could in part be due to the variability in the specific phosphene 
characteristics experienced by individual subjects (Luo et al., 2016) (see 
chapter 5), as well as the unpredictable phosphene persistence in relation to 
stimulation duration (Pérez Fornos et al., 2012).  
As discussed earlier in chapter 5, one possible explanation for these 
phosphene variances could be secondary to retinal remodelling and aberrant 
nerve regeneration within the severely diseased retina (Marc et al., 2007; 2003) 
(Jones et al., 2012; Jones and Marc, 2005). Furthermore, due to the prolonged 
period of blindness (all the subjects in our study have been blind for many years 
if not decades prior to receiving the retinal implant), it is likely that some form of 
cortical neural remodelling, or indeed colonisation of the primary visual cortex 
by other sensory modalities, may have occurred (Bavelier and Neville, 2002). It 
has been shown with cochlear implants that in deaf individuals with extensive 
cross-modal plasticity of the auditory cortex, the benefit of the implant is limited 
(Chen et al., 2016; Lee et al., 2001). As such, characterisation of the integrity of 
the primary visual cortex in blind patients, as well as demonstration of continual 
neural recruitment in the multimodal association areas (of the parietal cortex) in 
response to retinal stimulation, could be important predictive indicators of 
functional outcome in future retinal or other visual prosthetic implants. 
To achieve this ambition, the pre-requisite is to identify a reliable way of 
measuring real-time activation of the primary visual cortex in response to retinal 
stimulation. Following demonstration of the safety of performing MRI brain 
scans in chapter 6 (Luo et al., 2013), functional MRI would seem the imaging 
modality of choice for this study. However, safety of MRI brain scans in Argus® 
has only been demonstrated with the Argus® II device switched off during the 
scan, excluding the external image-capture and stimulating components. 
Secondly, on further discussion with our medical physicist collaborators from 
 Page 188 
University College London (UCL), there are concerns that the radiofrequency 
waves of the Argus® II system telemetry may be in the same wavelength 
spectrum as that of the radiofrequency pulse generating MRI scan signals, 
resulting in interference. As such, alternative method of measuring real-time 
cortical activation was sought. 
In this study, we set out to explore the feasibility of using functional near infra-
red spectroscopy (fNIRS) imaging as a mean of monitoring primary visual 
cortex activity, in response to direct retinal stimulation with the Argus® II retinal 
prosthesis. 
7.2 Methods 
7.2.1 Subject Inclusion / Exclusion Criteria 
This is a single-centre prospective study. All 6 subjects who took part in the 
phosphene characterisation study (Luo et al., 2016) in chapter 6 also took part 
in this study. These included all but one of the 7 subjects from Moorfields Eye 
Hospital NHS Foundation Trust implanted with the Argus® II retinal prosthesis 
system as part of the phase I/II clinical trial (clinicaltrials.gov Identifier: 
NCT00407602). One subject was excluded as his device ceased to function 
after developing retinal detachment and a thick epiretinal membrane as a result 
of a fall. The participating subjects’ demographic features and operation dates 
are as previously shown in Table 5.1 in chapter 5, and are presented here in 
Table 7.1 below. All but one subject (51-003) are right-handed according to the 
Edinburgh Handedness Inventory (Oldfield, 1971). The study was approved by 
the local ethics committee, and adhered to the tenets of the Declaration of 
Helsinki. 
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Subject ID Diagnosis Year of 
Operation 
Age at Time of 
Operation (yrs) 
Hand 
dominance 
51-001 Retinitis 
Pigmentosa 
2008 70 Right-handed 
51-003 Retinitis 
Pigmentosa 
2008 72 Left-handed 
51-005 Retinitis 
Pigmentosa 
2009 55 Right-handed 
51-006 Choroideremia 2009 66 Right-handed 
51-007 Retinitis 
Pigmentosa 
2009 63 Right-handed 
51-009 Retinitis 
Pigmentosa 
2009 45 Right-handed 
Table 7.1: Demographics and operation dates of the Argus® II subjects who 
participated in the fNIRS Study.  
7.2.2 Functional Near Infra-red Spectroscopy (fNIRS) Imaging 
In functional near infra-red spectroscopy (fNIRS), the relative transparency of 
human brain tissues to light in the near infra-red (NIR) spectrum (650 – 
1000nm) (Jobsis, 1977) is exploited to allow real-time measurement of changes 
in the concentration of oxygenated haemoglobin (O2Hb) and deoxygenated 
haemoglobin (HHb) in blood as it passes through small vessels (<1mm in 
diameter) in the brain (Ferrari and Quaresima, 2012; Scholkmann et al., 2014). 
Typically, light sources emitting two NIR wavelengths are utilised: one 
wavelength is selected to have high absorbance by oxygenated haemoglobin, 
while the other is preferentially absorbed by deoxygenated haemoglobin. By 
placing NIR detectors at pre-determined distances from the NIR light sources, 
the local concentration of O2Hb and HHb of the medium (in this case human 
brain tissues) can be calculated from the modified Beer-Lambert Law (Delpy et 
al., 1988): 
 
where A is the absorbance of the NIR by the medium; I0 is the initial intensity of 
the incident light (i.e. NIR emitted by the light sources), I is the intensity of the 
transmitted light after it leaves the medium (as measured by the NIR detectors); 
c is the density of the medium; ε  is the molar extinction coefficient characteristic 
of the medium for a light of wavelength λ; l is the distance that the light travels in 
the medium (which corresponds to the light source-detector distance); DPF is 
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the differential pathlength factor that accounts for the non-linear trajectory of 
light in biological media; and G is the scatter (Gervain et al., 2011).  
There are 3 main techniques in performing fNIRS: a) continuous-wave (CW) 
modality; b) frequency-domain (FD) modality; and c) time-domain (TD) modality. 
The CW modality consists of a constant illuminating light source, and the light 
attenuation through brain tissues is measured.  This technique, though relatively 
straightforward to perform, does not measure DPF and G, and as such cannot 
provide absolute values of O2Hb and HHb concentrations. Instead, changes in 
the O2Hb and HHb concentrations relative to a baseline resting levels are 
measured. In FD modality, the intensity of the light is varied at a certain 
frequency and the resultant phase difference and intensity attention as the light 
travels through the brain tissues can be analysed to calculate the DPF and G. 
The TD modality on the other hand, employs single light pulses and the DPF is 
calculated from the average time-of-flight of photons as individual photons travel 
through the brain tissues. Both FD and TD techniques therefore provide 
absolute value measurements of O2Hb and HHb concentrations in the medium 
as DPF and G values can be obtained. However, as both FD and TD 
techniques require much lower sampling rate, longer acquisition time and higher 
cost than CW modality, and for the purpose of research, relatively changes in 
O2Hb and HHb concentrations provide adequate information on cortical 
activation, CW modality has become the most widely employed technique in 
research studies with well-established data (Ferrari and Quaresima, 2012). The 
following study is performed with the CW technique, and FD and TD modality 
will not be discussed further. 
With the CW technique, the relative changes in the concentration of O2Hb and 
HHb (rather than absolute values) are calculated using: 
 
whereby Δcoxy and Δcdeoxy are changes in the concentration of oxygenated 
and deoxygenated haemoglobin respectively. By performing measurements 
using two wavelengths, thereby yielding two equations, the values of coxy and 
cdeoxy can be calculated from the change in absorbance (ΔA). 
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The penetrance of NIR light through tissue is calculated to be approximately 
between a quarter to three-quarters of the light source-detector distance 
(Gratton et al., 1994). The recommended source-detector distance is therefore 
between 2 – 3cm, so as to offer a good balance between topographical spatial 
resolution and tissue penetrance.  
During activation of a cortical area, due to the physiological neurovascular 
coupling (NVC) response (Obrig et al., 2000; Sandman et al., 1984), there is an 
initial rise in oxygenated haemoglobin level (from increased influx of 
oxygenated haemoglobin to the area), which then falls with time. This is 
mirrored by an opposite but smaller change in deoxygenated haemoglobin level 
(see Figure 7.1). By placing an array of alternating source and detector optodes 
over the scalp of the occipital lobe, one can measure the underlying NVC 
response, hence cortical activation, of the primary visual cortex (see Figure 
7.2).   
  
 Page 192 
 
Figure 7.1: A sketch of an optode channel showing typical haemodynamic 
response in cortical activation. There is a statistically significant increase in the 
O2Hb level, matched by a statistically significant decrease in the HHb level 
following stimulation, before returning to baseline. (Image from (Scholkmann et 
al., 2014)) 
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Figure 7.2: A schematic drawing based on the international 
electroencephalography (EEG) 10-5 system cap (Jurcak et al., 2007) showing 
optode arrangements for measuring visual cortex activity using the NIRScout 
system. The red dots denote the locations of NIR light sources; the blue dots 
denote the locations of the NIR detectors. The green lines represent optode 
channels between a specific light source and detector whereby local changes in 
O2Hb and HHb concentrations can be measured. The channels are numbered 
as shown for data collection. The source-detector distance is 3 cm. A total of 20 
optode channels are present in this arrangement. Photograph of a subject 
wearing the optode retaining cap is shown in the top left inset. 
 
All the fNIRS measurements were performed using the NIRScout imaging 
system (NIRx® Medical Technologies, LLC, New York, USA) with 8 sources 
and 7 detectors at a sampling rate of 7.81Hz. The LED sources emitted fixed 
NIR wavelengths of 760nm and 850nm. During each experiment, the Argus® II 
retinal prosthesis stimulations were programmed using a purpose written script 
(Matlab 8.6.0.267246, R2015b, The Mathworks Inc, Massachusetts, U.S.A) and 
routed through the NIRScout system to be read by the data acquisition program 
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(NIRStar 12.4), to ensure the timing of prosthesis stimulation was recorded 
accurately for data analysis.  
With the aid of a retaining cap akin to an electroencephalography (EEG) 10-5 
system cap, all the light sources and detectors (optodes) were arranged to 
overlie the occipital region as shown in Figure 7.2 and Figure 7.3, for recording 
of fNIRS signals of the primary visual cortex. The source-detector distance is 3 
cm. A total of 20 optode channels are available for data collection and analysis 
in this arrangement. 
Figure 7.3: Colour photographs showing an Argus® II subject undertaking 
fNIRS imaging of his primary visual cortex. The retaining cap akin to an EEG 
cap was worn over the Argus® II retinal prosthesis system. The optodes were 
placed into the appropriate optode holders as shown in Figure 7.2 (left image). 
An over cap was then placed over the EEG cap to ensure good optode contact 
with the scalp and reduce light pollution during the study (right image). 
7.2.3 Experiment Design  
To assess the feasibility of fNIRS as a tool of capturing visual cortex activation 
in response to retinal stimulation with Argus® II retinal prosthesis, we employed 
the classical block design (Gervain et al., 2011) to evaluate the fNIRS response 
under 3 different stimulation conditions (see Section 7.2.4). Each block consists 
of a stimulation followed by a rest period of no stimulation, to allow the 
haemodynamic response function (HRF) to return to the baseline level. For 
each experiment, 10 blocks of stimulation were repeated, and the average 
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NIRS response across the blocks were analysed to reduce the background 
noise and increase the strength and reliability of the signals (see Figure 7.4).  
 
Figure 7.4: Schematic drawing of the experiment design. Each experiment 
started with recording 2 minutes of fNIRS response without any stimulation to 
establish the baseline O2Hb and HHb concentrations, before leading on to 10 
repeat stimulation blocks. Each stimulation block consisted of a specified 
stimulation followed by 35 seconds of rest period during which the 
haemodynamic response returned to baseline, before ensuing the next 
stimulation block. The fNIRS responses across the 10 stimulation blocks were 
then averaged during data analysis, to reduce the background noise and 
strengthen the signal reliability in each experiment. 
Given the relatively short pulse stimulation duration with the Argus® II system 
electrodes set by the proprietary software (250ms at the frequency of 20Hz), 
and the small delay in haemodynamic response (typically around 5 seconds) to 
visual stimulation previously established in normal sighted humans (Colier et al., 
2001; Kato et al., 1993; Wenzel et al., 1996),  we set the stimulation block to 35 
seconds. At the beginning of each experiment, we also recorded the fNIRS 
response for 2 minutes without any stimulation, to establish the resting period 
(baseline) O2Hb and HHb concentrations, from which the relative change in the 
concentrations can be recorded and calculated.  
7.2.4. Stimulation Conditions 
Three stimulation conditions were employed in each subject, to explore if there 
is any variation in the fNIRS signals with varying degrees of retinal stimulation 
by the Argus® II retinal prosthesis. 
2 min 
baseline 
Stimulation block = 35 seconds 
Stimulation  
Rest period  
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The position of each electrode in the 6 x 10 Argus® II array is designated 
alphabetically by row (A to E), and numerically by column (1 to 10) as shown 
below in Figure 7.4 (also see chapter 5, Figure 5.1).  
 
Figure 7.5: Schematic drawing of an Argus® II retinal prosthesis microelectrode 
array on the retinal surface, with a magnified view of the electrode array on the 
right. The position of each electrode is designated alphabetically by row (A to E) 
and numerically by coloum (1 to 10). The position of electrode A01 and F10 are 
as labelled. 
Condition 1 
In the first stimulation condition, we chose a cluster of 4 electrodes (hereinafter 
referred to as a quad) closest to the fovea for stimulation in each subject. This 
area is chosen as the fovea is represented by a large region of the primary 
visual cortex near the occipital pole, so much so that around 20cm2 of surface 
area in each hemisphere of the occipital lobe is allocated to just the central 2˚ of 
visual field (Dougherty et al., 2003). The stimulating quad electrodes and 
parameters that elicited clear and consistent visual precepts closest to the fovea 
(i.e. foveal quad) in each subject were previously established (see chapter 5, 
table 5.2) (Luo et al., 2016) and are shown here in table 7.2.  
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Subject 
ID 
Foveal 
Quad 
Threshold 
(µA) 
Stimulating 
Current 
(µA) 
Phosphene 
Features 
Phosphene 
Duration, t 
(s) 
51-001 C07C08 
D07D08 
137 277 White filled-
in circle 
0.5 < t < 1 
51-003 A07A08 
B07B08 
250 350 Electric 
blue filled-in 
circle 
t < 0.5 
51-005 E05E06 
F05F06 
137 237 Bluish-grey 
vertical line, 
with fizzy 
vertical 
edges 
t < 0.5 
51-006 A07A08 
B07B08 
371 552 Yellow “7” 
shape 
0.5 < t < 1 
51-007 E07E08 
F07F08 
24 124 Orange 
filled-in ring 
which 
ripples out 
0.5 < t < 1 
51-009 E07E08 
F07F08 
97 124 Orange 
horizontal 
lines x 2, 
with fizzy 
brightness 
in between 
the lines 
0.5 < t < 1 
Table 7.2: The chosen quad electrodes (closest to the estimated fovea location) 
and the stimulating parameters for each subject in Condition 1 (Table modified 
from (Luo et al., 2016)). The phosphene features were as reported verbally by 
each subject, and remained consistent throughout the study. 
Condition 2 
To investigate how increasing the area of retina stimulated would be reflected in 
the fNIRS signals at the primary visual cortex, we stimulated a total of up to 6 
quads simultaneously in each subject. This included the initial foveal quad in 
Condition 1, as well as 5 other quads surrounding the foveal quad. Due to the 
constraint by the safety charge density limit of the electrode array (to prevent 
tissue damage), the stimulating current we applied for each quad when they 
were stimulated simultaneously was much lower than when each quad was 
stimulated separately. 
The chosen quads for simultaneous stimulation and their stimulating 
parameters for each subject were as shown in Table 7.3.  
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Subject ID 6 Quads Stimulated in Condition 2 & 3 
Stimulating Current 
per quad for 
Condition 2 (µA) 
Stimulating Current 
per quad for 
Condition 3 (µA) 
51-001 
A08B07B08* 
C05C06D06* 
C07C08D07D08 
E07E08F07F08 
*** 
155 
360 
360 
320 
335 
N/A 
51-003 
A06B05B06* 
A07A08B07B08 
A09A10B09B10 
C05C06D05D06 
C07C08D07D08 
C09C10** 
80  350 
51-005 
03D03D04* 
C05D05C06D06 
C07C08D08* 
E03F03E04F04 
E05F05E06F06 
E07F07E08F08 
50 237 
51-006 
A05B06** 
A07B07A08B08 
A09B09A10B10 
C05D05C06* 
C07D07C08D08 
C09D09C10D10 
110 552 
51-007 
C05C06D05* 
C07C08D07D08 
C09C10D09D10 
E06F05F06* 
E07E08F08* 
E09E10F09F10 
45 124 
51-009 
C05C06D06* 
C07C08D07D08 
C09C10D09D10 
E06F06** 
E07E08F07F08 
E09E10F09F10 
30 124 
Table 7.3: This table shows the chosen group of 6 quads stimulated 
simultaneously (in Condition 2) or sequentially (in Condition 3) for each subject 
during the study. The stimulating parameters for each Condition are also 
shown.  When all the quads were stimulated at the same current under the 
condition, only one figure is shown. When the individual quads were stimulated 
at different currents, the stimulating current for each quad was shown (subject 
51-001 Condition 3). 
* denotes an electrode within the selected quad has been disabled as its 
threshold exceeded the safety density charge, and/ or its supra-threshold 
stimulation caused discomfort in the subject. 
** signifies that 2 electrodes within the selected quad have been disabled for 
the above mentioned reasons. 
*** only 4 quads were stimulated in subject 51-001 as the remaining quads of 
his Argus® II system were not functioning. 
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Condition 3 
The same chosen group of 6 quads were also stimulated sequentially (foveal 
quad first, followed by the 5 surrounding quads in clock-wise manner) in 
Condition 3, to evaluate the fNIRS signals in response to moving retinal 
stimulations. Even though the stimulation duration of each pulse lasts only 
250ms (as set by the Argus® II system proprietary software), due to built-in 
safety features and delay in the radio frequency link transmission between the 
external and internal coil of the device, the inter-stimuli interval was around 1 
second. The stimulation duration in each block therefore lasted around 6 
seconds, leaving 29 seconds for HRF recovery. The stimulating parameters in 
Condition 3 for each subject were as shown in Table 7.3. 
7.2.5 Data Analysis 
All data were exported from NIRScout as raw data of O2Hb and HHb 
concentration levels and loaded into Matlab (version 8.6.0.267246, R2015b, 
The Mathworks Inc, Massachusetts, U.S.A) for further processing and analysis. 
A 3rd order low pass Butterworth digital filter was first applied, with the cut off 
frequency at 0.08 Hz, to suppress background and other high frequency noise 
such as heartbeats. The filtered signals were then decimated from the original 
sampling rate of 7.81Hz to 1Hz and detrended to remove the slow drift.  
The fNIRS responses from the 10 stimulation blocks were averaged to get a 
mean change in the concentrations of both O2Hb and HHb with time within the 
averaged block. From the averaged block, we selected the last 10 seconds 
(before the next stimulation) as the resting window. The resting (baseline) O2Hb 
and HHb concentration levels were calculated as the mean of the respective 
values over the resting window. We then selected the 10 seconds after the 
initial 5 seconds delay (i.e. time frame of 5s to 15s after stimulation) as the 
active window. The values of the activated O2Hb and HHb concentration levels 
were calculated as the mean of the respective values over the active window. 
A positive fNIRS response in an optode channel is defined as a statistically 
significant difference (either an increase or decrease) between the mean 
baseline and the mean activated O2Hb and HHb levels (paired T-test, p < 0.05) 
(Gervain et al., 2011). A Matlab script (version 8.6.0.267246, R2015b, The 
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Mathworks Inc, Massachusetts, U.S.A) was written to carry out the above 
analysis for each of the 20 optode channels in each experiment. 
7.3 Results 
7.3.1 Active Optode Channels per Subject 
A graph of changes in O2Hb and HHb concentration levels with time was 
automatically generated by Matlab when an optode channel showed a positive 
fNIRS response (as defined above). These active optode channels were 
mapped topographically on to a schematic drawing of the occipital lobe of the 
head to aid visualisation of the activated cortical region. The locations of the 
NIR sources were shown as red dots; the blue dots represented the locations of 
the detectors; and the active optode channels were shown as a green line 
labelled with the corresponding channel number. For each subject, the 
topographical map of optode channel activation and their respective O2Hb and 
HHb concentration graphs were presented for all the 3 stimulation conditions. 
51-001 
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Condition 1: Foveal Quad Stimulation 
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Condition 2: Simultaneous Stimulation of 6 Quads 
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Condition 3: Sequential Stimulation of 6 Quads 
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Condition 1: Foveal Quad Stimulation 
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Condition 2: Simultaneous Stimulation of 6 Quads 
None of the optode channels showed a positive fNIRS response under 
Condition 2 stimulations in subject 51-003. 
Condition 3: Sequential Stimulation of 6 Quads 
None of the optode channels showed a positive fNIRS response under 
Condition 3 stimulations in subject 51-003. 
51-005 
None of the optode channels showed a positive fNIRS response under all of the 
3 stimulation conditions in subject 51-005.  
51-006 
Condition 1: Foveal Quad Stimulation 
None of the optode channels showed a positive fNIRS response under 
Condition 1 stimulations in subject 51-006. 
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Condition 2: Simultaneous Stimulation of 6 Quads 
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Condition 3: Sequential Stimulation of 6 Quads 
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51-007 
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Condition 1: Foveal Quad Stimulation 
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Condition 2: Simultaneous Stimulation of 6 Quads 
 
-15 -10 -5 0 5 10 15
Time (s) from stimulation
-1
-0.5
0
0.5
1
1.5
2
Re
lat
ive
 C
on
ce
nt
ra
tio
n 
(M
)
×10-4 Channel:5  Duration:10s  Delay:5s  (Sig: O2Hb & HHb)
oxyhemoglobin (O2Hb)
deoxy- hemoglobin (HHb)
 Page 229 
 
-15 -10 -5 0 5 10 15
Time (s) from stimulation
-1
-0.5
0
0.5
1
1.5
Re
lat
ive
 C
on
ce
nt
ra
tio
n 
(M
)
×10-4 Channel:8  Duration:10s  Delay:5s  (Sig: O2Hb & HHb)
oxyhemoglobin (O2Hb)
deoxy- hemoglobin (HHb)
-15 -10 -5 0 5 10 15
Time (s) from stimulation
-3
-2
-1
0
1
2
3
4
5
6
Re
lat
ive
 C
on
ce
nt
ra
tio
n 
(M
)
×10-5 Channel:9  Duration:10s  Delay:5s  (Sig: O2Hb & HHb)
oxyhemoglobin (O2Hb)
deoxy- hemoglobin (HHb)
 Page 230 
 
 
-15 -10 -5 0 5 10 15
Time (s) from stimulation
-5
0
5
10
15
20
Re
lat
ive
 C
on
ce
nt
ra
tio
n 
(M
)
×10-5 Channel:10  Duration:10s  Delay:5s  (Sig: O2Hb & HHb)
oxyhemoglobin (O2Hb)
deoxy- hemoglobin (HHb)
-15 -10 -5 0 5 10 15
Time (s) from stimulation
-1
-0.5
0
0.5
1
1.5
2
2.5
Re
lat
ive
 C
on
ce
nt
ra
tio
n 
(M
)
×10-4 Channel:13  Duration:10s  Delay:5s  (Sig: O2Hb & HHb)
oxyhemoglobin (O2Hb)
deoxy- hemoglobin (HHb)
 Page 231 
 
  
-15 -10 -5 0 5 10 15
Time (s) from stimulation
-6
-4
-2
0
2
4
6
8
10
12
Re
lat
ive
 C
on
ce
nt
ra
tio
n 
(M
)
×10-5 Channel:15  Duration:10s  Delay:5s  (Sig: O2Hb & HHb)
oxyhemoglobin (O2Hb)
deoxy- hemoglobin (HHb)
 Page 232 
Condition 3: Sequential Stimulation of 6 Quads 
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51-009 
Condition 1: Foveal Quad Stimulation 
None of the optode channels showed a positive fNIRS response under 
Condition 1 stimulations in subject 51-009. 
Condition 2: Simultaneous Stimulation of 6 Quads 
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Condition 3: Sequential Stimulation of 6 Quads
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7.3.2 Summary of Optode Channel Activation 
The optode channels activated by the 3 stimulation conditions in each subject 
can be summarised as the table below: 
Subject ID 
Positive Optode Channels 
Condition 1 
(stim of foveal 
quad) 
Condition 2 
(simultaneous 
stim of 6 quads) 
Condition 3 
(sequential stim of 
6 quads) 
51-001 10, 11, 19 05, 10, 19 01, 18, 19, 20 
51-003 01, 04, 05, 06, 07, 
09, 12, 14, 15, 16, 17 
none none 
51-005 none none none 
51-006 none 5, 10, 15 05, 07, 08, 09, 10, 12, 
14, 15, 17, 18 
51-007 01, 04, 05, 07, 08, 
09, 15, 17 
05, 08, 09, 10, 13, 15 01, 04, 05, 07, 08, 09, 
15, 17, 18 
51-009 none 05, 08, 10 01, 04, 05, 07, 08, 09, 
10, 11, 12, 13, 15, 17, 
18 
Table 7.4: Summary of all the optode channel number(s) showing a statistically 
significant change in the O2Hb and HHb concentrations levels relative to 
baseline, for each of the 3 stimulation conditions in each subject. 
For ease of comparison, the topographical maps of optode channel activation 
for all the subjects are tabulated as below: 
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Subject 
ID Condition 1 Condition 2 Condition 3 
51-001 
   
51-003 
 
none none 
51-005 none none none 
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51-006 none 
  
51-007 
   
51-009 none 
  
Table 7.5: Topographical maps of optode channel activation for each subject 
under the 3 stimulation conditions. The locations of the NIR sources were 
shown as red dots; the blue dots represented the locations of the detectors; and 
the active optode channels were shown as a green line labelled with the 
corresponding channel number. For each subject, the topographical map of 
optode channel activation and their respective O2Hb and HHb concentration 
graphs were presented for all the 3 stimulation conditions. 
 
Opotode channel activations were observed in 5 out of the 6 subjects (all except 
subject 51-005) in at least one of the stimulation conditions. In 4 subjects, 
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sequential stimulation of different electrode quads appeared to generate a 
larger area of primary visual cortex activation than simultaneous quad 
stimulation. 
7.4 Discussion 
Since the first description of functional MRI (fMRI) demonstrating NVC with 
activation of the visual cortex (Belliveau et al., 1991), research into non-invasive 
imaging of the cortical activities in the field of neuroscience has exploded. While 
fMRI relies on changes in the local deoxygenated haemoglobin (HHb) levels to 
generate the BOLD (blood oxygenation level-dependent) signals to detect 
cortical activation, fNIRS measures the changes in both oxygenated (O2Hb) and 
deoxygenated haemoglobin (HHb) levels, and relies on changes in both 
parameters to detect cortical activation.  
The main advantage of fMRI over fNIRS is spatial resolution. With fMRI, BOLD 
signal from each 4mm3 voxel samples activity from around 100,000 neurones. 
The 3D co-ordinates of each voxels are also well specified. In fNIRS with 
source-detector distances of 2 – 3 cm, each optode channel samples a much 
larger pool of neurones (perhaps 3 – 5 times larger) than a voxel (Gervain et al., 
2011). Furthermore, owing to the relatively reduced tissue penetrance of NIR (in 
comparison to MRI), imaging of deeper cortical areas is limited. Despite these 
limitations, spatial resolution of as low as 1.7 cm with shifts of < 1 cm could be 
achieved (Zeff et al., 2007). Functional NIRS, on the other hand, has the 
advantage of high temporal resolution, with most machines capable of sampling 
rate of around 10Hz or much higher. By contrast, the temporal resolution of 
fMRI is around 0.5Hz. Other advantages of fNIRS imaging include the relatively 
low cost of the machine, as well as the portability of the system. In this study 
with a cohort of subjects implanted with the Argus® II retinal prosthesis, fNIRS 
has been particularly valuable as a tool of measuring cortical activities in the 
presence of real-time retinal stimulation using radiofrequency telemetry. 
The use of fNIRS to measure visual cortex activation in normal sighted human 
adults and infants has been published extensively (Colier et al., 2001; Correia et 
al., 2012; Gratton et al., 1995; Kato et al., 1993; Lloyd-Fox et al., 2010; Obrig et 
al., 2000; Wenzel et al., 1996; Wijeakumar et al., 2012; Zeff et al., 2007), and 
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the correlation between fMRI and fNIRS is well established, especially for visual 
cortex activation (Eggebrecht et al., 2012; Obrig et al., 2000). In this study, we 
have demonstrated that haemodynamic responses of primary visual cortex 
activation (as seen in normal sighted adult humans, see Figure 7.1) could be 
detected and recorded in real-time in 5 out of 6 our patients with end-stage 
outer retinal dystrophy patients, implanted with Argus® II retinal prosthesis. All 
these patients have previously been blind and deprived of visual input for many 
decades. An unusual common feature seen in all these patients is that the 
decrease in HHb concentration levels is much smaller than that observed in 
normal sighted humans, despite achieving statistical significance. It is 
interesting to note that the 2 subjects who had the best form visual function (i.e. 
51-007 and 51-009, see chapter 3) also have haemodynamic response curves 
most similar in appearance to that of normal sighted humans, with reasonable 
reduction in HHb concentration as well as a large increase in O2Hb. This may 
be a reflection of the relative preservation the primary visual cortex integrity in 
these 2 subjects compared with the other subjects. 
In order to assess the retinotopic localisation of signals, we compared the 
patterns of optode channel activation to the location of the stimulated quad 
relative to fovea (i.e. Condition 1) in each patient (see Table 7.6). The relative 
position of the stimulated quad to the presumed fovea location has previously 
been established (see chapter 5, Table 5.6) (Luo et al., 2016). 
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Subject 
ID 
Active Optode 
Channels 
Stimulated 
Quad  Quad Position Relative to Fovea  
51-001 
 
C07C08 
D07D08 
 
51-003 
 
A07A08 
B07B08 
 
51-005 none 
E05E06 
F05F06 
 
51-006 none 
A07A08 
B07B08 
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51-007 
 
E07E08 
F07F08 
 
51-009 none 
E07E08 
F07F08 
 
Table 7.6: Comparison of active optode channel patterns to the location of 
stimulated quad (relative to fovea) in each subject. The stimulated quad 
electrodes are enclosed in the red square. The fovea location is estimated as 
15.5 ± 1.1° from the centre of the optic disc horizontally, and -1.5 ± 0.9° 
vertically (Rohrschneider, 2004), and labelled with an arrow. 
Out of the 6 subjects, only 3 subjects showed positive optode channel activities 
with stimulation of foveal quad (condition 1), namely subject 51-001, 51-003 and 
51-007. Their responses will be discussed individually in detail.  
In subject 51-001, 3 optode channels (10, 11 and 19) were positive. Looking at 
the haemodynamic response curves for each channel, while channels 10 and 
11 displayed good response curves for both O2Hb and HHb concentration 
changes in keeping with the expected physiological NVC response, there is a 
mismatch in the timing of the increase in O2Hb levels and the decrease in HHb 
levels in channel 19. As such, we have discarded channel 19 as an active 
channel. The remaining 2 channels (10 and 11) corresponded to areas close to 
the midline in each hemisphere, which in turn corresponded to the foveal region 
(Dougherty et al., 2003). Given that the stimulated quad in 51-001 
encompassed the estimated fovea, the optode channels activated were as 
expected. 
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In subject 51-003, multiple channels in both hemispheres were activated. This 
could be due to the spread of electrical charges to a much larger area of retina 
than the area of direct stimulation. In fact, the patient reported seeing 
“shimmering” light after the initial phosphene with each stimulation, which would 
spread out to the peripheral visual field, before fading out. Interestingly, none of 
the channels showed a positive response when the total number of electrodes 
stimulated was increased (i.e. in Condition 2 and 3), despite the subject 
reporting seeing brighter phosphenes, especially with stimulation under 
Condition 2. 
In subject 51-007, while optode channels from both hemispheres were 
activated, there are many more channels activated in the left hemisphere (i.e. 6 
active channels) compared with the right hemisphere (i.e. 2 active channels). 
Given that the stimulated quad lied superonasal to the estimated fovea location, 
one would expect the contralateral hemisphere to be predominantly activated, 
and this is as the pattern we have observed in subject 51-007. 
Four subjects displayed positive optode channels with stimulation under 
Conditions 2 and 3, namely 51-001, 51-006, 51-007 and 51-009. With the 
exception of subject 51-001, all the other 3 subjects displayed more active 
channels under Condition 3 than Condition 2. This could be due to the fact that 
the simulating current applied to each quad in Condition 2 was much lower than 
in Condition 3 for safety concerns (as explained earlier). As such, some of the 
quads were probably stimulating at sub-threshold levels during the recording, 
resulting in less cortical activation. During Condition 3 stimulation, all the 
subjects also reported seeing moving phosphenes as the quads were 
stimulated sequentially. It is therefore plausible that some of the additionally 
activated optode channels could be related to activities in the dorsal stream for 
processing of motion perception (Goodale and Milner, 1992; Norman, 2002). 
One subject (51-005) did not display any active optode channels despite 
perceiving phosphenes with retinal stimulation. One explanation for this is that 
thus far, we have assumed that the haemodynamic responses in these subjects 
are the same as those observed in normally sighted individuals. In reality, these 
subjects have been blind for decades and it is therefore possible that in subject 
51-005, invasion of primary visual cortex by other sensory modalities has 
occurred as a result of cross-modal plasticity (Bavelier and Neville, 2002), 
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thereby disrupting the typical haemodynamic response we expected to see. In 
the future, we hope to be able to test for this by recording activities in the 
primary visual cortex while delivering auditory and / or touch stimuli, to 
investigate cross-sensory use of the cortex. 
To our knowledge this is the first demonstration of real-time haemodynamic 
responses in the primary visual cortex, in response to retinal prosthesis 
stimulation. Though electrically elicited visual evoked potentials (eVEPs) in 
Argus® II subjects has previously been recorded (Stronks et al., 2013), this 
yielded eVEP waveforms with very low signal-to-noise ratios, which required 
much longer recording time and substantial signal processing afterwards. 
Furthermore, the authors reported that all the functioning electrodes were 
stimulated at a stimulus level approximately twice that of the subjective 
threshold to obtain the results. Functional NIRS by contrast, was able to record 
responses from individual quad stimulations, and could provide information on 
focal areas of visual cortex activation. 
One limitation of this study is that presence of synchronous sound stimulation 
can suppress fNIRS signals to visual stimulus in the visual cortex compared to 
visual stimulus alone, due to cross-modality interactions in primary sensory 
cortices (Wiggins and Hartley, 2015). This effect may be particular pronounced 
or unexpectedly altered due to the presence cross-modal plasticity in this cohort 
of patients who have been blind for decades. During this study, we attempted to 
keep the sound and other stimuli to minimum by switching off all the lights in the 
room and leaving the subject alone in the room during the experiment. We also 
instructed the subjects to remain as still as possible during the experiments. 
However, we had no control over other noises in the background from the 
surrounding laboratory areas. Future experiments could be carried out in 
soundproof rooms to further reduce the interference from background noise. 
Secondly, although this study had a small sample size, it has been sufficient to 
clearly demonstrate the feasibility of using this neuroimaging technique in this 
patient group. It is hoped that in the future as Argus® II retinal prostheses 
becomes more widespread in clinical use, more subjects would be available. 
In conclusion, we have examined the feasibility of recording a cortical signal 
using fNIRS, following a retinal stimulus via the Argus® II retinal prosthesis 
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system. We have shown that consistent recording can be made and that it has 
a temporal and likely retinotopic association with the stimulus. As such, fNIRS 
appears to be a potentially useful and reliable method of recording cortical 
activities in this cohort of patients fitted with retinal prosthesis. This non-invasive 
and cost-effective imaging technique could be the method of choice for future 
studies involving other stimuli (e.g. sound) to assess cross-modality plasticity.  
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8.1 Original Aims 
This thesis aimed to: (1) examine certain aspects of long-term clinical and 
functional outcomes conferred by the Argus® II system in this early cohort of 
chronically implanted subjects; (2) to elucidate the characteristics of the artificial 
vision and its long-term repeatability and reproducibility in individual subjects; 
and (3) to explore the feasibility of real-time imaging of visual cortex activities in 
response to retinal stimulation using functional near infra-red spectroscopy. In 
the following sections, the key findings from Chapters 3, 4, 5, 6 and 7 are 
described, the strengths and limitations of the studies are summarised, and a 
possible future roadmap for prosthetic vision research is outlined based on 
these findings. 
8.2 Summary of Key Findings and Implications 
Chapter 3 of the thesis showed that patients with end-stage RP or outer retinal 
dystrophy who were fitted with Argus® II retinal prosthesis are able to identify 
2D distinct geometric shapes better with the device on than by chance. As well 
as this screen based, 2D form discrimination, patients were able to demonstrate 
a basic level of identification of 3D objects. Furthermore, the performance in 
identification of 2D and 3D testing was shown to improve by enhancing the 
outlines of the shape or object respectively. A wide inter-subject variation in the 
visual performance of form recognition has also been observed. 
In Chapter 4, we demonstrated that in addition to being able to point at bright 
targets on a 2D screen (Ahuja et al., 2011), Argus® II subjects can also localise 
objects in 3D space and reach out and grasp the objects (prehension) using the 
device – a task which they could not achieve with their native vision alone. 
Despite the potential misalignment between the direction of the camera view for 
image acquisition (i.e. camera position) and the direction of gaze (i.e. eye 
position), Argus® II subjects appeared to have developed an effective 
compensatory mechanism with which they could localise targets in both 2D and 
3D. 
As an attempt to explain the observed wide inter-subject variations in visual 
performance, as well as to establish the feasibility of constructing predictable 
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pixelated patterns to achieve useful artificial vision, we set out to investigate the 
characteristics of phosphenes in these chronically implanted Argus® II subjects 
in Chapter 5. We established that there is a wide variation in the shapes and 
sizes of the phosphenes perceived by each subject for a given standardised 
stimulation. This may in part account for the inter-subject variation in the visual 
performance observed. Despite the differences in shapes and sizes, the 
characteristics of the phosphenes are consistently reproducible within each 
subject for the same stimulating parameters. Such consistency and 
reproducibility of phosphenes form an encouraging basis upon which more 
complex patterns of artificial vision could potentially be constructed by varying 
stimulating parameters.  
Chapter 6 of the thesis looked at an important but unresolved issue about the 
use of the Argus® II system: the effect of undergoing MRI brain scan with 
internal components of the Argus® II retinal prosthesis in situ. Data on implant 
position (as evaluated by colour fundus photography, OCT scan and electrode 
impedances) and implant function (as evaluated by electrode thresholds) before 
and after the MRI scan were analysed and compared. We have concluded that 
MRI brain scans of up to 1.5-Tesla field strength appeared to have no 
detrimental effect on the subjects and their implant stability and function. The 
Argus® II implant produced an artifact of around 50mm x 50mm in size which 
would prevent visualisation of structures within the orbit, but visualisation of 
surrounding tissues outside this areas are unaffected. The demonstration of 
safety in MRI brain scanning was a prelude to, and had initially supported, our 
aim to analyse visual cortex activation using functional MRI (fMRI) in these 
patients. However, due to concerns of signal interference from the 
radiofrequency telemetry of the Argus® II system, and the impracticality of real-
time retinal stimulation during image acquisition, an alternative novel method of 
neuroimaging was sought and detailed in chapter 7. 
In chapter 7, we explored the feasibility of real-time imaging of visual cortex 
activation in response to retinal activation with Argus® II retinal prosthesis, 
using functional near-infrared spectroscopy (fNIRS). We have discovered that 
fNIRS is capable of detecting haemodynamic changes in the visual cortex in 5 
out of 6 subjects, with stimulating parameters much lower than those required 
for electrically elicited visual evoked potentials (eVEPs) (Stronks et al., 2013). In 
3 subjects, single pulse supra-threshold stimulation of one quad produced 
detectable cortical responses. In addition, as fNIRS imaging also provides 
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topographical activation maps of the cortex, this allows us to investigate further 
into signal localisation, as well as cross-modal plasticity in the future. 
The work in this thesis has shown that Argus® II retinal prosthesis system could 
improve visual function both in terms of form recognition as well as object 
localisation in 3D in real-life settings, in a cohort of patients with end-stage RP 
or outer retinal dystrophies. The wide variation in the visual performance level 
observed could in part be attributable to the diversity in the features of the 
phosphenes perceived by these subjects. Nevertheless, the consistency and 
reproducibility with which these phosphenes could be elicited, with fixed 
stimulating parameters within each subject, provides an encouraging basis for 
the construction of more complicated pixelated images. Functional near-infrared 
spectroscopy is capable of real-time recording of visual cortex activation in 
response to retinal stimulation in these patients, and provides an exciting 
neuroimaging tool for future investigation into neuroplasticity and cross-modal 
plasticity. Future research into this area may prove to be the key in 
understanding the wide variation in visual performance in the Argus® II subjects 
observed so far, and in turn help us to devise better visual prosthesis to improve 
the patients’ vision. 
8.3 Appraisal of Limitations & Strengths 
8.3.1 Strengths of the Thesis 
The main strength of this work has been the ability to document objectively the 
presence of form vision and object localisation in 2D and 3D, with the use of the 
Argus® II retinal prosthesis system. Furthermore, this has been demonstrated 
in a cohort of subjects who underwent implantation in the original feasibility 
study. At the beginning of this research work, all the participating subjects had 
already had their Argus® II implant for more than 3 years. By the end of the 
reported studies, the patients who had received their implants in 2008 had had 
their devices for more than 6 years. Our findings represent the long-term clinical 
and functional outcomes achievable with this cohort of chronically implanted 
Argus® II subjects. 
As the Argus® II device could be switched on and off, and the transmission 
signals could be artificially disorganised (i.e. scrambled mode, as described in 
Chapter 3), each subject acted as their on internal negative control (with device 
switched off), as well as positive control (with device in scrambled mode). The 
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studies described in Chapter 3, Chapter 4 and Chapter 5 are all prospective, 
internally controlled studies. 
8.3.2 Limitations of the Thesis 
Owing to the experimental nature of the initial phase I/II Argus® II retinal 
prosthesis feasibility clinical trial (clinicaltrials.gov identifier: NCT00407602), the 
number of patients who received the retinal implant during clinical trial and 
hence the number of available subjects for the subsequent functional studies, is 
limited. However as the Argus® II system has entered the commercial market 
and become available for clinical use world-wide, these data on long-term visual 
outcomes and functioning of the device are important to help both clinicians and 
potential patients make decisions on their treatment options.  
Another limitation is the inclusion of patients with advanced disease in the initial 
clinical trial. As a phase I feasibility study with safety being the primary concern, 
the clinical protocol specified for vision of logMAR 2.9 (bare light perception) or 
worse as the inclusion criteria, to minimise any potential harm to the patients. At 
this level of advanced disease, intraretinal remodelling and / or rewiring with 
aberrant nerve regeneration occur (Jones et al., 2012; Luo and daCruz, 2014; 
Marc et al., 2007; 2003; Stingl et al., 2015), which further complicates the 
process of intrinsic visual processing. Theoretically, this could compromise the 
potential visual outcome of pixelated vision achievable with focal retinal 
stimulations, and limit our understanding of the relationship between retinal 
stimulation and the artificial vision it presents. 
8.4 Future Work 
Future work to determine the underlying factors influencing the perceived 
phosphene characteristics for individual Argus® II subjects, may allow for better 
prediction of functional outcome, which could in turn be useful for patient 
selection and tailored pre-operative counselling. For the subjects already 
implanted with the Argus® II system, further research into determining the 
suitable stimulating parameters for each electrode / quad stimulation may be 
required for individual subjects, to achieve the construction of useful, pixelated 
prosthetic vision. 
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In terms of future developments for the retinal prosthesis systems, plans for 
improvement have been described and envisaged at both the software level 
and the hardware level of the device. 
8.4.1 Software Development 
Without changing the current hardware configuration of the Argus® II System, 
adjustments to the image processing software have already been applied to 
improve the level of vision obtainable with the device. As described in Chapter 
3, studies on shapes and objects recognition have shown an improvement in 
performance by enhancing the outlines of the targets, thereby maximising edge 
contrast. This finding has led to the on-going development of edge-detection 
and enhancement as part of image processing. Such innovation has shown the 
potential for future software changes to improve patient function, while using the 
existing device. 
Another example of software improvement was recently presented by Sahel et 
al. (Sahel et al., 2013), who described an image processing software known as  
Acuboost™. Acuboost™ utilises a combination of image magnification and 
minimisation (zoom), as well as some image enhancement features to achieve 
a visual resolution that exceeds the limit set by the number of electrodes. Using 
16x magnification, it allowed one Argus® II patient to achieve an equivalent 
vision of logMAR 1.0 (20/200) on gratings acuity measurement, while 4x 
magnification allowed the patient to read large-print (2.3 cm) letters from a 
notebook at 30cm.  
Other image processing features under development include signal coding for 
facial or obstacle recognition, whereby the camera automatically recognises a 
face (or obstacle), and the image is processed such that the facial image is 
extracted from the rest of the visual scene and presented alone to the patient in 
a zoomed-out view. This allows efficient identification and localisation of the 
face by the patient, and in real-life situations, allows the patient to look at the 
other person’s face during conversations (Stanga et al., 2013). 
More experimentally, Horsager et al. (Horsager et al., 2011; 2010) described 
the spatiotemporal interaction between adjacent active electrodes. Through 
phase difference interference of the electromagnetic waves, it may be possible 
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to create intermediate stimulating signals, thereby effectively creating pseudo-
electrodes (as observed in cochlear implants) to increase the potential 
resolution of the retinal implant. 
8.4.2  Hardware Development 
In terms of hardware development, increasing the number of electrodes with or 
without reducing the size of the electrodes, and increasing the area of retina 
stimulated and therefore visual field, are the most immediate areas of need. 
The Second Sight Company has alluded to a next generation device with 
possibly 240 electrodes, with the possibility of adding peripheral electrodes to 
increase the visual field (Holmes, 1945; Stronks and Dagnelie, 2014). In terms 
of electrode size, the ultimate aim would be to have individual electrodes 
comparable in size to that of RGC soma so as to allow individual RGC 
activation. At present this is not possible as the charge density of an electrode, 
being inversely proportional to the surface area of the electrode (πr2), renders 
this calibre of electrode unsafe.  
Ahuja et al. have demonstrated that the most critical factor affecting the 
electrode threshold is the electrode-retina distance (Ahuja and Behrend, 2013; 
Ahuja et al., 2013). To minimise this electrode-retina distance, OCT-guided 
custom-made electrode arrays have been proposed, which take into account 
the different curvatures of individual patients’ eyes to maximise array apposition 
(Opie et al., 2014). Researchers from California Institute of Technology, CA, 
USA have also described an origami implant design, whereby a 3D integration 
technique is employed to construct a spherical, 512-channel epiretinal implant 
conforming to the curvature of the macula. This would allow for larger areas of 
retina to be stimulated, while maintaining good electrode-retina contact (Y. Liu 
et al., 2013; Monge and Emami, 2014; Monge et al., 2013; Nakauchi et al., 
2006; Ohta et al., 2007; Tokuda et al., 2009; Zhou et al., 2008). 
To mitigate the misalignment between the glasses-mounted external camera 
position and a patient’s eye position (as described in Chapter 4) and so as to 
improve the patient’s perception of spatial localisation, intraocular cameras 
have been proposed (Hauer et al., 2009; Stiles et al., 2011). The intraocular 
camera would be placed within the capsular bag of the crystalline lens after 
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lensectomy, and the visual information could either be transmitted wirelessly to 
an external VPU for processing before being transmitting back to the epiretinal 
microelectrode array for stimulation, or the image processing could be 
performed entirely intraocularly. This has the potential advantage of controlling 
the direction of vision with eye movements rather than head movements, 
thereby allowing for the development of more natural hand-eye co-ordination. 
8.4.3 Deciphering the Neural Code 
Despite the effort to increase the number of stimulating electrodes (thereby 
improving the potential resolution of the prosthetic vision), and the use of 
various image processing techniques to maximise the vision obtainable with the 
current Argus® II System, the functional outcomes and resolution remains poor. 
The greatest obstacles to progress remain the lack of understanding of the 
electric field interaction between the active electrodes, the amplitude and 
frequency coding for signal transmission along the visual pathway to the visual 
cortex, and signal integration and interpretation at the cortical level. Without an 
understanding of the signal encoding and integration at this level, improvement 
in prosthetic vision synthesis would be limited irrespective of the number of 
electrodes available. This premise has already been demonstrated with the 
alpha-IMS subretinal implant which despite having 1500 channels in its 
stimulating array, does not have an appreciably greater acuity, only achieving a 
visual acuity of logMAR 1.43 (20/546) with Landolt C rings, and grating acuity of 
up to 3.3 cycles/degree at best (Stingl and Zrenner, 2013).  
Nirenberg et al. (Nirenberg and Pandarinath, 2012) demonstrated the 
importance of encoding visual information into patterns of action potentials that 
could potentially be understood by the visual cortex. Using data generated from 
stimulation of normal mice retina as a model, they developed a signal encoder 
consisting of a linear-nonlinear (LN) cascade – to capture stimulus / response 
relations for a broad range of visual stimuli; and the Poisson spike generator – 
to convert the visual stimuli into corresponding action potential patterns. The 
signal encoder therefore worked as a retinal input / output model, performing 
the role of information processing, as would a normal retina. 
Using blind rd mice and the Channelrhodopsin-2 (ChR2) optogenetic retinal 
prosthesis model, the authors showed that when visual scenes (captured by an 
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external camera) were presented to the rd mice using standard optogenetic 
retinal prosthesis stimulation without the signal encoder, the RGC firing patterns 
appeared haphazard. When the visual scenes were processed by the signal 
encoder first to generate the appropriate patterns for optogenetic prosthetic 
stimulation, the subsequent RGC firing patterns resembled that of the visual 
stimulation of a normal retina. Furthermore behaviourally, presentation of 
shifting sine wave gratings elicited optomotor eye tracking in normal mice as 
well as in blind rd mice stimulated with signal encoder-enhanced optogenetic 
prosthetic stimulation, but not when the standard optogenetic prosthetic 
stimulation (without the signal encoder) was applied. 
Other groups have also described different models to mimic the intricate image 
processing carried out by the retina, in the hope of replicating the physiological, 
interpretable output sent to the visual cortex. Olmedo-Payá et al. (Olmedo-Payá 
et al., 2013) described the RetinaStudio model whereby processing of the visual 
scenes is broken down into 3 stages. The first stage involves splitting the 
images into the 3 colour channels, red, green and blue (R, G and B), mimicking 
the outer plexiform layer. The second stage involves spatial filtering using the 
Difference of Gaussian (DoG) filters, mimicking the inner plexiform layer. The 
third stage mimics the ganglion cell layer, using the “leaky-Integrate & Fire 
spiking neuron” model. More importantly, they have also shown that 
incorporation of the effects of natural eye movements such as micro-saccades, 
drifts and tremors, improved the modelling of visual processing with greater 
sensitivity to light changes and improved edge recognition. Lorach et al. (Lorach 
et al., 2012) on the other hand, focused on reproducing the spatial and temporal 
properties of the different major types of RGCs, using an event-based, 
asynchronous dynamic vision sensor (DVS) to mimic the fundamentally 
asynchronous nature of biological vision.  
Perhaps more promisingly, Jepson et al. (Jepson et al., 2014) described a 
method of mapping spatio-temporal patterns of retinal activity in a group of 
identified RGCs, using a multi-electrode recording system in isolated primate 
(macaque monkey) retinas. It has been shown that ON parasol cells in 
particular could be electrically stimulated with high spatial and temporal 
precision to match the activity from visual stimuli.  
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Although an understanding and deciphering of the neural code may be useful, it 
needs to be remembered that intra-retinal remodelling and aberrant nerve 
regeneration in the degenerate retina may disrupt and interfere with normal 
spatio-temporal interaction (Alamusi et al., 2015; S. Liu et al., 2017; Marc et al., 
2007; 2003). As such, it may be that the signal characteristics need to be 
individualised to account for the variance in disease and the state of the 
patient’s residual retina, as exemplified by the widely varied phosphenes 
perceived by individuals as described in Chapter 5.  
8.5 Conclusions  
The Argus® II Retinal Prosthesis System has played an important role in 
establishing retinal prostheses as a viable and potentially beneficial treatment 
option in blinding outer retinal conditions. The ability of this device to provide 
stable, chronic retinal stimulation in a relatively safe manner over many years 
has been recognised and has led to regulatory approval across many countries. 
However, despite the increasing volume of published outcomes from clinical 
trials using the Argus® II device and a cumulative experience of over two 
hundred patient years, it still remains difficult to predict the outcome and 
usefulness of the device for a given patient. The future development of this 
treatment option will depend not only on improvements in the device hardware 
and software, but also on a greater understanding of retinal and central neural 
pathology.  Functional near infra-red spectroscopy (fNIRS), as a real-time 
neuro-imaging tool, will enable future investigations into the differences in the 
cortical activities in response to different stimulations and in different subjects. 
This may in turn help us understand the variability in their visual performance, 
as well as to further explore the extent and effect of cross-modal plasticity at the 
cortical level. Furthermore, any scientific advances will have to address the 
specific functional needs of the recipient patient group, before the milestone 
achieved by the Argus® II as a first-generation retinal prosthesis consolidates 
into a routine treatment for blinding outer retinal diseases. 
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